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In recent years there has been an explosion in the rates of obesity, defined as a body mass 
index greater than 30kg/ m
2
, and associated cardiovascular disease. Alterations in peripheral 
glucocorticoid metabolism have been suggested to play a role in the development of obesity. 
Obesity occurs in both sexes, but the risk of associated metabolic disturbance and vascular 
dysfunction is greater in men. Although there is no accepted definition of obesity in rodents, 
the term is used to describe animals with a significant increase in fat pad mass often 
achieved by feeding a high fat diet. Although animal models of obesity have been useful in 
delineating potential mechanisms linking obesity with its metabolic and vascular sequelae, 
most studies have been in male animals and, thus, have not addressed sex differences. 
Additionally, emerging evidence shows that obesity during pregnancy is associated with 
increased cardio-metabolic and vascular disease in offspring, although the processes 
underlying such ‘programming’ effects are unclear. 
This thesis addresses the hypothesis that exposure to postnatal, or maternal obesity will alter 
both metabolism and vascular function in mice. 
Male and female mice maintained on a high fat and sugar diet from 5 weeks of age had 
increased adipose tissue deposition in adulthood. However there were striking sex 
differences in glucose homeostasis, mRNA levels and glucocorticoid metabolism, with males 
being more severely affected. Treatment of male mice with 17β-estradiol ameliorated a 
number of the effects of the high fat diet, including weight gain and altered glucose 
homeostasis; additionally estradiol altered glucocorticoid metabolism in the adipose so that it 
resembled that of females. Suprisingly, given the changes in metabolism, obesity in adult 
mice produced only small changes in vascular function and did not alter vascular 
remodelling following injury. 
The effects of maternal obesity were studied using male offspring aged 3 and 6 months. The 
offspring of obese mothers had similar body weight, adiposity, plasma lipid and plasma 
hormone concentrations to controls. In contrast, exposure to obesity in utero was associated 
with receptor specific changes in agonist-mediated contraction and decreased endothelium-
dependent relaxation in male offspring. Despite these changes in vascular function, no 
alterations in blood pressure or vascular remodelling following injury were present. 
These results demonstrate that the more profound changes in glucose-insulin homeostasis 
associated with obesity in male humans can be recapitulated in rodent models and imply that 
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estradiol plays a role in protecting the metabolism of female mice, potentially by alteration 
of glucocorticoid metabolism. Despite altered metabolism in postnatal obesity vascular 
function remained normal suggesting metabolic and vascular dysfunction are not 
intrinsically linked. Conversely, maternal obesity did not cause any overt changes in 
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The prevalence of obesity has escalated dramatically in recent years and is believed to be the 
leading cause of type-2 diabetes and cardiovascular disease (WHO, 2011). Scotland has one 
of the highest rates of obesity in the world, and in 2010 27% of adults in Scotland were 
classed as obese (Keenan et al., 2011). It has been estimated that 47% of type2 diabetes can 
be attributed to obesity, as well as 36% of hypertension and 18% of myocardial infarction 
(Grant et al., 2007). Interestingly in most countries there is a greater proportion of obese 
women than men, including women of child-bearing age (Brooks and Maklakov, 2010). 
Despite the higher incidence of obesity, pre-menopausal women have less cardiovascular 
disease than men (British HeartFoundation, 2010) and are, therefore, somewhat protected 
from the effects of excess adipose deposition. Evidence suggests that visceral obesity, 
primarily seen in men, is more likely to be associated with insulin resistance than the 
peripheral distribution of
 
adipose tissue which is more commonly found in pre-menopausal 
women (Fox et al., 2007), although the mechanisms for this remain unclear. One potential 
mechanism which may be important in the metabolic sequelae associated with obesity is 
altered glucocorticoid metabolism (Seckl et al., 2004; Walker and Andrew, 2006); and 
glucocorticoid metabolism differs between the sexes (Endres et al., 1979; Handa et al., 1994; 
Mitev et al., 2003; Mattsson et al., 2007; Paulsen et al., 2007; Weiser and Handa, 2009) until 
menopause (Andersson et al., 2009). The first half of this thesis explores sex differences in a 
murine model of obesity and the potential role of glucocorticoid metabolism in mediating 
these. 
While changes in diet and lifestyle are believed to be the primary factors in the increasing 
prevalance of obesity, evidence suggests that the developmental environment can 
programme future disease risk. Many epidemiological studies have demonstrated a link 
between low birth weight and the subsequent development of hypertension, type-2 diabetes, 
and cardiovascular disease (Barker et al., 1993a). With rising levels of obesity in women of 
child-bearing age attention has turned to the potential for programming as a result of 
exposure to maternal obesity during development. Early evidence suggests babies born to 
obese mothers have increased adiposity (Catalano et al., 2009b) and are heavier during 
childhood  (Gale et al., 2007). This thesis also uses a new murine model to investigate the 
effects of maternal obesity on offspring metabolism. 
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There is a link between obesity and vascular dysfunction (Stapleton et al., 2008) which may 
underlie the associated increase in cardiovascular disease. However, in rodent models of 
obesity, vascular dysfunction is not consistently reported. Recent studies in animal models 
have suggested that programming of vascular function may result from exposure to maternal 
obesity (Koukkou et al., 1998; Samuelsson et al., 2008). The final part of this thesis uses the 
models of postnatal and maternal obesity, established for metabolic studies, to investigate the 
link between obesity and altered vascular function and arterial lesion formation.  
This chapter will introduce the sex differences in obesity and associated cardiovascular 
disease as well as the key processes in lipid and glucose metabolism. A detailed review of 
glucocorticoid metabolism and the evidence implicating its dysregulation in the pathogenesis 
of obesity is also included. Finally, changes in vascular physiology induced in obesity and 
type-2 diabetes are presented along with evidence for programming by maternal obesity. 
1.1 Obesity 
Obesity is now one of the biggest health problems in the world. The World Health 
Organisation (WHO) predicts that by 2015 there will be approximately 2.3 billion 
overweight people aged 15 years and above, and of these over 700 million will be obese 
(defined as a body mass index (BMI) greater than 30kg/m
2
) (WHO, 2011). Worryingly, the 
number of obese children has also increased at an alarming rate, with the prevalence 
predicted to worsen with advancing age (Deckelbaum and Williams, 2001).  
A very small proportion of people suffer from inherited diseases which are associated with 
marked obesity, with most of these resulting from genetic disruption of the leptin-
melanocortin pathway (Farooqi and O'Rahilly, 2005). However, most obesity is believed to 
be due to the relatively rapid increase in food availability and sedentary lifestyles in 
Westernised countries in the late 20
th
 century, resulting in energy intake exceeding usage. 
Additionally, with the decreasing cost of food and increasing portion sizes the opportunity to 
over-eat has become the norm. A shift from careers requiring physical exertion to office 
based jobs and increasing sedentary leisure time has also added to the increase in obesity. 
Changes in lifestyle and eating have been reasonably widespread; however, the susceptibility 
to obesity varies among people in the same environment. This suggests that the propensity to 
become obese is polygenic in origin, and involves many signalling pathways and molecules 
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both in the central nervous system and periphery, in addition to the imbalance of energy 
intake and usage. 
1.1.1 Sex differences in obesity 
The rates of obesity differ enormously among countries, although in most the incidence of 
obesity is higher in women than in men. The Scottish Health Survey 2003 found 22% of 
males and 24% of females aged between 16-64 years were obese, (Government, 2005). To 
date, few studies have explained the reason for the disparity in obesity between the sexes 
although socioeconomic state (Wardle et al., 2002) and reproductive capacity (Brooks and 
Maklakov, 2010) have both been correlated with obesity in women. Lean women naturally 
have a higher percentage of body fat than men and the difference in rates of obesity has been 
attributed to the expansion of this larger depot thought to be necessary for reproduction 
(Power and Schulkin, 2008). Despite the higher prevalence of obesity in women rates of 
associated cardiovascular diseases are usually lower; part of the explanation for this may lie 
in the sex differences in adipose deposition. 
1.1.1.1 Adipose distribution 
The anatomical distribution of adipose tissue is the most noticeable sex difference in obesity. 
In men and post-menopausal women an ‘apple’ shape is common which is characterised by a 
greater abdominal or visceral adipose deposition. In pre-menopausal females a ‘pear’ shape 
predominates which is characteristed by a peripheral deposition around the hips and gluteals. 
In some cases excess lipid is also deposited in organs other than the adipose, the most 
common being the liver leading to non-alcoholic fatty liver disease (NAFLD) (Mehta et al., 
2002). This is particularly dangerous as the liver, unlike adipose tissue, is not designed to 
accommodate excess lipid. Sex steroids have been proposed as key regulators of sex specific 
patterns of adipose distribution, exemplified by the changes in fat distribution observed 
following puberty and after the menopause (further details in section 1.3.3). The precise 
mechanisms through which sex steroids regulate deposition of adipse tissue are not clear, but 
altered lipid metabolism, through sex steroid effects on the transcription of lipoprotein lipase 
(LPL) and leptin and the activation of hormone sensitive lipase (HSL), has been proposed as 
mediators of these effects (reviewed in (Mayes and Watson, 2004)). 
Amount of visceral adipose tissue increases with age in both sexes and for all body weights, 
though the increase is greater in males (Enzi et al., 1986). Visceral adipose is associated with 
increased incidence of the metabolic syndrome and insulin resistance (Despres et al., 2008). 
This may be due to the proximity of visceral adipose to the portal system into which it can 
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release hormones and, thus, gain direct access to the liver (Bergman et al., 2006). 
Subcutaneous adipose tissue area is greater than visceral adipose area in women, regardless 
of overall weight, until the menopause when the ratio shifts to favour an android deposition 
(Enzi et al., 1986). In contrast to visceral adipose tissue, hormones synthesised in 
subcutaneous adipose are released into the systemic circulation. In addition the different 
adipose depots have unique patterns of gene expression and hormone synthesis. For example 
the expression and secretion of interleukin-6 (IL-6) is relatively high in the visceral adipose 
compared with the subcutaneous, where the expression and secretion of leptin is greater 
(Fain et al., 2004). Receptor expression is also depot specific with greater androgen and 
glucocorticoid receptor expression in the visceral adipose (Kershaw and Flier, 2004). 
1.1.1.2 Sex differences in cardiovascular disease 
The pathogenesis of cardio-metabolic disease is introduced later in this chapter (section 
1.1.6); however, the incidence of these diseases is normally higher in men and correlated 
with the abdominal deposition of adipose. Insulin resistance and type-2 diabetes are more 
prevalent in males than females. The amount of intra-abdominal adipose tissue has been 
shown to be a strong predictor of insulin resistance (Ross et al., 2002a; Ross et al., 2002b) 
and, as this distribution pattern is more common in men, it may be one reason for the higher 
incidence of the disease. In addition to insulin resistance, an epidemiological study of 
dyslipidemia in hypertensive individuals also found the prevalence to be higher in men than 
women (O'Meara et al., 2004). Currently, no studies have addressed this disparity which 
suggests a lack of lipid storage, or greater propensity to release free fatty acids (FFAs) from 
adipose, in males. As well as higher prevalence of primarily metabolic conditions in men; 
obesity also affects the vasculature and blood pressure in a sex specific manner. 
Hypertension is more common in men than pre-menopausal women, although after the 
menopause blood pressure levels are comparable between men and women and may increase 
with age (Reckelhoff, 2001). Interestingly, sex differences in hypertension have also been 
reported in animal models such as the spontaneously hypertensive rat and Dahl salt-sensitive 
rat (Reckelhoff, 2001). The exact mechanisms controlling these sex differences are unknown 
but are likely to involve many molecular pathways. Measurements of intima-media 
thickness, an early predictor of atherosclerosis and cardiovascular events (Lorenz et al., 
2007), are lower in younger females than in males but become comparable in older women, 
in association with increased atherosclerotic plaque formation (Sinning et al., 2011). Sex 
steroids have been suggested to mediate the differences in atherosclerosis by altering FA 
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metabolism and circulating lipid concentrations in addition to exerting direct effects on the 
vasculature such as estrogen-mediated nitric oxide production (Majmudar et al., 2000). 
1.1.2 Fatty acid metabolism 
Lipids are a primary energy source in the mammalian diet and their storage and metabolism 
is tightly regulated. Obesity is associated with excess calorie intake which can alter the 
balance of lipid storage and metabolism such that storage predominates and adipose tissue 
expands. 
1.1.2.1 Lipogenesis, fatty acid re-esterification and lipolysis 
The synthesis of fatty acids (FAs) is called lipogenesis and involves de novo synthesis of 
FAs from glucose precursors, while the production of triglycerides (TGs) from their FA and 
glycerol substrates is called re-esterifcation (Figure 1.1). Lipogenesis is stimulated by insulin 
in the fed state to generate FAs and TGs for storage, and inhibited during fasting when 
insulin levels fall. Insulin promotes lipogenesis by increasing glucose uptake in adipocytes 
through the recruitment of glucose transporters (GLUT-4) and activating lipogenic enzymes 
through covalent modification (Kersten, 2001). The adipokine leptin can inhibit lipogenesis, 
opposing the effects of insulin and repressing the expression of genes involved in FA and TG 
synthesis (Soukas et al., 2001) and additionally stimulating FA oxidation (Bai et al., 1996). 
Leptin deficiency in humans is extremely rare but is associated with severe early onset 
obesity which resolves when recombinant leptin is administered (Licinio et al., 2004). An 
important transcription factor in adipose tissue is peroxisome proliferator-activated receptor 
γ (PPARγ), which triggers adipocyte differentiation. Evidence suggests that PPARγ can be 
stimulated by insulin, and regulates many genes in the adipose inducing those involved in 
lipogenesis and adipogenesis (Lehrke and Lazar, 2005). PPARγ agonists are used 
therapeutically as insulin sensitising agents, although patients using them frequently gain fat 
mass (Fuchtenbusch et al., 2000). 
As well as synthesising lipids, adipose tissue can take up and store free fatty acids (FFAs) in 
the form of TGs, known as FA re-esterification. Uptake is believed to occur either by 
diffusion of FAs to the inner membrane of the cell and/or active transport of FAs by 
transmembrane proteins. FFA uptake can also occur following hydrolysis of TGs by LPL. 
Due to the insolubility of lipids they travel through the bloodstream in lipoproteins, along 
with cholesterol and apolipoproteins. LPL is found on the luminal surface of capillaries and 
arteries where it hydrolyses circulating TGs from lipoproteins, producing FFAs which can be 
taken up by adipocytes (Wang and Eckel, 2009).  
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Figure 1.1 Lipogenesis, fatty acid re-esterification and lipolysis 
Dietary lipids circulate in the blood stream as triglycerides (TGs), these can be metabolised 
by lipoprotein lipase (LPL) to release free fatty acids (FFAs) that enter the adipose tissue. 
TGs also undergo lipolysis inside the adipocytes in reactions catalysed by hormone sensitive 
lipase (HSL) and adipose triglyceride lipase (ATGL). The enzymes are activated and move 
to their site of action in response to catecholamines, whereas insulin deactivates them. FAs 
are oxidised in the liver to produce energy, the processes involved are up-regulated by the 
transcription factor peroxisome proliferator receptor (PPAR) α  
Opposing lipolysis FFAs, which can be produced by fatty acid synthase (FAS), and glycerol-
3-phosphate (P) are combined to produce TGs for storage. Lipogenesis and FA re-




Lipolysis is the process of hydrolysing TGs to produce FAs and glycerol which can be 
released in to the bloodstream and used for energy. This occurs in times of fasting or 
exercise when energy is required. Lipolysis, like lipogenesis, is under hormonal regulation 
and can be stimulated by catecholamines during fasting or exercise. Catecholamines bind to 
β-adrenoreceptors which cause a signalling cascade ending in the activation and 
translocation of HSL and adipose triglyceride lipase (ATGL) (Greenberg et al., 2011). HSL 
and ATGL are believed to be the rate determining enzymes in stimulated lipolysis due to 
their high expression in adipose tissue and high hydrolytic capacity (Schweiger et al., 2006). 
Insulin inhibits lipolysis in the fed state when energy sources are abundant and storage 
necessary, by inhibiting the activation and translocation of HSL (Holm et al., 2000; Su et al., 
2003). Obesity is associated with altered lipolysis, including increased basal rates of lipolysis 
and FA release which contribute to the development of insulin resistance (Arner, 1999). 
1.1.2.2 Fatty acid oxidation 
FAs can be oxidised in all tissues except the brain to produce energy. The enzymes involved 
in FA oxidation are situated in the mitochondria although very long chain FAs are 
preferentially metabolised in peroxisomes (Bronfman et al., 1979). Before entering into the 
mitochondria for oxidation, FAs must be activated in the cytoplasm to produce Acyl-CoA. 
The subsequent process inside the mitochondrion, β-oxidation, occurs through sequential 
removal of 2-carbon units by oxidation at the β-carbon position of the fatty acyl-CoA 
molecule. These reactions generate NADH and FADH2 which enter the electron transport 
chain and produce ATP. Each round of β-oxidation also produces a molecule of acetyl-CoA 
which enters the tricarboxylic acid cycle generating further cofactors to produce ATP 
(reviewed in (Rinaldo et al., 2002). Acetyl-CoA also has a regulatory role; it inhibits its own 
production from glucose-derived pyruvate precursors, promoting gluconeogenesis (section 
1.1.3.2). The oxidation of FAs produces much more energy per gram of substrate than that of 
carbohydrates, denoting their importance as an energy source. 
Changes in FA oxidation have been suggested to play a role in the pathogenesis of obesity. 
Obese humans oxidise less fat after a meal than lean controls (Astrup et al., 1997), and rats 
with inherited susceptibility to obesity have reduced capacity for fatty acid oxidation when 
lean or obese (Ji and Friedman, 2007). Lipid-lowering drugs, such as fibrates, have been 
proposed to elicit some of their effects by enhancing FA oxidation. This is due to their 
capacity to activate the perixosome-proliferator receptor α (PPARα) which induces 
expression of the enzymes that control β-oxidation (Minnich et al., 2001). The role of 
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PAPRα in FA metabolism has been confirmed by the generation of KO mice which have 
both reduced FA oxidation and gluconeogenesis in the fasted state (Le May et al., 2000). 
1.1.3 Glucose metabolism 
Glucose is the other primary source of energy in the body and can be used for metabolism or 
stored for later release. The product of glucose metabolism, 3-glycerophosphate (glycerol) is 
vital in lipid synthesis as it combines with FAs to generate TGs. Due to the importance of 
glucose and glycerol derived energy they can both be synthesised from non-carbohydrate 
sources in the liver and adipose tissue when their natural precursors are unavailable. This 
section discusses glucose synthesis and metabolism which primarily occurs in the liver, 
while most FA re-estrification and breakdown occurs in the adipose tissue.  
1.1.3.1 Glucose storage 
Although FA metabolism yields a greater amount of energy than carbohydrate, the brain and 
red blood cells can only metabolise glucose and thus a constant supply is required. Following 
feeding and increases in insulin, the liver removes excess glucose from the circulation and 
stores it as glycogen (which can be depolymerised when blood glucose begins to fall, in 
order to maintain glucose supply to the body). The first step in hepatic glycogenesis is the 
retention of glucose. This is achieved by the enzyme hexokinase which phosphorylates 
glucose, preventing it from leaving the cell. Enzymes involved in glycogen synthesis are 
activated by secondary messengers in response to insulin receptor activation (Miller and 
Larner, 1973). When insulin concentrations fall enzymes capable of glycogen degradation 
are activated. 
1.1.3.2 Gluconeogenesis 
When glycogen stores are exhausted following extended periods of fasting or starvation the 
liver begins de novo production of glucose from non-carbohydrate sources (Figure 1.2). This 
process, termed gluconeogenesis, drives the conversion of pyruvate to glucose and requires 
energy input. Due to their bi-directional nature most of the enzymes required for 
gluconeogenesis are also used in glycolysis, the process of generating energy from glucose. 
The main exception is phosphoenolpyruvate carboxykinase (PEPCK) which catalyses the 
conversion of oxaloacetate to phosphoenolpyruvate and is believed to be the rate limiting 
enzyme in gluconeogenesis (Rosella et al., 1993). There are two forms of PEPCK, one 
cytosolic and one mitochondrial, although little is known about the function and regulation 
of the mitochondrial form (Hanson, 2009). The following information and references in this 
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Figure 1.2 Gluco- and glyceroneogenesis 
When glucose is not available in the liver it can be produced by gluconeogenesis from 
pyruvate. The rate limiting step in the process is the production of phosphoenolpyruvate 
from oxaloacetate which is catalysed by phosphoenolpyruvate carboxykinase (PEPCK). In 
the adipose tissue the same enzyme is responsible for glyceroneogenesis; generating glycerol 
3-phosphate (G3P) from pyruvate. This can be used to store fatty acids in the form of 
triglycerides (TG). PEPCK is regulated by hormones; in the liver and adipose tissue insulin 
inhibits transcription of the enzyme whereas glucocorticoids activate transcription in the 





thesis refer to the cytoplasmic enzyme. Transcription of PEPCK is rapidly inhibited by 
insulin, mediated by the insulin receptor-induced reduction of cAMP, which alters the 
transcription of many factors that normally initiate and activate PEPCK transcription (such 
as PPARγ coactivator-1α and CREB binding protein) (O'Brien et al., 1990). Insulin also 
activates protein kinases which alter the phosphorylation state of proteins required for 
PEPCK transcription such as forkhead transcription factor, rendering it inactive (Nakae et 
al., 2001). In the fasting state when gluconeogenesis is vital, PEPCK is stimulated by 
glucagon and glucocorticoids. Glucagon increases cAMP concentrations, through the 
activation of adenylyl cyclase, which can phosphorylate proteins that bind to sites in the 
PEPCK promoter initiating transcription (reviewed in (Chakravarty et al., 2005)). Cortisol 
binds to glucocorticoid receptors (GR) which bind to glucocorticoid response elements in the 
PEPCK gene promoter and up-regulate transcription (Imai et al., 1990). Insulin is believed to 
have the greatest transcriptional control over PEPCK due to the number of pathways and 
transcription factors it affects, and also due to its ability to overcome glucocorticoid-
mediated activation (Sasaki et al., 1984). 
1.1.3.3 Glyceroneogenesis 
PEPCK is also present in adipose tissue where it modulates glyceroneogenesis, the synthesis 
of 3-glycerophosphate in an abbreviated version of gluconeogenesis. Glyceroneogenesis can 
also occur in the liver, when pyruvate is converted to glycerol rather than glucose as in 
gluconeogenesis (Beale et al., 2002). Mice over-expressing PEPCK in adipose tissue become 
obese due to the increased production of glycerol backbones required for FA re-esterification 
(Franckhauser et al., 2002). Interestingly, despite obesity these mice do not become diabetic, 
further implicating circulating FFAs in the pathogenesis of insulin resistance. PEPCK is 
under hormonal control in the adipose tissue, as in the liver, although the same hormones do 
not elicit the same responses. In the fed state, glyceroneogenesis is decreased as glucose can 
be used to generate glycerol-3-phosphate and subsequently TGs. In contrast, on fasting or a 
low carbohydrate diet the synthesis of glycerol-3-phosphate is initiated in the adipose tissue 
(reviewed in (Reshef et al., 2003). This pathway must be used to generate glycerol-3-
phosphate as adipose does not express the enzymes required to produce it from glycerol 
released as a result of TG lipolysis (Schlender and Reimann, 1977). Insulin suppresses the 
transcription of PEPCK as in the liver; however, glucocorticoids also repress transcription of 
PEPCK in adipose, highlighting the tissue specific regulation of the enzyme (Nechushtan et 
al., 1987). A separate promoter region to that important in liver, which lies further upstream 
from the transcription start site, controls PEPCK expression in the adipose tissue (Short et 
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al., 1992). Glucocorticoids diminish the binding of adipocyte-derived nuclear proteins that 
normally activate the PEPCK promoter, inhibiting their effects and therefore transcription of 
the gene (Olswang et al., 2003). The transcription factor PPARγ, implicated in adipogenesis, 
is required to initiate transcription of PEPCK, by binding to elements in the gene promoter 
(Olswang et al., 2002). 
Obesity is associated with insulin resistance and type 2 diabetes with increased endogenous 
glucose production. This is due to dysregulation of gluco- and glyceroneogenesis in the liver 
such that PEPCK expression is enhanced and glucose and glycerol are still produced in the 
fed state (Gastaldelli et al., 2000). Increases in plasma FFAs also promote insulin resistance 
and reduced expression of PEPCK in adipose tissue (Forest et al., 1997) which stops their re-
esterification into TGs resulting in further release of FFAs in to the plasma. PPARγ agonists 
have been promoted as insulin-sensitising agents and are believed to elicit their effects partly 
by enhancing expression of PEPCK in adipose and promoting FA re-esterification (Glorian 
et al., 2001). 
1.1.4 Adipose tissue 
Whether genetic or dietary in origin, obesity is a disease of weight gain and, more 
specifically, fat accumulation. When the energy input is greater than demand the body stores 
the excess in adipose tissue for release in periods of fasting. Obesity does not occur instantly, 
but is a gradual process of adipose expansion occurring as the energy balance is consistently 
tipped in favour of input. For this reason, until recently, obesity was mainly seen in middle 
aged adults; however increasing rates of obesity are now seen in children. Adipose tissue is 
made up of adipocytes which contain lipid droplets. They are dynamic cells in normal 
physiology responsible for lipid uptake, synthesis, storage, and release. 
1.1.4.1 Adipocyte hypertrophy and hyperplasia 
Adipocytes are formed by differentiation of stromal preadipocytes. This requires growth 
arrest and clonal expansion of the precursors in response to several transcription factors 
including PPARγ (Rosen et al., 1999). During the terminal phases of differentiation insulin 
sensitivity is conferred on the cell and the expression of many lipid metabolising enzymes 
increases (Gregoire et al., 1998; Wu et al., 1999). Evidence suggests adipogenesis can occur 
throughout life (Deslex et al., 1987; Gregoire et al., 1995) and in response to high fat and 




In addition to hyperplasia, adipocytes have the capacity to increase in size and, therefore, in 
capacity for lipid storage. This hypertophy can occur by increased lipogenesis and/or 
decreased lipolysis in response to physiological changes. Adipose hypertrophy is important 
in protecting the liver and muscle from lipid accumulation. Indeed, a lack of adipose tissue, 
as in lipodystrophy, is associated with insulin resistance in the muscle and liver steatosis 
(Carr et al., 1998; DeFronzo, 2004). However, increases in adipocyte size have also been 
correlated with insulin resistance, and obese individuals with fewer but larger adipocytes are 
more glucose intolerant and hyperinsulinemic than comparable individuals with a greater 
number of smaller adipocytes (Arner et al., 2009).  
1.1.4.2 The endocrine capacity of the adipose tissue 
Over the last two decades much research has resulted in the recognition that adipose tissue is 
a metabolically active endocrine organ, rather than a simple lipid storage site (reviewed in 
(Ahima and Flier, 2000)). Adipocytes produce a wide range of factors involved in glucose-
insulin homeostasis, inflammation, appetite regulation and vascular function. These include 
adiponectin, leptin, resistin, tumour necrosis factor α, IL-6, LPL, 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), aromatase and unidentified vaso-dilatory factors. Of 
particular interest to this thesis is the capacity of adipose to metabolise steroid hormones, 
which will be introduced later (sections 1.2.3 & 1.3.1). 
1.1.5 Rodent models of obesity 
To allow further studies of the mechanisms involved in the progression of obesity and the 
associated metabolic disturbance, many rodent models have been developed. Unlike in 
humans where BMI is widely used to classify obesity there is no accepted definition in 
rodents. In addition to using BMI the WHO state that obesity is an abnormal or excessive fat 
accumulation that may impair health (WHO, 2011), therefore for the purpose of this thesis 
the term obesity is used to describe rodents with a significant increase in fat mass who have 
been consuming a high fat and sugar diet. The earliest models were found in large colonies 
of rodents and resulted from spontaneous genetic mutations. Subsequently, polygenic models 
of obesity were generated by breeding of selected obese individuals. Most recently attention 
has turned to diet-induced models of obesity that involve feeding rodents high fat and/or 
sugar diets somewhat reflective of the nutritional habits of obese humans. 
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1.1.5.1 Monogenic models 
Monogenic models of obesity, often in combination with diabetes, exist in rats and mice and 
have proved useful in understanding energy expenditure. Ob/ob and db/db mice and the 
Zucker fatty rat were all discovered following spontaneous mutations generating obesity. 
Subsequent characterisation of the mutations revealed a defect in leptin production in the 
ob/ob mice (Zhang et al., 1994b) and the leptin receptor in both the db/db mouse (Chen et 
al., 1996a) and Zucker fatty rat (Phillips et al., 1996). The loss of either the signalling 
molecule or receptor in ob/ob and db/db mice and Zucker fatty rats causes hyperphagia, 
obesity and insulin resistance. Both the ob/ob mouse (Herberg and Coleman, 1977) and 
Zucker fatty rat can maintain normal circulating glucose concentrations (Bray, 1977). 
However, the db/db mouse develops hyperglycaemia by 8 weeks of age (Herberg and 
Coleman, 1977), as does a sub-strain of Zucker fatty rats termed Zucker diabetic fatty rats 
(Friedman et al., 1991), establishing these strains as models of obesity and diabetes. Models 
of monogenic obesity have been useful in understanding the function of leptin signalling and 
the regulation of energy intake. Some models also display similar microvascular 
complications to humans, such as diabetic retinopathy and nephropathy (Oltman et al., 2005; 
Drel et al., 2006). However, mutations in leptin are only responsible for a handful of 
obesity/diabetes cases in humans and have a different etiology to the worldwide epidemic of 
obesity and type 2 diabetes (Loos and Bouchard, 2003). 





. The agouti gene normally functions to control production of melanin that 
gives rise to coat colour (Lu et al., 1994). A range of dominant and recessive alleles of 
agouti exist, with those encoding yellow (
Y
) being dominant. Expression of these 
Y
 alleles 
leads to maturity onset obesity, increased hepatic lipogenesis and hyperinsulinemia (Bultman 
et al., 1992). In contrast to models in which leptin signalling is disrupted, these phenotypes 
do not arise as a consequence of marked hyperphagia.  
1.1.5.2 Genetic modifications 
In 2005 the murine obesity gene map identified 248 genes which affect body weight and 
adiposity when mutated or over-expressed in mice (Rankinen et al., 2006). This number has 
increased since that report, particularly with the advances in technology which allow for the 
generation of tissue-specific modification of gene expression. Introducing transgenic models 
is, therefore, beyond the spectrum of this introduction. However, models pertinent to the 
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understanding of the results are introduced and discussed as necessary in subsequent sections 
and chapters.  
1.1.5.3 Polygenic models 
Most human obesity is likely to be mediated by multiple genes rather than single 
polymorphisms, suggesting polygenic rodent models may be more relevant in laboratory 
studies. Male New Zealand Obese mice are hyperphagic and have increased adiposity and 
type-2 diabetes (Herberg and Coleman, 1977) and their phenotype is believed to be due to a 
combination of hyperphagia, reduced energy expenditure and insufficient physical activity. 
A fat (F) line of mice was generated by Bunger and colleagues in Edinburgh following long-
term selection for fatness over 60 generations; with the phenotype shown to be independent 
of leptin and the leptin receptor (Bunger et al., 2002). These mice have increased weight 
gain and adiposity compared to controls, as well as reduced physical activity. Polygenic 
models of obesity are often fed high fat and sugar diets to exacerbate their phenotypes. 
1.1.5.4 Diet-induced models 
Although particular genes are likely to play a role in human obesity, the imbalance of energy 
input and usage is the primary causative factor. To reflect this, many rodent models of diet-
induced obesity have been generated. Initial studies fed rats a ‘cafeteria’ type diet, this 
involved refined human foods high in fat and sugar which promote hyperphagia (Rolls et al., 
1980). The main problem with cafeteria diets is the unknown micro and macronutrient 
composition which makes it difficult to ascertain which additional dietary components may 
be important in the generation of the phenotype. Despite this problem, cafeteria diets are 
very good at promoting obesity and the associated metabolic consequences and, as such, are 
still used in both rat and mouse models. To try and control for micro and macronutrient 
content, highly palatable homogenous commercial diets are more frequently used. These can 
be high in fat and cholesterol, known as the ‘Western’ diet, or high in fat and sugar - the 
‘obesogenic’ diet. Body fat accumulates in correlation with the amount of dietary fat in rats 
and mice; this increase is gradual and only plateaus when extreme fat deposition occurs 
(Boozer et al., 1995; West et al., 1995). The effects of obesogenic and cafeteria diets are not 
uniform across strains, with some displaying apparent resistant to weight gain. A study 
investigating 9 strains of mice found 6 to be sensitive to the effects of consuming a high fat 
diet, with the other 3 apparently resistant to the development of obesity (West et al., 1992). 
Outbred Sprague-Dawley rats have a spectrum of responses within the strain when fed a high 
fat diet; some animals show excessive weight gain while others are resistant (Levin and 
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Keesey, 1998). These studies support the proposed polygenic nature of obesity, and the use 
of dietary obesity in the selection of obesity sensitive animals. 
One of the most frequently used murine models of diet-induced obesity (DIO) is the 
C57BL/6 strain. This was originally identified as being obesity sensitive by Surwit and 
colleagues in 1988. It remains lean when fed a chow diet but becomes obese when fed an 
obesogenic diet (Surwit et al., 1988). The mice develop many of the physiological changes 
associated with human obesity including insulin resistance and dyslipidemia. Because of 
their propensity to develop obesity and type 2 diabetes they have been extensively used to 
investigate the molecular events which may underlie changes in feeding, and fuel storage 
and usage in obesity 
1.1.6 Obesity increases risk of cardiovascular disease 
With the rise in obesity comes an increase in the incidence of many other conditions and 
diseases, particularly those which increase risk of cardiovascular disease. This is a huge 
economic burden and a review of the published literature from Europe suggested an obesity-
related healthcare cost of €10.4 billion in 2009 (Muller-Riemenschneider et al., 2008). 
1.1.6.1 Insulin resistance and type-2 diabetes 
Insulin resistance is a pre-cursor for type 2 diabetes and is characterised by excess insulin 
production due to lack of a physiological effect. Insulin enhances glycogenesis and glucose 
uptake whilst inhibiting gluconeogenesis, thus, promoting the usage and storage of ingested 
carbohydrate (see section 1.1.3). In insulin resistance this shift of metabolism does not occur 
and the body responds by increasing insulin synthesis and release. It is possible to maintain 
blood glucose within the normal range by increasing insulin production; however, type-2 
diabetes develops when glucose can no longer be kept in the normal physiological range, due 
to increased insulin resistance at a tissue level and inadequate insulin secretion. In Scotland, 
over 80% of people diagnosed with type-2 diabetes are overweight or obese (SDSM Group, 
2011), and the correlation between the prevalence of the two conditions has led to the term 
‘diabesity’ being used. The exact aetiology of insulin resistance and type 2 diabetes is not 
clear, although improvement in insulin sensitivity following weight loss highlights the 
detrimental effects of adipose deposition. It has been proposed that elevated FFAs and the 
expansion of adipose tissue mediate the development of insulin resistance. Data suggests that 
FFAs may: (1) compete with glucose as the energy substrate, decreasing glucose oxidation, 
(2) inhibit insulin signalling which reduces glucose uptake, (3) antagonise the effects of 
insulin promoting gluconeogenesis and (4) potentially affect insulin secretion (reviewed in 
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(Boden, 1999)). In addition to the changes in lipid metabolism, obesity is accompanied by 
chronic low-grade inflammation in the adipose tissue which may also play a role in the 
development of insulin resistance (Dandona et al., 2004). Diabetes can lead to other health 
problems including nephropathy and retinopathy; both due to the effects of elevated blood 
glucose concentrations on the vasculature. 
1.1.6.2 Dyslipidemia 
An elevated lipid concentration in the blood may be mediated by an increase in dietary 
cholesterol and triglycerides, increased lipid storage and release by lipolysis, and changes in 
FA oxidation. Whilst lipids are vital in many physiological functions, in excess they can 
disrupt metabolism causing conditions such as insulin resistance (section 1.1.6.1) or 
accumulate in atherosclerositic plaques in the vasculature (section 1.1.6.5). 
1.1.6.3 Vascular dysfunction 
Obesity is associated with hypertension and atherosclerosis (discussed in subsequent sections 
1.1.6.4 & 1.1.6.5), both of which may involve changes in vascular function. In addition, 
poorly controlled type 2 diabetes can cause microvascular diseases, such as retinopathy, by 
decreased tissue perfusion. The association of these diseases suggest that vascular 
physiology can be modulated by excess adiposity and glucose. In obese subjects (Arcaro et 
al., 1999; Van Guilder et al., 2006) and those who are insulin resistant (Steinberg et al., 
1996; Steinberg and Baron, 2002) endothelium-dependent, such as response to acetylcholine, 
but not -independent vasodilation is impaired. Insulin can activate endothelial nitric oxide 
synthase (eNOS) resulting in local production of nitric oxide and the relaxation of smooth 
muscle cells (Steinberg et al., 1994). In obesity it is proposed that insulin resistance affects 
endothelium-dependent relaxation as a consequence of inadequate insulin receptor activation 
and inhibition of eNOS-dependent nitric oxide production. A blunted response to 
endothelium-dependent vasodilators is found in some animal models of obesity and type 2 
diabetes (Bourgoin et al., 2008; Belin de Chantemele et al., 2009), in association with 
decreased Akt and eNOS phosphorylation as well as reduced basal transcription of eNOS 
and dimer formation (Molnar et al., 2005; Kim et al., 2008; Fulton, 2009; Symons et al., 
2009). One study in mice found evidence for insulin resistance in the vasculature before liver 
and adipose tissue (Kim et al., 2008) suggesting it may be an early complication of obesity. 
In addition to altered nitric oxide production in obesity and insulin resistance, studies suggest 
increased removal may also be responsible for the changes in vasodilation. This is due to 
higher concentrations of reactive oxygen species, which act as scavengers to clear nitric 
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oxide, reported in obesity (Cai and Harrison, 2000; Williams et al., 2002; Bakker et al., 
2008). Increased concentrations of NEFAs, due to increased endogenous lipolysis seen in 
obesity, may also affect endothelium-dependent vasodilation. Infusion of NEFAs blunts the 
response to metacholine, a muscarinic receptor agonist activating the same pathways as 
acetylcholine. The mechanisms involved are not clear but reduced nitric oxide production 
and release, and increased release of vasoconstrictor substances have been proposed 
(Steinberg and Baron, 2002). 
1.1.6.4 Hypertension 
Hypertension is a chronic medical condition in which the arterial blood pressure is elevated. 
Around 90% of hypertension does not have an identified cause but obesity is considered to 
be a major risk factor. Activation of the renin-angiotensin-aldosterone system, increased 
sympathetic nervous system activity, insulin resistance, leptin resistance, increased pro-
coagulatory activity and endothelial dysfunction have all been proposed as mechanisms 
linking obesity to hypertension (reviewed in (Davy and Hall, 2004). Normal weight 
hypertensive individuals are more likely to become obese than normotensive individuals, 
suggesting that the link may be bidirectional (Julius et al., 2000). 
1.1.6.5 Atherosclerosis  
Obesity is an independent risk factor for atherosclerosis which is characterised by lesions in 
medium and large sized arteries due to lipid accumulation in vessel walls. The development 
of atherosclerosis involves an interaction between plasma lipids, the vascular endothelium, 
inflammatory cells, platelets, and vascular smooth muscle cells (VSMCs); initiated by 
chronic vascular injury (reviewed in (Ross, 1999; Libby, 2002). The lesions are largely 
asymptomatic but can limit blood flow leading to tissue hypoxia such as in angina. The most 
damaging consequence of atherosclerosis occurs when a plaque erodes or ruptures often 
leading to myocardial infarction and stroke. Endothelial cell dysfunction is proposed as an 
early event in the pathogenesis of atherosclerosis (Bonetti et al., 2003), and its occurrence is 
increased in obesity. In addition to changes in vascular physiology, the increased circulating 
lipid concentrations in obesity are likely to increase risk of the disease. 
1.1.6.6 Lesion formation 
Treatment for atherosclerosis includes changes to diet and lifestyle as well as 
pharmacotherapy. However, mechanical procedures such as percutaneous coronary 
intervention (PCI) can revascularise the affected vessel and are the most common treatment 
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in advanced stages of the disease. Although this treatment is successful, it inevitably causes a 
degree of damage to the vessel wall particularly when a stent is implanted. The acute injury 
results in formation of intimal lesions (Kibos et al., 2007) which are rich in VSMCs and 
extracellular matrix, unlike atherosclerotic lesions. Greater intimal-media thickness is found 
in obese subjects, which is correlated with increased risk of lesion formation and 
cardiovascular events (O'Leary et al., 1999; Kotsis et al., 2006). In addition restenosis 
following bare metal stent implantation is more common in obese patients (Asakura et al., 
1998; Nikolsky et al., 2005). Increases in insulin concentrations, common in obesity, can 
contribute to increased arterial wall thickness by direct trophic effects as well as by changes 
in second messengers which stimulate growth and proliferation of VSMCs and may alter 
lesion formation in response to vascular injury (Stapleton et al., 2008). 
1.2 Glucocorticoids 
In addition to the effects of dietary composition already introduced, steroid hormones play a 
role in controlling metabolism and have been implicated in the pathogenesis of obesity. 
Glucocorticoids are synthesised from cholesterol in the adrenal cortex. They are involved in 
many physiological processes including development, metabolism, response to stress and 
immunity. In recent decades evidence has emerged proposing a link between altered 
glucocorticoid metabolism and the development of obesity and associated cardiovascular 
diseases. The link will be further explored in this thesis and therefore glucocorticoids are 
introduced in the following section. 
1.2.1 Synthesis and secretion of glucocorticoids 
Both the synthesis and the secretion of glucocorticoids are controlled by the hypothalamic-
pituitary-adrenal (HPA) axis (Figure 1.3). The hypothalamus secretes corticotrophin-
releasing hormone (CRH) and arginine vasopressin (AVP) which cleave pro-
opiomelanocortin (POMC) in the anterior pituitary to produce adrenocorticotrophic hormone 
(ACTH). This hormone is released in to the circulation to travel to the adrenal glands and 
stimulate glucocorticoid synthesis. ACTH can also induce the synthesis and secretion of 
mineralocorticoids and androgen precursors from the adrenal. 
Glucocorticoids are synthesised from cholesterol in the zona fasciculata of the adrenal 
cortex. Their synthetic pathway is catalysed by many enzymes including members of the 




Figure 1.3 Hypothalamic-pituitary-adrenal axis 
The hypothalamic-pituitary-adrenal (HPA) axis is responsible for the production of 
glucocorticoids from their cholesterol precursors in the adrenal glands. The HPA axis is 
regulated by circadian rhythms and negative feedback. Stimulation of the hypothalamus 
induces secretion of corticotrophin-releasing hormones (CRH) and arginine vasopressin 
(AVP). This causes release of adrenocorticotrophin (ACTH) from the pituitary gland which 
travels through the circulation to the adrenal gland where it instigates production of cortisol 
in humans and corticosterone in rodents. Glucocorticoids inhibit production of CRH and 




Figure 1.4 Steroid synthesis 




by increasing cholesterol uptake in cortical cells, stimulating the transport of cholesterol to 
the mitochondria and increasing cholesterol binding to an enzyme which cleaves cholesterol 
to pregnenolone (Simpson and Waterman, 1988). In man, cortisol is the primary 
glucocorticoid, whereas in rodents corticosterone is dominant due to the lack of 17α 
hydroxylase (van Weerden et al., 1992). 
The HPA axis is tightly controlled by many different mechanisms. CRH is released in 
response to physical and psychological stressors such as heat, infection or emotional stress. 
Glucocorticoids regulate their own concentrations in plasma by negative feedback, with 
elevated levels inhibiting the transcription and release of CRH, and the transcription and 
cleavage of POMC (Gagner and Drouin, 1985; Ma et al., 2001). Additionally there is a 24hr 
circadian rhythm of circulating glucocorticoid levels. In humans, glucocorticoid 
concentrations are highest in the morning with the nadir in the evening (Nussey and 
Whitehead, 2001). In nocturnal animals, levels are lowest in the morning, rising over the day 
during the rest phase (Windle et al., 1998). Glucocorticoid availability is also controlled by 
its interaction with carrier proteins; 80-90% is bound to corticosteroid binding-globulin 
(CBG) and 10-15% is bound to albumin (Lewis et al., 2005). The remaining ~5% is free to 
diffuse into cells and bind to receptors. Hormones bound to carrier proteins are believed to 
be inactive and provide a ‘back-up’ of circulating hormone if required. 
1.2.2 Glucocorticoid signalling 
The effects of glucocorticoids are mediated by two nuclear receptors; glucocorticoid 
receptors (GR) and mineralocorticoid receptors (MR). GRs are widely expressed and are 
responsible for the majority of the physiological effects of glucocorticoids. MRs have a 
higher affinity for glucocorticoids than GRs but are only expressed in certain tissues 
(Rupprecht et al., 1993). Illicit activation of MR by glucocorticoids in these tissues is 
controlled by co-localisation of MRs to the enzyme 11β-hydroxysteroid dehydrogenase type 
2 (11β-HSD2) (introduced later in section 1.2.3.2) which can metabolise glucocorticoids to 
inert metabolites.  
When glucocorticoids are not present, GR is held in the cytoplasm as part of a large protein 
complex which maintains an inactive conformational state which is favourable to high-
affinity ligand binding. Upon binding of glucocorticoids the protein complex dissociates and 
the active receptor dimerises and translocates to the nucleus. Once in the nucleus the 
activated GR binds to DNA at glucocorticoid response elements (GRE), upstream of the 
promoter region in glucocorticoid sensitive genes (Smoak and Cidlowski, 2004). The 
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resulting effect is to either induce or repress transcription of the target gene. The number of 
target genes of GR differs between cell types with at least 100 in some (Barnes, 1998; Reddy 
et al., 2009). GR can also indirectly regulate gene expression in its monomeric form through 
interaction with other transcription factors (Beck et al., 2009). Recent studies have shown 
that glucocorticoids can also exert effects through many non-genomic pathways. This 
includes incorporation into lipid membranes to alter the activity of membrane bound 
proteins, association with membrane-bound receptors and changing the phosphorylation state 
of caveolin resulting in activation of the protein kinase B/Akt pathway (Stahn and Buttgereit, 
2008). 
1.2.3 Glucocorticoid metabolism 
Glucocorticoid concentrations are additionally regulated by metabolism within target tissues 
(Figure 1.5). The steroids can be converted between active and inactive forms by two 
isozymes of the 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme, thus controlling the 
activation of GR and MR. Permanent clearance and metabolism of glucocorticoids 
predominantly occurs in the liver controlled by a series of enzymes which catalyse A-ring 
reduction. The enzymes involved in glucocorticoid metabolism will be introduced below. 
1.2.3.1 11β-HSD1 
11β-HSD1 is a bi-directional enzyme in vitro but reductase activity predominates in vivo, 
converting inactive 11-keto metabolites into their active form. Transgenic mice lacking 
functional 11β-HSD1 cannot convert 11-dehydrocorticosterone to corticosterone 
(Kotelevtsev et al., 1997). The direction of the reaction in vivo is controlled by a second 
enzyme hexose-6-phosphate dehydrogenase (H6PDH). Both 11β-HSD1 and H6PDH are 
found in the lumen of the ER, where H6PDH generates the reduced cofactor nicotinamide 
adenine dinucleotide phosphate (NADPH) which is required for the reductase activity of 
11β-HSD1 (Bujalska et al., 2005). The reliance of 11β-HSD1 on the provision of this 
cofactor is demonstrated in H6PDH knock-out mice which cannot perform the reductase 
reaction (Lavery et al., 2006). 11β-HSD1 is widely expressed in the body, mainly in tissues 
with a high proportion of GR such as liver, adipose tissue, skeletal muscle, lung, brain, 
gonads and VSMCs and its expression and activity is controlled by many factors including 
cytokines, insulin, growth factors, sex steroids and glucocorticoids. Studies suggest that the 
expression and activity of 11β-HSD1 is lower in adipose tissue of lean women than men 
(Paulsen et al., 2007) which may result in sex specific profiles of glucocorticoids. It is 
widely believed that 11β-HSD1 is important in amplifying local glucocorticoid 
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Figure 1.5 Glucocorticoid metabolism 
Pathways and enzymes involved in the metabolism of corticosterone, the active 





concentrations in target tissues as well as contributing to circulating concentrations (Seckl 
and Walker, 2001). 
1.2.3.2 11β-HSD2 
The second isozyme of 11β-HSD is dependent on the cofactor NAD+ for dehydrogenation of 
glucocorticoids in vivo (Brown et al., 1993). 11β-HSD2 catalyses the conversion of active 
glucocorticoids, cortisol and corticosterone, to their inactive 11-keto metabolites. The 
enzyme is predominantly expressed in mineralocorticoid target tissues such as the kidney, 
salivary glands and sweat glands (Walker and Stewart, 2003). It is believed that the primary 
function of 11β-HSD2 is to inactivate glucocorticoids and thus protect MRs from 
inappropriate activation (Funder et al., 1988). 11β-HSD2 is also highly expressed in the 
placenta, where it is thought to protect the developing fetus from unnecessary glucocorticoid 
receptor activation which could affect development (see section 1.4.1). 
1.2.3.3 5α-Reductase 
5α-Reductase (5αR) catalyzes the reduction of a double bond in active glucocorticoids 
yielding 5α-dihydro metabolites. Two isozymes of 5αR exist, which are products of 2 
different genes (Russell and Wilson, 1994). While both are involved in the reduction of 
steroids, their location and substrate preferences differ. 5αR (type 1) is found in the liver, 
adipose tissue and brain; this isozyme is predominantly discussed in this thesis due to its role 
in glucocorticoid metabolism (thus any references to the enzyme should be considered to be 
type 1 unless otherwise stated). 5αR2 (type 2) is expressed in male reproductive tissues such 
as prostate, epidydimis and seminal vesicles (Russell and Wilson, 1994). The type 2 isozyme 
reduces testosterone to 5α-dihydrotestosterone, which is a more potent ligand at the 
androgen receptor than testosterone (Siiteri and Wilson, 1974). In rodents 5αR1 has a greater 
affinity for androgens, progesterones and glucocorticoids than 5αR2 (Normington and 
Russell, 1992). In the liver and adipose tissue, 5αR1 is involved in the reduction of active 
glucocorticoids, though the products of the reaction are still able to activate the 
glucocorticoid receptor (McInnes et al., 2004). 
1.2.3.4 5β-Reductase 
5β-Reductase (5βR) is also involved in the metabolism of steroids, reducing the double bond 
within the A ring. Unlike the products of 5αR, the resulting 5β-dihydro metabolites have a 
cis formation. The expression of this reductase is also more limited, mostly found in the liver 
with a small amount expressed in kidney (Charbonneau and The, 2001). Mutations in 5βR 
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lead to defects in bile acid metabolism suggesting this is one of its key functions (Palermo et 
al., 2008). In terms of glucocorticoid metabolism, 5βR can reduce both active and inactive 
metabolites, with the resulting products unable to elicit a response at the glucocorticoid 
receptor (McInnes et al., 2004). 
1.2.3.5 3α-Hydroxysteroid dehydrogenase 
5α- and 5β-dihydro metabolites are rapidly reduced in vivo by 3α-hydroxysteroid 
dehydrogenase (3α-HSD) to produce 5α- or 5β-tetrahydro metabolites. It is believed that the 
role of 3α-HSD is to catalyze permanent metabolism of steroids to inactive forms. However 
in vivo, 3α-HSD can function in both directions depending on the availability of cofactors 
NADP
+
 and NADPH. In prostate 3α-HSD regenerates 5α-dihydrotestosterone (Rizner et al., 
2003) which, as mentioned, is more potent than testosterone itself, suggesting that 3α-HSDs 
are important in controlling the concentrations of biologically active 5α-dihydro metabolites. 
1.2.4 Physiological effects of glucocorticoids 
Glucocorticoids have a broad range of effects throughout the body; these depend upon the 
target tissue, the receptor that is activated and the length of exposure to the steroid. The 
importance of glucocorticoids is highlighted in two diseases: Addison’s disease which is due 
to a deficiency in glucocorticoid production, and Cushing’s syndrome associated with 
glucocorticoid excess. Patients with Addison’s disease suffer muscle weakness, hypotension, 
weight loss, hypoglycaemia and depression. Cushing’s syndrome is characterised by 
abdominal obesity, hypertension, insulin resistance, dyslipidemia and increased 
cardiovascular disease risk. Glucocorticoids are involved in many physiological processes 
and have a key role in mediating inflammation; those discussed below are of particular 
relevance to this thesis. 
1.2.4.1 Developmental effects 
Glucocorticoids are vital for normal fetal development. Evidence for this comes from both 
mouse and man; mice with genetic disruption of GR die within a few hours of birth due to 
respiratory failure (Cole et al., 1995a) and synthetic glucocorticoids are administered 
clinically to fetuses at risk of pre-term delivery in order to accelerate lung development 
(Crowley et al., 1990). GR is expressed from mid-gestation, corresponding with a rise in 
maternal cortisol levels which correlates with increased organ maturity of the fetus (Cole et 
al., 1995b). Glucocorticoids are important for the growth and development of the brain, 
heart, lungs and many other organs. While the evidence clearly demonstrates glucocorticoid 
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signalling is vital during development, excess exposure of the fetus is associated with an 
increased risk of diabetes, hypertension and obesity in adulthood (Doyle et al., 2000; Dalziel 
et al., 2005), discussed in more detail in section 1.4.1. 
1.2.4.2 Metabolism 
Glucocorticoids mobilise energy sources for usage in the form of glucose and NEFAs, 
opposing the effects of insulin which induces fuel storage. The effects are mediated by many 
tissues; in the brain glucocorticoids increase appetite, to boost intake of fat and sugar 
(Dallman et al., 2004). In the liver, glucocorticoids activate gluconeogenic pathways through 
increased transcription of the enzymes PEPCK (Imai et al., 1990) and glucose-6- phosphate 
(G6P) (van Schaftingen and Gerin, 2002). Additionally, glucocorticoids initiate the release 
of hepatic fatty acids and decrease liver mitochondrial β-oxidation (Macfarlane et al., 2008). 
In skeletal muscle, glucocorticoids induce proteolysis to generate substrates for 
gluconeogenesis in the liver (Jackman and Kandarian, 2004), and reduce glucose uptake to 
maintain a circulating energy source. The effects of glucocorticoids in the adipose tissue are 
dependent on other hormones, namely insulin and catecholamines. When insulin is low and 
catecholamines high, glucocorticoids induce lipolysis to provide an energy source in the 
form of NEFAs to the surrounding tissues. When insulin is high and catecholamines low, 
and therefore lipolysis is suppressed, glucocorticoids have the opposite effect and promote 
lipid storage (Macfarlane et al., 2008). 
1.2.4.3 Blood pressure 
Glucocorticoids act through multiple mechanisms in the kidney, heart and vasculature to 
maintain normal blood pressure. The importance of glucocorticoids in the maintenance of 
blood pressure is evident in the clinical conditions Cushing’s disease, in which excess 
glucocorticoids cause hypertension, and Addison’s disease, in which a lack of 
glucocorticoids is associated with hypotension. In the kidney, glucocorticoids increase salt 
retention leading to water retention and an increase in plasma volume. This is due to the 
effects of GR and MR on sodium retention in the nephron, although subtle effects in other 
organs may also be involved (Grunfeld, 1990). Glucocorticoids have direct effects on the 
vasculature through GR, and are proposed to increase contractility and therefore peripheral 
resistance. The exact mechanisms of glucocorticoid-dependent arterial contraction are 
imperfectly understood. Although glucocorticoids characteristically contract vessels in vivo 
they do not directly induce contraction in isolated arteries and veins (Hadoke et al., 2006b). 
The changes in peripheral resistance may also reflect a reduction in vasodilation as 
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glucocorticoids have been shown to reduce-acetylcholine mediated vasorelaxation and also 
reduce the synthesis of nitric oxide and prostaglandins (Mangos et al., 2000). However, this 
has not been reproduced in the literature or our laboratory without concomitant inhibition of 
11β-HSD1 which may also impair endothelial cell function (Personal communication Dr. P 
Hadoke, University of Edinburgh). Glucocorticoids can cause hypertension by activation of 
MR, which is highly expressed in the kidney and has a higher affinity for the steroid than 
GR. Renal MR is normally protected by 11β-HSD2 which metabolises cortisol; however, 
deficiency of this enzyme in humans (Ferrari, 2010) and rodents (Kotelevtsev et al., 1999) 
results in hypertension. 
1.2.5 Glucocorticoids and obesity 
There is undoubtedly a correlation between circulating levels of cortisol and the 
development of obesity and metabolic complications seen in Cushing’s disease. Diet-induced 
obesity is also associated with many cardiovascular risk factors such as insulin resistance, 
dyslipidemia and hypertension; collectively termed the metabolic syndrome (see section 
1.1.6). The similarities between Cushing’s disease and the metabolic syndrome led to a 
number of studies investigating the hypothesis that alterations in glucocorticoid production 
or secretion may contribute to the development of obesity and the metabolic syndrome. 
Secretion of cortisol from the adrenals is increased in obese subjects and plasma 
concentrations correlate with features of the metabolic syndrome (reviewed in (Seckl et al., 
2004). Many studies in humans and animal models have demonstrated the importance of 
local, or pre-receptor, glucocorticoid metabolism in the liver and adipose tissue in the 
development of obesity and the associated cardiovascular risk factors. 
1.2.5.1 Human studies 
The development of stable isotope tracers enabled the activity of 11β-HSD1 to be measured 
in humans and demonstrated substantial peripheral regeneration of cortisol (Sandeep et al., 
2005). In obese subjects, hepatic glucocorticoid metabolism by 11β-HSD1 is reduced 
whereas expression and activity of the enzyme is increased in subcutaneous adipose tissue 
biopsies (Rask et al., 2001), with the latter confirmed by in vivo microdialysis (Sandeep et 
al., 2005). However, this is not the case in all studies; one study reported no difference in 
11β-HSD1 transcription in subcutaneous adipose tissue from lean and obese subjects, and a 
negative correlation between BMI and 11β-HSD1 activity in omental preadipocytes 
(Tomlinson et al., 2002). More heterogeneity in the human literature exists with respect to 
glucocorticoid regeneration in visceral adipose tissue, with some studies reporting that this is 
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increased in obesity (Desbriere et al., 2006; Michailidou et al., 2007; Veilleux et al., 2009), 
whereas others report no change (Tomlinson et al., 2002; Simonyte et al., 2009). It is likely 
that conflicting results can be attributed to the type of adipose material (preadipocyte, 
adipocytes or whole tissues), the health of the patients, and the level of analysis (mRNA 
expression or enzymatic activity). Interestingly, most studies investigating the activity of 
11β-HSD1 in humans report higher levels in visceral adipose than subcutaneous (Bujalska et 
al., 1999; Simonyte et al., 2009; Veilleux et al., 2009) which may suggest greater 
glucocorticoid regeneration in males due to their propensity to store adipose in this depot. In 
addition the enzyme activity is correlated with adipocyte size (Veilleux et al., 2009). 
1.2.5.2 Rodent models 
Obese Zucker rats, which are leptin resistant due to a mutation in the leptin receptor gene, 
have tissue specific alterations in glucocorticoid metabolism. In the liver, 11β-HSD1 
expression and activity are decreased whilst 5αR activity is increased (Livingstone et al., 
2000a), suggesting reduced local concentrations of active glucocorticoids. In contrast, in 
visceral adipose tissue, 11β-HSD1 activity is increased, predicting enhanced regeneration of 
glucocorticoids and potentially promoting obesity (Livingstone et al., 2000a). Another group 
demonstrated changes in 11β-HSD1, and GR and MR signalling in the brains of obese 
Zucker rats (Mattsson et al., 2003) which may influence the HPA axis. Studies in ob/ob mice 
report similar tissue-specific changes in glucocorticoid metabolism to those seen in Obese 
Zucker rats. In ob/ob mouse liver, 11β-HSD1 activity, but not mRNA, is decreased and 5βR 
expression and activity increased, whereas no changes in 5αR expression were seen 
(Livingstone et al., 2009). In adipose tissue, 11β-HSD1 expression and activity were 
increased in visceral depots but decreased in subcutaneous depots (Livingstone et al., 2009). 
This suggests that the anatomical location of adipose may be important in controlling 
glucocorticoid metabolism and is in agreement with the findings that the metabolic 
complications associated with visceral adipose accumulation are more profound than those 
seen with subcutaneous deposition. Whilst the obesity in Zucker rats and ob/ob mice is 
primarily due to changes in leptin signalling, treatment with glucocorticoid receptor 
antagonists reverses the obese phenotype (Yukimura et al., 1978; Shimomura et al., 1987). 
This highlights alterations in glucocorticoid metabolism as a secondary, or additional, 
mechanism leading to obesity and the metabolic syndrome in these models. 
Changes in glucocorticoid metabolism are also apparent in rodent models of diet-induced 
obesity. Wistar rats fed a high fat, normal carbohydrate, diet had reduced 11β-HSD1 activity 
in liver, subcutaneous and omental adipose tissue after just 3 weeks. However, after 20 
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weeks of the feeding regimen these changes were no longer present (Drake et al., 2005a). 
Interestingly, mice fed an obesogenic diet for 18 weeks showed decreased 11β-HSD1 
activity in adipose tissue (Morton et al., 2004), similar to the short term changes seen in rats. 
Given that increased local glucocorticoid regeneration causes adipose accumulation, this 
may reflect a protective mechanism to stop lipid deposition and maintain insulin sensitivity. 
In support of this, mice with adipose-specific over-expression of 11β-HSD1 show features of 
the metabolic syndrome (Masuzaki et al., 2001), and mice with targeted disruption of the 
enzyme have improved glucose tolerance and insulin sensitivity when fed a high-fat diet 
(Morton et al., 2001). Transgenic over-expression of 11β-HSD1in the liver leads to insulin 
resistance and dyslipidemia (Paterson et al., 2004) suggesting that tissue specific patterns of 
glucocorticoid regeneration may be important in determining the deleterious effects of an 
obesogenic diet. 
As well as changes in 11β-HSD1, increased glucocorticoid metabolism by the A-ring 
reductases was reported in the obese Zucker rat and ob/ob mouse as mentioned above. 
Increased activity of hepatic 5βR was found in high fat fed rats (Drake et al., 2005a) and 
ob/ob and db/db mice (Livingstone et al., 2009). Furthermore, 5αR knock-out mice develop 
fatty liver and glucose intolerance (Livingstone, 2009). These studies support the suggestion 
that increased concentrations of glucocorticoid have a role in the pathogenesis of the 
metabolic syndrome in rodents. 
The exact mechanisms controlling peripheral glucocorticoid metabolism, and the changes in 
obesity, are not clear. However, the consistent finding of alterations in obese humans and 
rodents, as well as the results of deletion or over-expression of key enzymes in the metabolic 
pathway, have led to the consensus that reduction of active glucocorticoids is beneficial to 
metabolism.  
1.2.5.3 Pharmacological inhibition of 11β-HSD1 
Glucocorticoids are administered as replacement therapy in glucocorticoid deficiency, and in 
higher doses as anti-inflammatory agents or as immunosuppressants. Following the 
discovery that changes in peripheral glucocorticoid metabolism are evident in obese humans 
and animals, many laboratories have focused on developing inhibitors of 11β-HSD1 in 
recent years. Successful and selective pharmacological inhibition of 11β-HSD1 has been 
reported by many companies. Treatment with these inhibitors has been consistently shown to 
improve insulin sensitivity in both dietary and genetic rodent models of obesity (Alberts et 
al., 2002; Alberts et al., 2003; Hermanowski-Vosatka et al., 2005). Translation of these 
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inhibitor studies to the clinical environment has recently been undertaken with trials in early 
stages; one randomised placebo controlled study of patients with type 2 diabetes has reported 
that treatment with an 11β-HSD1 inhibitor for 12 weeks improved hyperglycaemia 
(Rosenstock et al.). However, studies using a second inhibitor did not report alterations in 
fasting plasma glucose but did find modest improvements in body weight and blood pressure 
(Feig et al., 2011). The results of ongoing trials by several drug companies are therefore 
eagerly awaited. 
1.3  Sex steroids 
A potential role for sex hormones in the development of obesity and associated 
cardiovascular disease is alluded to by the sex specific incidence of these conditions 
(introduced in section 1.1.1). There are three main classes of sex steroid, androgens, 
estrogens and progestogens which all act on nuclear receptors in a variety of tissues. The 
relative concentrations of androgens, estrogens and progestogens are sex dependent with 
androgens predominant in males and estrogens and progestogens predominating in females 
pre-menopause. In recent years, sex steroids have been shown to play a role in determining 
the anatomical deposition of adipose tissue (section 1.1.1.1) and development of 
cardiovascular diseases (section 1.1.1.2). Estrogen is of particular interest due to the apparent 
protection of women from cardiovascular disease despite high incidence of obesity. 
Therefore, this thesis and introduction will concentrate on the role of estrogen in the 
development of obesity and cardiometabolic disease, however, a role for androgens has also 
been proposed which has been extensively reviewed elsewhere (Pasquali, 2006; Renato, 
2006; Mammi et al., 2012). 
1.3.1 Synthesis and secretion 
Sex hormones are primarily synthesised and secreted from the gonads and their production is 
regulated by the hypothalamic-pituitary-gonadal (HPG) axis (Figure 1.6). The hypothalamus 
secretes gonadotrophin releasing hormone (GnRH) which binds to receptors in the pituitary 
inducing the release of the gonadotrophins, luteinising hormone (LH) and follicular 
stimulating hormone (FSH). In the ovaries the gonadotrophins activate production of 
estrogens and progesterone which control the ovarian and menstrual cycle. In males, LH 




Figure 1.6 Hypothalamic-pituitary-gonadal axis 
The hypothalamic-pituitary-gonadal (HPG) axis controls the production of sex steroids in the 
gonads. Stimulation of the hypothalamus induces secretion of gonadotrophin-releasing 
hormone (GnRH). This causes release of luteinising hormone (LH) and follicular stimulating 
hormone (FSH) from the pituitary gland which travel through the circulation to the gonads 
instigating production of estrogen (E) and progesterone in the ovary and testosterone in the 
testes. Sex steroids regulate their own production; testosterone inhibits production of GnRH, 
LH and FSH; low concentrations of estrogen similarly regulate negative feedback but high 





Like all steroids, sex hormones are synthesised from pregnenolone, a derivative of 
cholesterol. Oxidation reactions produce progestogens which can, in turn, be oxidised to 
androgens and, finally, estrogens (Figure 1.4). While the gonads are the primary sites of sex 
steroid synthesis, the placenta has an important role in their production during pregnancy and 
the adrenal cortex produces some progestogens and androgens in humans which can then be 
converted to more active metabolites in the gonads. Other tissues contain the necessary 
enzymes to produce sex steroids, including bone and adipose. In women this is particularly 
noticeable following the menopause when ovarian function reduces. Estrogens can then be 
formed by aromatisation of androgens, catalysed by the enzyme aromatase (CYP19A1) 
(Figure 1.4). In women, aromatase expression increases after the menopause (Cleland et al., 
1985), this has also been found in rats following ovariectomy (Zhao et al., 2005). 
The HPG axis is regulated by negative feedback. Both estrogen and testosterone can inhibit 
the production of GnRH in the hypothalamus, and gonadotrophins in the pituitary. In women 
the feedback is dependent on the concentrations of estrogen; low levels are associated with 
negative feedback but high levels can have a positive effect, increasing GnRH and LH 
release to induce ovulation. The two mechanisms of feedback activated by estrogens control 
the maturation and release of the ovum for fertilisation, and explain the cyclic nature of its 
production. In humans, the bioavailability of androgens and estrogen is also controlled by 
sex hormone binding globulin (SHBG). SHBG is synthesised and secreted from the liver into 
the bloodstream where it binds androgens and estrogens, leaving only low concentrations 
free to activate receptors. SHBG synthesis is increased by high concentrations of estrogens, 
decreased by androgens and glucocorticoids, and reduced in obesity in children and adults. 
While SHBG is an important determinant of the bioavailability of sex steroids in humans, 
rodents do not have circulating binding proteins for androgens and estrogens postnatally 
(Corvol and Bardin, 1973; Renoir et al., 1980). 
1.3.2 Androgen and estrogen signalling 
Estrogens mediate their effects via α and β estrogen receptors (ER) and both isoforms of the 
ER are expressed in a wide range of tissues. ERα and ERβ are expressed in classic estrogen 
target tissues, such as the female reproductive system, as well as in blood vessels and 
adipose. ERα alone is found in the hippocampus, hepatocytes, and interstitial cells of the 
kidney while ERβ is expressed in the thyroid and non hippocampal areas of the brain (Taylor 
and Al-Azzawi, 2000). Androgens bind the androgen receptor (AR) which is found in testis, 
prostate, adipose tissue (Pedersen et al., 1996) and many other cells. The intracellular 5α-
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reduced form of testosterone, dihydrotestosterone, has a much higher affinity for the receptor 
(Siiteri and Wilson, 1974). 
ERs and ARs are both nuclear receptors which act as ligand regulated transcription factors to 
induce or repress gene expression. Upon ligand activation the receptors dimerise and bind to 
hormone response elements in the promoter regions of target genes in concert with other 
proteins and transcription factors. ERs and ARs can also have rapid effects on proteins which 
do not have hormone response elements in their genes, demonstrating non-genomic actions 
of the steroids. These are suggested to be mediated by membrane or cytosolic receptors 
which activate protein kinase cascades resulting in alterations in the function of the target 
protein (Heinlein and Chang, 2002; Bjornstrom and Sjoberg, 2005). 
1.3.3 Estrogens and obesity 
Although estrogen has been proposed to play a role in obesity and the associated metabolic 
complications the exact mechanisms through which it acts are incompletely understood. It is 
likely to involve many factors including; changes in lipid metabolism, glucose metabolism, 
and the anatomical distribution of adipose tissue. 
1.3.3.1 Humans 
The effect of estrogen on obesity and cardiovascular disease is demonstrated by the 
increased prevalence of both following the menopause. The discontinuation of estrogen 
synthesis in the ovaries is associated with increased adipose accumulation in central or 
visceral depots (Tchernof and Poehlman, 1998). Treatment of post-menopausal women with 
hormone replacement therapy (HRT), which includes estrogens, reduces visceral adipose 
accumulation and alters the plasma lipid profile (Sorensen et al., 2001; Sumino et al., 2003). 
Discrepancies have been found between observational and randomised clinical trials of HRT, 
with an increased incidence of cardiovascular disease reported in some clinical trials 
(Manson et al., 2003; WHISC, 2004). This often occurred in the early years of taking HRT 
and diminished with time, and has been suggested to be due to an increase in thrombogenesis 
which is not sustained in the longer term (Stevenson, 2004). Further analysis of studies has 
suggested the benefits of HRT may be limited in certain populations, such as those with 
diabetes (Salpeter et al., 2006) and may be dependent on the dose of steroids, type of 
preparation used and route of administration (Stevenson, 2004). Another population of 
patients with abnormal concentrations of endogenous estrogen are those suffering from 
polycystic ovary syndrome (PCOS), in whom estrogen concentrations are within the normal 
range for half of the cycle but fail to increase pre-ovulation (Franks, 1995). Aside from 
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chronic anovulation and fertility issues, PCOS is associated with central obesity and insulin 
resistance (Gambineri et al., 2002). However, in addition to changes in estrogen PCOS is 
characterised by hyperandrogenism which is also likely to play a role in the associated 
metabolic complications.  
1.3.3.2 Animal Models 
In animals (rats and mice) ovariectomy is used as a model of menopause and results in 
increased adiposity which can be ameliorated by exogenous estradiol treatment (McElroy 
and Wade, 1987; Hong et al., 2009). The role of estrogen in controlling adiposity is further 
demonstrated in transgenic mice with altered estrogen signalling and synthesis. Following 
deletion of ERα, both male and female mice become obese and develop insulin resistance 
(Heine et al., 2000). Aromatase KO mice, which are unable to synthesise estrogen from 
testosterone, also accumulate intra-abdominal adipose tissue and have fasting 
hyperinsulinemia (Jones et al., 2001). Interestingly, ERβ KO mice are not obese, suggesting 
that the effects of estrogen on adiposity are mediated by the α-receptor. Recently, an in depth 
study of neuron specific ERα deletion found that lack of estrogen signalling increases 
adiposity and causes changes in metabolism (Xu et al., 2011). This suggests the effects of 
estrogen on obesity may be modulated by both central and peripheral mechanisms in a 
variety of tissues. 
1.3.4 Estrogens and the vasculature 
In addition to its beneficial effects on metabolic status (section 1.3.3), it has been proposed 
that estrogen has direct effects on the vasculature (White, 2002). This may play a role in the 
decreased incidence of cardiovascular disease seen in women despite greater prevalence of 
obesity. 
1.3.4.1 Estrogen and vascular function 
Both ERα and ERβ are expressed in endothelial cells and VSMCs, though their expression is 
heterogeneous and depends on vascular bed and gender (Mendelsohn and Karas, 2005). Sex 
differences have been reported in the expression and function of endothelium-derived 
vasodilators (Kauser and Rubanyi, 1994; McCulloch and Randall, 1998; Villar et al., 2008). 
Estrogen treatment can induce endothelium-dependent and independent vasodilation in the 
forearm of postmenopausal women, as well as increasing nitric oxide (Tagawa et al., 1997). 
In addition it has been reported that endothelium-dependent hyperpolarizing factors can 
mediate vasodilation in the absence of nitric oxide to a greater extent in females than males 
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(McCulloch and Randall, 1998). Although sex differences in nitric oxide and vasodilation 
are consistently found, changes in vasoconstriction are more controversial. Some studies 
report a decreased response to vasoconstrictors in females, while others suggest no sex 
differences or even an increased reactivity (Sader and Celermajer, 2002; Thompson and 
Khalil, 2003). Many studies have proposed a role for estrogen in calcium flux, either in 
attenuating influx or stimulating efflux, which would reduce vascular contraction and 
enhance dilation (Ho and Liao, 2002).  
1.3.4.2 Estrogen and vascular lesion formation 
Estrogen has been proposed to slow the progression of atherosclerosis in humans and 
animals (Bourassa et al., 1996). Although changes in plasma lipids and a reduction in other 
metabolic risk factors contribute to this effect, a further protection independent of these 
parameters suggests specific effects on the vessel wall (Bourassa et al., 1996). Estrogen 
treatment of rabbits undergoing balloon injury surgery to the aorta and iliac arteries reduces 
neointimal proliferation (Foegh et al., 1994). This may be due to reduced expression of 
adhesion molecules such as vascular cell adhesion molecule-1, intercellular adhesion 
molecule-1, and E selectin (Frazier-Jessen and Kovacs, 1995; Caulin-Glaser et al., 1996) 
which recruit inflammatory cells to sites of vascular injury, though this has not been 
consistently reported. Estrogen has been found to inhibit the expression of other pro-
inflammatory cytokines which enhance lesion formation and reduce mitogenic cytokine 
expression and activity, reducing VSMC proliferation (Foegh et al., 1994; Chen et al., 
1996b). Interestingly, exogenous estrogen was shown to reduce neointimal proliferation to a 
similar extent in ERα KO and WT mice (Iafrati et al., 1997), suggesting a role for ERβ or 
another mechanism independent from the classic receptor activation. 
1.4 Early-life programming 
The environment experienced in utero and during early-life has been hypothesised to 
program disease risk in adulthood (Barker, 1998). In many populations around the world, 
insults during pregnancy have been shown to increase the prevalence of later disease, 
independent of other known risk factors (such as smoking and social class). Programming 
effects were first described in association with low birth weight, suggesting exposure to an 
adverse environment in utero as a stimulus (Barker et al., 1989). Two major hypotheses have 
been advanced to explain this link between low birth weight and later disease: over-exposure 
to glucocorticoids during development (e.g. as a consequence of exposure to maternal stress) 
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and inadequate fetal nutrition (e.g. as a consequence of a poor or restricted maternal diet 
during pregnancy). It has been proposed that the fetus adapts in order to maximise survival 
in a poor extra-uterine environment; however this results in a predisposition to disease when 
the pre- and postnatal environments are not matched (Hales and Barker, 1992). 
1.4.1 Glucocorticoid exposure 
Steroids have long-term effects on tissue structure and function. Neonatal exposure to 
androgens programs hepatic metabolism of steroids, alters sexually dimorphic structures in 
the brain and affects sexual behaviour (Gustafsson et al., 1975; Gustafsson et al., 1983). 
Over-exposure of the fetus to glucocorticoids has been proposed as a potential mechanism of 
early-life programming. GRs are expressed in the fetus (Cole et al., 1995b) and placenta 
(Sun et al., 1997) from early in development. MRs, which can also be activated by 
glucocorticoids, are expressed in fetal tissues but with a more distinct pattern and at a later 
stage in gestation (Brown et al., 1996). As discussed (section 1.2.4.1) glucocorticoids are 
important in the growth and maturation of organs, such that they are administered to women 
at risk of pre-term delivery. 
In humans, antenatal glucocorticoid treatment results in reduced birth weight and long-term 
increases in blood pressure and changes in myocardium structure (Doyle et al., 2000; Bloom 
et al., 2001). As well as affecting the cardiovascular system, prenatal exposure to 
glucocorticoids alters brain structure associated with changes in memory and behaviour 
(Welberg et al., 2001). Intrauterine growth retardation itself is associated with increased 
circulating concentrations of cortisol in the fetus (Goland et al., 1993). Additionally, cortisol 
can affect placenta size, by inhibiting the production of growth factors, with subsequent 
effects on the fetus such as reduced nutrient supply and growth retardation. In sheep and rat 
models of in utero glucocorticoid exposure birth weight is reduced. When offspring of rats 
treated with the synthetic glucocorticoid dexamethasone are followed to adulthood they have 
higher blood pressure, changes in vascular function and structure, hyperglycaemia and 
hyperinsulinemia (Nyirenda et al., 1998; O'Regan et al., 2004; Hadoke et al., 2006a). 
Exposure to glucocorticoids during development can also permanently program HPA axis 
activity, which, given the many functions of glucocorticoids (section 1.2.4), is likely to 
influence physiology and disease risk. The timing of exposure to glucocorticoids is critical in 
programming these long term outcomes, in rats, glucocorticoid administration in the last 
week of pregnancy confers the changes in adult physiology, whereas exposure in the first 
week has no effects on glucose-insulin homeostasis and blood pressure (Levitt et al., 1996). 
As well as exogenous treatment, fetal glucocorticoid over-exposure can also occur as a 
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consequence of inhibition or transgenic deletion of 11β-HSD2 which deactivates 
glucocorticoids in the placenta. The resulting outcome is similar to that seen in the 
dexamethasone-treated rat, with reduced birth weight and altered behaviour (Holmes et al., 
2006). Maternal glucocorticoids are likely to be increased by stress as a consequence of 
many stimuli including unbalanced nutrition. It is therefore possible that early life 
programming occurs as a consequence of both changes in nutrition (introduced below) and 
glucocorticoids. 
1.4.2 Maternal under-nutrition 
The ‘Dutch Hunger Winter’, a period of famine in 1944-1945 which affected the western 
Netherlands, provided a data set to study the effects of maternal under-nutrition. Babies 
exposed to the famine in utero have higher incidence of glucose intolerance (Ravelli et al., 
1998) and hypertension (Roseboom et al., 1999) in adulthood. Interestingly, the same 
increase in later diseases was not seen in a population from Leningrad that were conceived 
and born during a severe famine (Stanner et al., 1997). However, the children exposed to 
malnutrition in utero also had little food post-natally and this consistency in diet is 
hypothesised to have mitigated any effects of programming. In many other populations food 
restrictions or specific diets during pregnancy have led to low birth weight and increases in 
cardiovascular disease have been reported (Prentice et al., 1987; Godfrey et al., 1994; 
Reynolds et al., 2001; Reynolds et al., 2010). Dietary composition, as well as calorific or 
nutritional value, has been shown to influence fetal development with studies suggesting that 
deficiencies in specific micronutrients may also program the fetus (Boucher, 1998). 
Although trials providing expectant mothers with micronutrient supplementation have not 
shown effects on offspring birth weight (Fall et al., 2003; Merialdi et al., 2003), effects on 
adult health are still possible so that long-term follow up studies are required. 
Animal studies have demonstrated similar effects of maternal under-nutrition during 
pregnancy. Rats fed a low protein diet during pregnancy have low birth weight offspring, 
which display insulin resistance and hyperglycaemia in later life (Langley et al., 1994; 
Langley-Evans et al., 1996). In mice maternal dietary restriction also causes decreased birth 
weight and increased weight gain and features of type 2 diabetes in adult offspring (Bol et 
al., 2009). Maternal caloric or protein restriction increases blood pressure in offspring, and 
alters vascular function, with increased vasoconstriction response (Ozaki et al., 2001) and 
decreased endothelium-dependent vasodilation (Brawley et al., 2003) in adult offspring. 
While results differ slightly between models used and parameters tested data is consistent in 
suggesting an increased risk of cardiovascular disease is associated with low birth weight. As 
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well as alteration of maternal diet, fetal nutrition can be reduced by surgical ligation of 
uterine vessels (McMillen and Robinson, 2005). This also leads to reduced birth weight and 
long term changes in cardiovascular health. 
1.4.3 Maternal obesity 
As maternal undernutrition has been shown to program the long-term health of the offspring, 
it has been hypothesised that maternal/fetal overnutrition may also exert programming 
effects.  
1.4.3.1 Human studies 
Obese mothers have more complications during pregnancy and spend longer in hospital 
following delivery of their children. Neonates born to mothers with a pregravid BMI over 25 
had increased adiposity when compared with controls (Catalano et al., 2009a) and 
preliminary follow up studies of children born to obese mothers show that they are heavier 
and have a higher BMI (Whitaker, 2004; Ogden et al., 2006; Mesman et al., 2009), which is 
still evident when they are young adults (Stuebe et al., 2009; Tequeanes et al., 2009). In 
addition to overall weight gain, there is also increased adipose mass in the children of obese 
mothers (Gale et al., 2007) which is maintained into adulthood independent of current 
lifestyle factors (Mingrone et al., 2008; Reynolds et al., 2010). As has been introduced 
previously obesity is associated with hyperglycaemia and hyperinsulinaemia (section 
1.1.6.1). One small study found neonates of obese mothers were more insulin resistant than 
those of lean mothers (Catalano et al., 2009a). Recent evidence from the large 
hyperglycaemia and pregnancy outcome study found an association between maternal BMI 
and fetal hyperinsulinaemia even after adjustment for maternal glycaemia (Study 
Cooperative Research Group, 2008). A higher prevalence of insulin resistance is starting to 
be reported in offspring followed to early adulthood whose mothers were obese (Mingrone et 
al., 2008) or had diabetes (Boerschmann et al., 2010). Gestational diabetes, which is often 
associated with obesity, causes macrosomia in the offspring as well as hyperglycaemia, both 
of which are believed to predict obesity in adulthood (Gillman et al., 2003). Although 
incidence of obesity and gestational diabetes correlate they are not characterised by the same 
parameters and could induce different programming stimuli and therefore data should be 
interpreted accordingly.  
Studies investigating maternal obesity and cardiovascular risk in their offspring are currently 
very limited. Some isolated studies have shown an association between blood pressure and 
gestational weight gain (Lawlor et al., 2004; Mamun et al., 2009; West et al., 2011), though 
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this may be due to increased BMI in the offspring. Attention is turning to potential 
interventions to improve maternal health, which may impact on offspring health in the short 
and long term. One study found exercise during pregnancy reduced offspring birth weight 
but did not alter maternal insulin sensitivity (Hopkins et al., 2010). Longitudinal studies of 
such interventions are obviously lacking, and this may mean offspring birth weight is being 
over-analysed as an indicator of future health. Birth weight is a crude measure of the in utero 
environment and is not always elevated in offspring of obese mothers (Artal et al., 2007; 
Hopkins et al., 2010).  
Despite variation most studies demonstrate extra or excess growth in utero may lead to 
increases in cardiovascular disease risk as has been well documented in those with growth 
retardation in early life. One major consideration of human studies is the ‘obesogenic 
environment’ that the children are being born in to. Obese mothers are likely to pass on their 
eating habits and behaviours to their children, and thus they are likely to show the effects of 
diet and lifestyle induced obesity in addition to any programmed effects. 
1.4.3.2 Rodent models 
Whilst studies in humans are on-going, animal models have proved invaluable in predicting 
the future impact of maternal obesity, as well as in attempting to uncover the mechanisms by 
which early-life programming occurs. In animals, the post-weaning environment can be 
tightly regulated, reducing the environmental effects which confound human studies. Models 
have been developed in a variety of species and have used females that are already obese or 
females placed on an obesogenic diet during pregnancy and lactation. The effects of 
maternal obesity can already be seen in the unborn fetus: maternal obesity in sheep increases 
pancreatic weight and β-cell number in the fetus (Ford et al., 2009) while in Japanese 
Macaques it increases fetal hepatic triglyceride content (Aagaard-Tillery et al., 2008). 
1.4.3.2.1 Timing of insult 
Unlike glucocorticoid-induced programming, in which the timing of the insult is critical in 
determining the programming effects, most models of maternal over-nutrition (including pre-
conception and during gestation), lead to the same metabolically-compromised phenotype in 
the offspring, as does offspring exposure to excess nutrition during the suckling period 
(Armitage et al., 2005b; Khan et al., 2005; Bayol et al., 2007; Samuelsson et al., 2008; 
Bruce et al., 2009). Some debate remains, however, with a study demonstrating the offspring 
of rats rendered obese before mating but maintained on standard diet during pregnancy 
became obese in adulthood (Shankar et al., 2008) and another suggesting pre-conception 
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obesity has no additional effect over the exposure to a high fat diet during pregnancy in 
terms of programming effects on offspring adiposity (Howie et al., 2009). While White et al. 
found maternal obesity was necessary for the programming effects of a high fat diet on 
offspring adiposity in a rat model (White et al., 2009). Studies of the physiology of obese 
dams are beginning to be reported and may shed some light on the mechanisms leading to 
the differential effects on the offspring. 
1.4.3.2.2 Programming of offspring obesity and metabolism 
Another major difference between programming by maternal obesity and under-nutrition or 
glucocorticoid exposure is the lack of influence of maternal obesity on offspring birth weight 
(Boullu-Ciocca et al., 2005; Buckley et al., 2005; Bruce et al., 2009; White et al., 2009). 
However, in adulthood the offspring of obese rats and mice are generally heavier, with more 
adipose tissue than controls, and this effect is amplified by feeding an obesogenic diet post-
weaning (Buckley et al., 2005; Khan et al., 2005; Taylor et al., 2005; Srinivasan et al., 2006; 
Bayol et al., 2007; Samuelsson et al., 2008; Elahi et al., 2009). Rats exposed to a junk food 
diet in utero have increased intramuscular lipid content (Bayol et al., 2005) and increased 
liver triglyceride content has been reported in offspring of obese rats (Buckley et al., 2005) 
and mice (Elahi et al., 2009). Increases in body weight and adiposity may be due to 
hyperphagic activities of offspring (Kirk et al., 2009; Nivoit et al., 2009) and decreased 
energy expenditure (Samuelsson et al., 2008) and alterations in brain regions controlling 
appetite are also apparent in the offspring of obese dams (Chang et al., 2008)  
In addition to increased weight gain and adiposity, changes in metabolism have also been 
described in offspring of obese dams. Hyperglycaemia and hyperinsulinemia have been 
reported following either a period of fasting or a glucose tolerance test, and lipid handling is 
also affected with higher plasma concentrations of triglycerides and cholesterol (Guo and 
Jen, 1995; Buckley et al., 2005; Khan et al., 2005; Samuelsson et al., 2008; Elahi et al., 
2009). These changes are likely to be associated with the increase in weight and adiposity 
discussed though reduced β-cell number, volume (Cerf et al., 2005) and insulin secretory 
capacity (Taylor et al., 2005) have been described. On a molecular level changes in the 
expression of glucose transporter 2 (Cerf et al., 2005) and components of the insulin 
signalling pathway (Buckley et al., 2005; Shelley et al., 2009; Martin-Gronert et al., 2010) 
are evident.  
Despite the known association between altered local glucocorticoid metabolism and obesity 
(section 1.2.5) few studies have investigated glucocorticoid metabolism in models of 
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maternal obesity. Neonatal over-feeding studies in rats (achieved by reducing litter size) 
showed that the mRNA abundance and/or activity of 11β-HSD1 was increased in visceral 
(Boullu-Ciocca et al., 2005) and retroperitoneal (Hou et al., 2011) adipose tissue. An 
increase in GR expression in visceral adipose was also reported in one study (Boullu-Ciocca 
et al., 2005). These results suggest that maternal obesity might be associated with altered 
glucocorticoid regeneration and signalling in the offspring, changes which may be associated 
with adiposity and insulin resistance (section 1.2.5). 
1.4.3.2.3 Programming of vascular function 
In addition to metabolic changes, exposure to maternal obesity increases cardiovascular 
disease in offspring, as is seen in other models of early-life programming. There is evidence 
for hypertension (Khan et al., 2003; Khan et al., 2004; Samuelsson et al., 2008; Elahi et al., 
2009) in offspring of obese dams and this may deteriorate with advancing age (Samuelsson 
et al., 2008; Liang et al., 2009). In rats blood pressure can be measured from as early as 
30days using remote telemetry. Using this technology it has been reported that blood 
pressure is raised in offspring of obese dams before changes in adiposity are evident, 
although the mechanisms are not clear a sympathetic origin was proposed (Samuelsson et al., 
2010). Other changes in the vasculature may also play a role in the development of 
hypertension, particularly differences in structure and function which may increase 
peripheral resistance. Rodent offspring of obese dams demonstrate endothelial dysfunction 
seen as reduced endothelium-dependent vasodilation (Samuelsson et al., 2008; Koukkou et 
al., 1998; Ghosh et al., 2001; Taylor et al., 2004; Chechi et al., 2009). In addition reports 
suggest altered vascular fatty acid content (Ghosh et al., 2001), increased aortic stiffness and 
reduced smooth muscle cell number (Armitage et al., 2005a) which may all contribute to 
hypertension. 
To date, lesion formation following vascular injury has not been studied in offspring of 
obese dams. However, a study of ischemia/reperfusion injuries of the myocardium found 
increased susceptibility in male offspring of genetically obese mothers (Calvert et al., 2009) 
though the mechanism was not investigated. Atherosclerosis is hypothesised to form in 
response to chronic vascular injury (introduced in section 1.1.6.5), though lesions are seen in 
young children and animals. Offspring of hypercholesterolemic rabbits have increased lesion 
size at birth, however swine exposed to a high cholesterol diet in utero were not different 
from those of control sows at birth or at 5months (Norman and LeVeen, 2001). Interestingly 
the study in swine included an amplification protocol which found those fed the 
atherosclerotic diet during early and postnatal life had less plaques than those reared by 
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control sows (Norman and LeVeen, 2001). It was hypothesised that programming of 
cholesterol metabolism inferred a protection from atherosclerosis in this animals (Norman 
and LeVeen, 2001), whether this is true in other species is unknown and warrants further 
investigation.  
  
1.4.4 Potential programming mechanisms 
The exact mechanisms by which the environment experienced in early life can cause long-
term changes in tissue structure and function are still unclear. Many changes in gene 
expression and enzyme activity have been reported in animal models but how these are 
elicited or maintained is unclear. Programming of the HPA-axis and epigenetic regulation of 
gene expression have both been proposed though further research is required to confirm their 
involvement. It is possible that similar mechanisms are involved in programming regardless 
of stimulus, though this is currently not known. To allow for further investigation, and 
intervention studies, robust reproducible models of programming are required. This is 
particularly important when considering the future health of children being born to obese 




1.5 Hypotheses and aims  
The work described in this thesis addressed the hypotheses that: 
(1)  As a consequence of the protective effects of estrogens, the metabolic and 
cardiovascular changes caused by obesity are more severe in male than in female 
mice. 
(2) Exposure to maternal obesity in utero programmes metabolic and cardiovascular 
dysfunction in adult offspring. 
 
In order to address these hypotheses, the aim of the specific studies performed was to answer 
the following questions: 
 Are obesity-induced changes in metabolic function less severe in female, than in 
male, mice? 
 Does maternal obesity predispose offspring to metabolic dysfunction in adulthood? 
 Does obesity in adulthood, or exposure to obesity in utero, induce vascular 








All chemicals and reagents were from Sigma-Aldrich (Dorset, UK) unless otherwise stated. 
2.2 Buffers and Solutions 
2.2.1 1kb DNA ladder 
20% v/v 20µg 1Kb ladder (Invitrogen, Strathclyde, UK) in distilled water with 20% v/v 
loading buffer. 
2.2.2 10x TBE buffer 
0.9M Tris base, 0.9M boric acid, 20mM EDTA in distilled water. Autoclaved, diluted to 0.5x 
before use. 
2.2.3 Acidified Potassium Permanganate  
0.3%v/v concentrated sulphuric acid (Fisher Scientific, Leicestershire, UK) and 0.3% v/v 
potassium permanganate were mixed with distilled H2O immediately prior to use and kept 
for no more than 48 hours. 
2.2.4 BABB 
34% v/v benzyl alcohol (Acros Organics, Fisher Scientific, UK), 66% v/v benzyl benzoate 
(Acros Organics) 
2.2.5 Borate buffer 
8.25g boric acid, 2.7g NaOH, 3.5ml conc. HCl (33%), 5g BSA made up to 1L with distilled 
water, pH 7.4. Stored at -20°C, thawed at room temperature before use. 
2.2.6 Gomori’s Aldehyde fuschin 
Pararosaniline was dissolved 1% w/v in 60% ethanol, followed by addition of 1% v/v HCl 
(VWR, Leicestershire, UK) and 2% v/v paraldehyde. The solution was left in sunlight for 2 
days to develop then vacuum filtered using Whatman #1 paper (GE Healthcare, 
Buckinghamshire, UK). 
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2.2.7 Gomori’s Trichrome Reagent 
The following compounds were dissolved in distilled H2O; 0.6% w/v phosphotungstic acid, 
0.6% w/v chromotrope 2R and 0.3% w/v fast green FCF, mixed vigorously and finally 1% 
v/v acetic acid (Fisher Scientific) was added. 
2.2.8 Homogenisation Buffer (for microsome preparations) 
250mM sucrose, 10mM HEPES in distilled water, pH 7.5. Stored at 4°c for no more than 
one week 
2.2.9 Krebs Buffer 
2.54mM CaCl2, 1.19mM MgSO4, 3.80mM KCl, 1.19mM KH2PO4, 25mM NaHCO3, 118mM 
NaCl in distilled water, pH 7.4. Stored at 4°C for no more than one week. 
2.2.10 Mobile Phase for HPLC (WAM) 
WAM 60: 15: 25 (v/v/v) HPLC grade water (Fisher Scientific): acetonitrile (VWR): 
methanol (Fisher Scientific), was mixed and filtered through 0.45µm filter paper (Millipore, 
MA, USA). 
2.2.11 Phosphate buffered saline (PBS) 
1 tablet was dissolved in 200ml deionised water to give 0.01 M phosphate buffer, 0.0027 M 
potassium chloride and 0.137 M sodium chloride, pH 7.4. 
2.2.12 Potassium Physiological Saline Solution (KPSS)  
124.6mM KCl, 2.5mM CaCl2, 1.2mM MgSO4, 25mM NaHCO3, 1.2mM KH2PO4, 27µM 
EDTA, 5.5mM glucose. Stored at 4°C until use, bubbled with 95% O2/ 5% CO2 during 
myography. 
2.2.13 Physiological Saline Solution (PSS) 
119mM NaCl, 3.7mM KCl, 2.5mM CaCl2, 1.2mM MgSO4, 25mM NaHCO3, 1.2mM 
KH2PO4, 27µM EDTA, 5.5mM glucose. Stored at 4°C until use, bubbled with 95% O2/ 5% 
CO2 during myography 
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2.2.14 Weigert’s Haematoxylin  
Weigert’s Haematoxylin solution A and solution B (Sigma Aldrich) were mixed 1:1 
immediately prior to use and kept for no more than 48 hours. 
2.3 In vivo procedures 
2.3.1 Animal maintenance 
All animal procedures were carried out under the terms of the Animals Scientific Procedures 
Act 1986 (project licence numbers 60/3962 and 60/5867, personal licence for Rachel Dakin 
60/11838). Animals were under the care of the animal research technicians at the University 
of Edinburgh Biomedical Research Facility at Little France throughout the experimental 
period. C57BL/6 mice were bred in house for studies. Mice were maintained in a 
temperature (19-23°C) and humidity controlled environment on a 12h light/dark cycle (lights 
on 0700 daily). Mice were weaned from dams at ~21 days and ears notched to allow 
identification throughout studies. Mice were kept 4-6 per cage, except where stated, and 
cages were cleaned weekly. Mice had free access to standard laboratory chow (Special Diet 
Services, Essex, UK) and drinking water unless stated.  
2.3.2 Generation of obese mice 
C57BL/6 mice were bred in house; pups were weaned at 3 weeks of age and housed in single 
sex experimental groups. Groups were selected randomly from as many litters as possible. 
From 5 weeks of age mice were fed ad libitum with either control (CON; 11% kcal from fat, 
73.1% Kcal from carbohydrate as corn starch, D12328) or obesogenic (DIO; 58% kcal from 
fat, 25.5% Kcal from carbohydrate as sucrose, D12331) diet (details in Table 2.1), both from 
Research Diets Inc. (NJ, USA). Animals were maintained on experimental diet for the 
remainder of the study as outlined in each chapter. 
2.3.3 Generation of offspring exposed to maternal obesity 
Obese and control female C57BL/6 mice were generated as in section 2.3.2 in collaboration 
with Dr V King. The mice, which were first time breeders, were mated with C57BL/6 males 
(maintained on standard diet) at 15 weeks of age and remained on experimental diet during 
gestation and suckling. Maternal characteristics are listed in Table 5.1, chapter 5. Litters 
were reduced to 5 pups on postnatal day one and offspring were weaned at postnatal day 23,  
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 D12331  
High fat and sucrose 
 D12328  
Control fat and corn 
starch 
  gm % kcal % gm % kcal % 
Protein 23.0 16.4 16.8 16.4 
Carbohydrate 
(sucrose) 
35.5 25.5 74.3 73.1 
Fat 35.8 58 4.8 10.5 
Total  100  100 
 5.56 kcal/gm  4.07 kcal/gm  
 
 D12331   D12328  
 gm kcal gm kcal 
Casein 228 912 228 912 
DL-Methionine 2 0 2 0 
Maltodextrin 10 170 680 170 680 
Corn Starch 0 0 835 3340 
Sucrose 175 700 0 0 
Soybean Oil 25 225 25 225 
Coconut Oil 
(hydrogenated) 
333.5 3001.5 40 360 
Mineral Mix 40 0 40 0 
Sodium Bicarb`onate 10.5 0 10.5 0 
Potassium citrate 4 0 4 0 
Vitamin Mix 10 40 10 40 
Choline Bitartrate 2 0 2 0 
Coloured dye 0.1 0  0.1 0 
Total 1000.1 5558.5  1366.6 5557 
 
Table 2.1 Diet composition 
High fat and control fat diets were purchased from Research Diets Inc. (NJ, USA). Diets 
were matched for micro and macronutrients with the exception of carbohydrate source and 
quantity of fat. Table shows the % of grams and kcalories (kcal) provided by protein, 
carbohydrate and fat and the full composition of the diets as provided by the manufacturers. 
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housed in single sex cages and fed standard laboratory chow diet. Only one mouse from each 
litter was used in subsequent experiments; this is because litter mates cannot be considered 
independent as they shared the same in utero environment.   
2.3.4 Terminal procedures and harvesting of tissues 
Animals were killed by CO2 asphyxiation or perfusion fixation at the times reported in 
individual chapters. Adult female mice were killed in estrus assessed by vaginal smear 
(section 2.3.10). 
2.3.4.1 CO2 asphyxiation 
Mice were placed in a tank filled with increasing concentrations of CO2 until breathing 
stopped. Upon removal from the tank death was confirmed by checking for pedal reflex 
reactions.  
2.3.4.2 Perfusion fixation 
Mice which underwent femoral artery injury surgery were killed by perfusion fixation. 
Formalin, an aldehyde fixative, helps maintain tissue structure by forming methylene 
crosslinks between tissue amino groups. By perfusing formalin through the vasculature the 
rigidity and therefore lumen structure of the vessels was maintained.  
Firstly animals were deeply anaesthetised by intraperitoneal injection with 80mg/kg sodium 
pentobarbital (Ceva Animal Health Ltd., Buckinghamshire, UK). Once anaesthesia was 
induced, determined by lack of reflex reactions, the chest cavity was opened and the heart 
exposed. The circulation was flushed with PBS containing heparin 10U/ml (Leo 
Laboratories, Buckinghamshire, UK) by placing a 23 gauge needle into the left ventricle and 
making a small cut in the right atrium for blood and perfusate to escape. The PBS flow was 
maintained at 6ml/min by a peristaltic pump (Gilson, Bedfordshire, UK) for ~3 min. Once 
the blood was cleared, 10% neutral buffered formalin was perfused through the system in the 
same way for approximately 7 min. Fixation was determined by bleaching of the liver and 
muscle rigidity.  
2.3.4.3 Tissue collection 
Blood was collected from the Inferior Vena Cava with 1%(v/v) 0.5M EDTA; samples were 
centrifuged at 5,000rpm for 10min at 4°C and the supernatant plasma aliquotted and stored at 
-80°C. Liver, kidney, adrenal gland, spleen and adipose depots (subcutaneous, mesenteric, 
retroperitoneal and epididymal) were dissected, weighed where appropriate, snap frozen on 
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dry ice and stored at -80°C. For studies of vascular function femoral arteries were collected 
and immediately stored in PSS. 
Mice that underwent luminal wire injury surgery had their femoral arteries dissected; from 
the lowest suture left in place after surgery past the femoropopliteal branch to the branch 
with the iliac artery. Any residual adipose and connective tissue was removed and vessels 
stored in formalin for a further 24 hours then transferred into 70% ethanol until processed for 
optical projection tomography (OPT). 
2.3.5 Surgical techniques 
2.3.5.1 Preparation for surgery 
Mice were anesthetised in a chamber with increasing concentrations of 4-5% isoflurane 
(Merial Animal Health Ltd, Essex, UK). Once unconscious, determined by lack of reflexes, 
mice were transferred to a heat pad where administration of anaesthetic (2% isoflurane in 
oxygen) was maintained via a nose cone. For post-operative analgesia, 0.1mg.kg
-1
 
buprenorphine (Alstoe Animal Health, Yorkshire, UK) was administered subcutaneously 
before the surgical procedure. Surgical instruments were sterilised using a bead steriliser 
prior to surgery and between each animal.  
2.3.5.2 Recovery from surgery 
Immediately following surgical procedures animals were placed in a cage alone, to recover 
from the anaesthesia. Once fully alert and active, normally within 1 hour, the animals were 
returned to the home cage. Animals and wounds were checked for the subsequent 4 days; 
firstly for general health and well being, and secondly for signs of infection. No major 
problems occurred as a result of the surgical procedures undertaken. A small number of mice 
required repeated suturing one or two days post femoral artery injury, due to the stitches 
having been chewed and removed by the animals.  
2.3.5.3 Estradiol pellet implantation 
Ninety-day release, 0.25mg 17β-estradiol pellets (Innovative Research of America, FL, 
USA) were implanted in male mice to administer the hormone (~2.8µg/day) over the 
duration of the study. The lipophilic properties of the pellet allow the drug to be slowly and 
consistently released into the interstitial fluid of the animals and thus into the circulation. 
This method of estradiol administration has previously been reported in the literature in 
studies of obesity in both rats and mice (Geisler et al., 2002; D'Eon et al., 2005; Andersson 
52 
et al., 2010). Sham surgery was performed on control animals; mice underwent the same 
surgical procedure with the exclusion of the pellet being inserted. 
Animals were prepared for surgery as described (section 2.3.5.1). The surface of the surgery 
site, the left mid-dorsal region, was shaved and a small incision the size of the pellet made. A 
superficial pocket was created by blunt dissection of subcutaneous tissue, distal to the site of 
incision. The pellet was inserted, the skin incision closed with 6-0 silk sutures and the 
animals left to recover (section 2.3.5.2).  
2.3.5.4 Femoral artery injury surgery 
Intra-luminal injury was performed on murine femoral arteries to induce neointima 
hyperplasia. The model used was previously described by Sata et al. (Sata et al., 2000).  
Mice were prepared for surgery as described (section 2.3.5.1). The inner surface of the left 
hind limb was shaved and an incision made at the top of the leg. The femoral neurovascular 
bundle was exposed by blunt dissection of the surrounding muscles. The femoral artery and 
vein were isolated from the nerve around the femoropopliteal bifurcation. Temporary suture 
loops (6-0 silk sutures, Mersilk, Ethicon, West Lothain, UK) were placed around the vessels 
both proximal and distal to the popliteal branch point to allow a temporary halt to blood flow 
in the artery and vein. 
The popliteal artery was also ligated and tension placed upon the ligature in order to bring 
the artery into the plane of the femoral artery. The area was irrigated with 1% w/v lignocaine 
(1% lidocaine hydrochloride, Hamlen Pharmaceuticals, Gloucestershire, UK) to dilate 
vessels as necessary. An angioplasty guidewire (0.014” diameter, Cook Inc., IN, USA) was 
inserted through an arteriotomy in the isolated popliteal artery, 2mm from the 
femoropopliteal bifurcation. The temporary ligature was loosened to allow the wire to be 
advanced approximately 5mm along the femoral artery. The wire was left in place for 1 
minute then tension re-applied to the temporary ligature as it was removed. The artery was 
permanently ligated proximal to the arteriotomy and blood flow to femoral artery and 
surrounding tissues restored by removal of temporary sutures. The skin incision was closed 
with 6-0 silk sutures and animals left to recover (section 2.3.5.2). 
2.3.6 In vivo blood sampling 
Blood samples were taken from mice (2.3.7 & 2.3.8) allowed free movement on top of their 
cage. The tip of the tail ~1mm was cut off with a pair of fine scissors and the blood gently 
massaged through the tail. Drops of blood were collected from the distal end of the tail by 
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capillary action into EDTA coated tubes, centrifuged at 2.3g for 10min at 4°C and the 
supernatant plasma stored at -20°C or -80°C. Following blood collection mice were returned 
to the cage immediately. This procedure can be used repeatedly without harm to the mice. 
2.3.7 Intraperitoneal glucose tolerance test 
Mice were fasted for 6 hours prior to the test; free access to water was permitted. A basal 
blood sample was taken by tail nick within 1 minute of cage disturbance (to reduce glucose 
response to stress). Glucose (40% w/v) was injected intraperitoneally to give a dose of 2g 
glucose per kg body weight. Blood samples were taken at 15, 30, 60 and 90 min post 
injection as in section 2.3.6. Animals were returned to clean cages with access to 
experimental diet and water immediately following the test. 
2.3.8 Diurnal blood sampling 
Tail tip blood samples were taken at 7am and 7pm, when the lights were changing from dark 
and light and light to dark. Samples were taken within 1 minute of cage disturbance before 
stress response would be detected in the blood. Samples were collected and stored as in 
section 2.3.6. 
2.3.9 Tail cuff plethysmography 
Systolic blood pressure was measured using tail cuff plethysmography as previously 
described (Krege et al., 1995). This technique uses light transmittance to monitor blood flow 
through the rodent tail, which is inversely proportional to tail volume. The transmittance is 
traced during inflation and deflation cycles of a pressurised cuff surrounding the mouse tail. 
The pressure at which the cyclical changes in tail volume, and therefore blood flow, stop 
indicates systolic blood pressure. 
Mice were placed in a 40°C chamber for approximately 8 min prior to measurement, to 
ensure good circulation particularly through the tail. The mouse was then placed in a small 
restraint tube above a heated pad to limit movement during the blood pressure measurement. 
The tail cuff containing a photo sensor sleeve (Harvard Appartus, Kent, UK) was placed 
around the base of the tail and equipment adjusted until a cyclic change in tail volume, 
representative of pulse, was seen on the connected data acquisition computer (IBM, 
Hampshire, UK). Pulse traces were recorded during 4 inflation and deflation cycles to just 
above and below the point where pulse was no longer apparent, or reappeared. The average 
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of the last 3 deflate measurements was recorded as systolic blood pressure. This was 
repeated on 3 days and the average was calculated for each mouse. 
2.3.10 Vaginal Smear 
Vaginal smears were used to determine the stage of estrus cycle in adult female mice. Day of 
estrus can be determined by microscopically inspecting the type and relative numbers of 
cells present in the vagina. 
The mice were allowed to move freely on top of their home cage. The tip of a plastic pipette 
containing 0.5ml 0.9% w/v saline solution was gently inserted approximately 3mm into the 
vagina. The vagina was lavaged with saline, samples smeared onto histology slides and left 
to air dry. 
2.4 Ex vivo functional analysis 
Wire myography was used to determine the functional response of femoral arteries.  
2.4.1 Tissue preparation 
Mice were killed (section 2.3.4.1) and femoral arteries dissected under 10x magnification, 
from the abdominal wall to the bifurcation of the common femoral artery. Vessels were 
stored in PSS (2.2.13) and further cleaned of peri-adventitial adipose and connective tissue 
before two rings approximately 2mm long were cut from each vessel. Exact vessel lengths 
were measured with a calibrated graticule eyepiece. The arterial rings were mounted in the 
organ baths of a Mulvany-Halpern myograph (Multi-myograph 610M, Danish Myotech, 
Aarhus, Denmark) containing PSS, to record isometric tension. The vessel was mounted 
using two wires thread through the lumen and secured on two opposing supports, one 
connected to a force transducer. The output from the transducer was passed to a data 
acquisition computer (Apple Inc, CA, USA) via a converter (Maclab/8, AD Instruments, 
Oxfordshire UK) and recorded using Chart 4.3.4 software (AD Instruments). Two rings from 
each animal were mounted, one left intact and the other denuded of endothelium by lightly 
rubbing the lumen with a hair. Vessel diameter was not measured in arteries used for 
functional anaylsis. Measurements were made in histology slides from separate cohorts of 
animals generated using the same protocols (Table 6.5 & 6.6). No differences between 
groups were found; diameters ranged from 210-336µm. 
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Myography baths were kept at 37°C and bubbled with 95% O2 / 5% CO2. Resting tension of 
approximately 7.5mN was gradually applied to vessels over 30min by adjustment of the 
micrometer. This optimal resting force has been previously determined in our laboratory (Dr 
N Kirkby, personal communication) and is in accordance with published literature 
investigating function in femoral arteries (Widmer et al., 2006; Bhattacharya et al., 2008). 
2.4.2 Functional response 
To determine contractility of vessels and ‘rejuvenate’ responses following dissection and 
mounting PSS was replaced with KPSS (2.2.12), ~6ml. The contraction was left to stabilise 
then baths emptied and tissues washed with PSS until they returned to resting tension. This 
was repeated twice more, the tension reached with the third KPSS wash was recorded as the 
maximum contractility for that tissue. 
For all arterial rings cumulative concentration-response curves to the α1-adrenoreceptor 




 using half log unit 
steps. Rings were then washed with PSS until baseline tension was returned. The same 
protocol was then used with the G-protein coupled receptor agonist 5-hydroxytryptamine 
(5HT). To measure relaxation responses vessels were pre-contracted to 80% of maximal 
contraction (EC80) with 5HT. Once contraction was stabilised the endothelium-dependent 





. Tissues were again washed with PSS before pre-contraction (EC80) with 5-HT and 





2.4.3 Data analysis 
Data was recorded as tension developed following administration of drug to the bath. 
Functional responses were expressed as force per length of muscle contracted normalised to 





Dose-response curves were created using non-linear regression and compared by 2-way 
ANOVA followed by Bonferroni’s post-hoc analysis. Responses to dilators were expressed 
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as percentage of the pre-existing tension prior to drug addition. Summary data for dose-
response curves (Emax, maximum response; pD2 or –logEC50, concentration eliciting 50% 
Emax) were calculated using iterative least squares fit equation. All graphs and statistics 
were generated using GraphPad Prism 5.0 software (Graphpad Software, CA, USA) 
2.5 Molecular Biology 
2.5.1 Quantitative real time PCR (qPCR) 
The transcript (mRNA) abundance of specific genes of interest was quantified using 
quantitative real time PCR (qPCR). Firstly RNA was extracted from tissues, and reverse 
transcribed to generate cDNA. The cDNA underwent qPCR using specific primers and Taq 
DNA polymerase to amplify the gene of interest. The 5’ to 3’ exonuclease activity of Taq 
DNA polymerase allows the use of florescent probes to quantify the amplification. The 
probes have a fluorescent reporter and quencher attached; the proximity stops any emission 
of fluorescence. As the probes are broken up by the Taq DNA polymerase the fluorescent 
reporter is released and the rate of change of fluorescence followed to determine mRNA 
abundance. The mRNA levels of genes are assessed relative to the mRNA levels of reference 
genes, to control for reverse transcription efficiency (Zhu and Altmann, 2005). 
2.5.1.1 RNA extraction from liver 
RNA extraction was carried out using RNeasy mini kits from Qiagen, West Sussex, UK. 
Liver tissue (~30mg) was homogenised in RLT buffer (600µl), samples were then 
centrifuged at 12,500g for 3 min. The supernatant was removed and mixed with an equal 
volume of 70% v/v ethanol; this solution was placed on the RNeasy spin column and spun 
8,000g 15 sec and the eluate discarded. The column was washed with RW1 buffer (700µl) 
followed by RPE buffer (700µl), spun at 8,000g for 15 sec, the eluate being discarded after 
each spin. A final wash with buffer RPE (500µl) was carried out followed by centrifugation 
at 8,000g for 2 min, the spin column was then transferred to a clean collection tube and spun 
at 12,500g for 1 min to fully dry the membrane and eliminate any carryover of wash buffers. 
The spin column was then placed in a clean eppendorf tube and RNA eluted with 50µl 
RNAse free water and centrifuged at 8,000g for 1 min. RNA was immediately placed on ice 
and stored at -80°C.  
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2.5.1.2 RNA extraction from adipose tissue 
RNA extraction from adipose used the same method as liver (2.5.1.1) except for tissue 
homogenisation. Tissue (~60mg) was homogenised in 1ml Qiazol Lysis reagent (Qiagen). 
300µl chloroform was added, mixed thoroughly and incubated at RT for 5min. Samples were 
centrifuged 4°C, 13,000g, 15min, to separate phases. The supernatant containing RNA was 
transferred to a new tube and an equal volume of 70% ethanol added as with the liver 
samples. The remainder of the procedure was the same as with liver (2.5.1.1), except RNA 
was eluted with 30µl RNase free water.  
2.5.1.3 RNA quality assessment  
Quality of RNA was assessed by separating ribosomal RNA (rRNA) using electrophoresis. 
8μl loading dye was added to 2μl RNA, centrifuged and loaded on an agarose (Lonza, 
Berkshire, UK) gel (1.5%w/v in 0.5x TBE buffer) containing SYBR safe DNA dye 
(Invitrogen), 1:10,000. Gels were electrophoresed at 100v for ~1hr. RNA integrity was 
determined by the existence of two clear rRNA bands, 28s and 18s, with no smearing, and no 
genomic DNA band. If degradation was found RNA was extracted again from a new piece of 
tissue. If DNA contamination was found samples were treated with DNAse (section 2.5.1.5). 
A 2100 Bioanalyzer system (Agilent Technologies, Cheshire, UK) was also used to 
investigate RNA quality in one experiment, although desirable due to cost it could not be 
used in all experiments. The Bioanalyzer uses micro chips containing a sieving polymer and 
fluorscent dye. Samples and ladder are loaded in to the wells and the chip becomes an 
electrical circuit. As in normal gel electrophoresis the RNA is electrophoretically driven by 
the voltage gradient and molecules separated by size. The dye molecules intercalate in to the 
RNA so that the complexes can be detected and speed of movement compared to a reference 
ladder. Data is translated in to gel like images and electropherograms (Figure 2.1b) by the 
provided software and an RNA integrity number (RIN) calculated. A RIN value of 10 
indicates intact RNA and a value of 1 fully degraded, values over 7.15 are believed to be 
acceptable for microarray anaylsis (Kiewe et al., 2009) the RIN of the sample shown was 8.3 
(Figure 2.1a). This is a user-independent, automated system for RNA quality control and 
therefore robust in predicting integrity (Schroeder et al., 2006). Although the gel images 
produced by the Agilent Bioanalzyer are of a very high resolution compared to standard gel 
electrophoresis the results were found to be comparable such that one sample containing 




Figure 2.1 Representative gel electrophoresised RNA, Bioanalyzer gel and 
electropherogram and qPCR standard curve 
Quality of RNA samples was analysed visually using gel electrophoresis. Samples were 
separated on a 1.5%w/v agarose gel at 100v for 1hr. RNA integrity was deemed acceptable if 
clear 18s and 28s ribosomal RNA bands were visible without smearing as is seen in these 
samples (a). The intensity of the band was reflective of RNA quantity, accurately assessed 
using spectrophotmetry (section 0). The quality of one set of RNA was also assessed using a 
Bioanalzyer (Agilent Technologies). This also separated RNA by electrophoresis but 
software provides user-independent gel images and electropherograms by measuring 
fluorescence (FU) against time (s). These images are used to generate a RNA integrity 
number (RIN) which was 8.3 for the sample shown. 
qPCR was used to analyse the transcript abundance of mRNA. The crossing point (Cp), a 
measurement of fluorescence emission, decreases as log concentration of mRNA increases. 
Cp of standards was plotted against log ‘concentration’ (c) by Lightcycler Software (Roche). 
The mRNA abundance of unknown samples was determined from their Cp by interpolation 
of the standard curve and presented relative to the abundance of reference genes.  
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This sample had a RIN value of 5.2, while all others tested were above 7.15.   
2.5.1.4 RNA quantification 
RNA was quantified using a NanoDrop (ND) Spectrophotometer (Thermo Fisher, 
Leicestershire, UK) measuring absorbance at 260nm. The ND-1000 software provided 
concentrations in ng/µl using Beer Lamberts law. Purity of RNA with respect to 
contaminating protein and salts was also monitored by the software. The ratio of absorbance 
at 260nm was compared to 230nm (260/230), for phenol, and 280nm (260/280), for protein, 
with values between 1.8 and 2.1 deemed acceptable. 
2.5.1.5 DNAse treatment 
Genomic DNA contamination was removed using a DNA-free kit from Ambion (Applied 
Biosystems, Cheshire, UK) according to the manufacturers’ protocol. DNase 1 buffer (10x, 
4µl) and rDNase 1 (1µl) was added to 40µl RNA (diluted 1:4 in RNase free water) and 
incubated at 37°C for 30 min. DNase inactivation reagent (4µl) was added; samples agitated 
before centrifugation 10,000g 1.5min. Supernatant containing RNA was removed and 
underwent RNA quality (2.5.1.3) and quantity (0) measurements. 
2.5.1.6 Reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA (liver -0.25µg, adipose – 0.5µg) was reverse transcribed using the Access RT-
PCR system (Promega, Hampshire, UK) according to manufacturers’ protocol, samples were 
incubated in a PCR machine (G-Storm1, Labtech International, East Sussex, UK) Briefly, 
each RNA sample was diluted to the appropriate concentration (liver – 30ng/µl, adipose - 
60ng/µl) with RNase free water, 8.7µl of which was incubated at 75°C for 10 min to 
denature samples. Following denaturation 11.3µl of ‘mastermix’ was added: 
RT-PCR mastermix composition, reagents from Access RT-PCR system (Promega): 
5x AMV-RT Buffer - 4µl 
MgCl2 (5mM) - 4µl 
dNTP mixture (1mM) - 2µl 
Oligo dTs – 0.2µl 
Recombinant RNasin® Ribonuclease Inhibitor (1u/μl) – 0.5µl 
AMV (Avian Myeloblastosis Virus) RT polymerase (15u/μg) – 0.6µl 
 
Samples were incubated at room temp for 10min for annealing and extension, followed by 
42°C, 15min for AMV-RT to transcribe cDNA and 95°C, 5min to inactivate enzymes. Two 
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negative controls were included, one with no RNA and the second with no AMV-RT enzyme 
to ensure reagents were not contaminated and did not contain genomic DNA. Samples of 
cDNA were stored at -20°C. 
2.5.1.7 Quantitative real time polymerase chain reaction (qPCR) 
Abundance of mRNA was quantified using a LightCycler 480 (Roche Applied Science, West 
Sussex, UK). Primers (details in Table 2.2) were designed to match intron-spanning 
boundaries wherever possible using the Roche Universal Probe Library (UPL). Where a 
satisfactory assay was not available using the UPL system a commercially designed assay 
was used (TaqMan® Gene Expression Assays; Applied Biosystems). Approximately 2µl of 
each cDNA sample to be analysed was pooled, a standard curve was created (1:4 – 1: 512) 
from the pool. Samples (diluted in LightCycler H2O; liver 1:40, adipose 1:20), standards and 
controls, negative reverse-transcriptase control (diluted as samples) and H2O, were added to 
the plate, 2µl of each in triplicate followed by 8µl of Master Mix. 
qPCR mastermix composition: 
 UPL system ABI system 
LightCycler H2O 2.7µl 2.5µl 
Roche Probes Master 5µl 5µl 
Primers (12pmol/µl) 0.1µl N/A 
Probe (Roche) (4pmol/µl) 0.1µl N/A 
Primer Probe mix N/A 0.5µl 
 
qPCR plates were centrifuged at 8,000g for 2min, to ensure all samples and mastermix were 
at the bottom of the well. Samples were denatured (95°C, 5min), then underwent 50 PCR 
amplification cycles; denaturation (95°C, 10sec), annealing (60°C, 30sec) and elongation 
(72°C, 0.1sec). The LC480 Software (Roche) monitored fluorescence during the PCR and 
plotted amplification curves, fluorescence against PCR cycle number. The crossing point 
(Cp) was calculated as the maximum point of the second derivative of the amplification  
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Gene accession number 
 
Primer sequence UPL 
probe 
5α reductase (5αR) 
Srd5a1 (NM_175283.3) 
For – gggaaactggatacaaaataccc 






Rev - gggacatgctctgtattccataa 
103 




Rev - gccccagtgacaatcactt 
1 
Estrogen receptor (ER) 
Esr1 (NM_007956.4) 
For – gctcctaacttgctcctggac 
Rev - cagcaacatgtcaaagatctcc 
97 
Fatty acid synthase (FAS) 
fasn (NM_007988.3) 
For – ccaaatccaacatgggaca 
Rev - tgctccagggataacagca 
34 
Glucocorticoid receptor (GR) 
Nr3c1 (NM_008173.3) 
For – tgacgtgtggaagctgtaaagt 
Rev - catttcttccagcacaaaggt 
56 
Hormone sensitive lipase (HSL) 
lip (NM_010719.5) 
For – gcgctggaggagtgttttt 
Rev - ccgctctccagttgaacc 
3 
Lipoprotein lipase (LPL) 
lpl (NM_008509.1) 
For – ctcgctctcagatgccctac 
Rev - ggttgtgttgcttgccatt 
95 
Peroxisome proliferator activated receptor-α (PPARα) 
ppara (NM_011144.2) 
For – ccttccctgtgaactgacg 
Rev - ccacagagcgctaagctgt 
5 
Peroxisome proliferator activated receptor-γ (PPARγ) 
pparg (NM_011146.1) 
For – tgctgttatgggtgaaactctg 
Rev - ctgtgtcaaccatggtaatttctt 
2 
phosphoenolpyruvate carboxykinase (PEPCK) 
pck1 (NM_011044.2) 
For – gatgacattgcctggatgaa 
Rev - cgttttctgggttgatagcc 
105 
Tata box binding protein (TBP) 
tbp (NM_013684.2) 
For – gggagaatcatggaccagaa 
Rev - gatgggaattccaggagtca 
97 








Androgen receptor (AR) 
ar (NM_013476.3) 
Mm00442688_m1 
Glyceraldehyde-3phosphate dehydrogenase (GAPDH) 
Gapdh (NM_008084.2) 
Mm99999915_g1 
Table 2.2 Details of primers for qPCR 
Primers were designed using the Roche Universal Probe Library (UPL) or a commercially 
designed assay was used (TaqMan® Gene Expression Assays; Applied Biosystems). 
Abbreviations in brackets are used in this thesis (for, forward; rev, reverse). 
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curve. Triplicates were deemed acceptable if the standard deviation of crossing point <0.3 
cycles. Negative controls were deemed acceptable if Cp >10 cycles were higher than that of 
the lowest standard. A standard curve of Cp against log ‘concentration’(serial dilution) was 
generated (Figure 2.1c) for each gene and deemed acceptable if reaction efficiency was 
between 1.8 and 2.1. The mRNA ‘concentration’ of unknown samples were interpolated 
from the standard curve and expressed relative to the abundance of a reference gene. 
Reference genes were chosen for each study and tissue independently and are listed in the 
relevant chapters. Ideally reference genes are not affected by any treatment in the study; 
however this was not always possible particularly when dealing with sex differences. Where 
there were group differences in mRNA abundance for reference genes, the pattern of 
abundance was comparable for all reference genes tried (CYC, β-actin, TBP,GAPDH) and 
therefore the variation could be due to actual amount of cDNA in the well rather than effect 
of treatment. mRNA abundance of 18S rRNA is often used as a reference gene for q PCR. 
This was not possible in these studies because cDNA was synthesised using dTT primers, as 
18S does not have a polyA tail (Zhu and Altmann, 2005) efficient synthesis could not be 
ensured. The mRNA abundance was normalised to cyclophilin, β-actin or an average of both 
in all chapters. These were chosen as the mRNA was abundant in the tissues used, the Cp of 
the highest standard being between 23-25 cycles. The standard deviation between samples 
was also very low, <0.1 cycles further indicating high levels of mRNA. Finally the reference 
genes chosen have been used by other studies investigating murine metabolism (D'Eon et al., 
2005; Bruce et al., 2009; Livingstone et al., 2009). 
2.6 Biochemical assays 
All spectrophotometric measurements were carried out with an OPTImax Tunable 
Microplate Reader (Molecular Devices, CA, USA). Standard curves were plotted SoftMax 
Pro Software (Molecular Devices) using linear regression, with the exception of the 
corticosterone assay (2.6.8). 
2.6.1 Quantification of protein 
Protein concentrations were determined using the DC Protein Assay (Biorad, Hertfordshire, 
UK) based on the Lowry method (Lowry et al., 1951)). Standards of BSA Protein 
concentrations were determined using the DC Protein Assay (Biorad) as directed by 
manufacturers; the assay is based on the Lowry method. Standards of BSA were made 
ranging from 2 to 0.1mg/ml. Standards and samples were added to a 96 well plate, 5µl in 
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duplicate, followed by 25µl of reagent A then 200µl reagent B. Plates were incubated at 
room temperature for between 20-50 minutes and absorbance measured at 750nm. 
Absorbance of protein standards was used to generate a standard curve (absorbance against 
concentration) which was deemed acceptable if r
2
>0.95 and duplicates differed by less than 
<10%. Sample protein concentrations were calculated from the standard curve, where 
samples absorbance was not in the standard curve further dilutions were carried out and the 
assay repeated. 
2.6.2 Quantification of plasma insulin using Enzyme-Linked 
Immunosorbent Assay (ELISA) 
Insulin was quantified in plasma samples taken during glucose tolerance tests (section 2.3.7) 
using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc., IL, USA) as directed 
by the manufacturer. Briefly, a series of insulin dilutions were prepared (6.4-0.1ng/ml) in 
sample diluent provided with the kit. Samples (5µl, in singlicate due to the limited 
availability of plasma) and standards (5µl, in duplicate) and 95µl sample diluent were added 
to wells which had been precoated with primary guinea pig anti-insulin antibody, and 
incubated for 2hrs 4°C. Plates were washed 5 times with wash buffer to remove unbound 
insulin. 100µl horseradish peroxidise (HRP) conjugated anti insulin was added to each well 
and incubated for 30min. Plates were washed 7 times with wash buffer before the addition of 
100µl of enzyme substrate solution containing tetramethylbenzidine (TMB). The plate was 
incubated in the dark for 40min and 100µl sulphuric acid (0.5M) added to stop the reaction. 
Absorbance was measured spectrophotomically at 630 and 450nm, and values at 630nm 
subtracted (deemed to be due to artefacts on the plate). A standard curve was fitted, 
absorbance against concentration and deemed acceptable if r
2
>0.95 (Figure 2.2), duplicates 
of standards were accepted if they varied by <10%. Unknown sample concentrations were 
interpolated from the curve. 
2.6.3 Quantification of testosterone in plasma by ELISA 
Testosterone was quantified in plasma samples taken at post mortem (section 2.3.4.3) using 
the Demeditec Testosterone rat/mouse ELISA (Demeditec Diagnostics GmbH, Kiel, 
Germany) following manufacturer’s instructions. The ELISA is based on the principle of 
competitive binding; an unknown amount of testosterone in the sample competes with a 
known amount of testosterone (provided) conjugated to HRP for the binding sites in the 
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Figure 2.2 Example of insulin ELISA standard curve 
Concentration of insulin bound to the plate increased with increasing concentrations of 
standards, as measured by absorbance (λ450-630). Graphs were plotted with SoftMax Pro 
Software (Molecular Devices) using linear regression. Standard curves were deemed 
acceptable if r
2
 >0.95 and variation between standards was <10%. The insulin concentration 
of samples was determined from their absorbance (λ450-630) by interpolation against the 
standard curve.  
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wells of the plate. Following washing of unbound steroid and addition of substrate for HRP 
the concentration of testosterone is inversely proportional to the optical density measured.  
Samples (10µl, in singlicate) and standards (10µl, duplicate, provided with kit) were added 
to the plate, followed by 100µl incubation buffer and 50µl enzyme conjugate. The plate was 
incubated at RT with shaking for 60mins and unbound protein removed by washing (4 x 
300µl), this was followed by the addition of 200µl substrate solution and further incubation 
for 30mins without shaking. The reaction was stopped with 50µl stop solution and 
absorbance read at 450nm. A standard curve (absorbance against concentration) was plotted 
on a semi-logarithmic scale and deemed acceptable if r
2
>0.9 and duplicates of standards 
varied by <10%. Sample concentrations were then interpolated from the curve. 
2.6.4 Quantification of plasma glucose 
Glucose was quantified in plasma samples taken during glucose tolerance tests (section 
2.3.7) using the Infinity Glucose Hexokinase Liquid Stable Reagent (Thermo Electron, PA, 
USA). The reagent contained substrates, cofactors and enzymes which phosphorylate and 
oxidise glucose by reducing NAD
+
 to NADH, this cofactor can be measured 
spectrophotomically. 
Serial glucose standards were made (22-2.5mmol/L) from standard provided diluted in 
distilled water. Samples (2µl, in singlicate due to scarcity of plasma) and standards (2µl, 
duplicate) were added to a 96-well plate followed by 200µl reagent and incubated in 
darkness (10min, RT). Absorbance was measured at 340nm and a standard curve generated 
(absorbance against concentration), deemed acceptable if r
2
>0.95 and duplicates of standards 
varied by <10%. Sample concentrations were then interpolated from the curve. 
2.6.5 Quantification of cholesterol in plasma 
Cholesterol was quantified using the Infinity Cholesterol Liquid Stable Reagent (Thermo 
Electron). The reagent contained substrates, cofactors and enzymes which catalysed 
hydrolysis and oxidation of cholesterol to form H2O2; this was turned in to a chromophore, 
by peroxiadase, which was measured spectrophotometrically. 
Serial dilutions of cholesterol standard (provided) were made (20-0.5mmol/L) in distilled 
water. Samples and standards (2µl, duplicate) were added to a 96-well plate followed by 
200µl reagent and incubated 37°C, 5min. Absorbance was read at 600nm (plate background) 
and 500nm (proportional to cholesterol concentration). Difference in absorbance readings 
66 
(A500 – A600) was plotted against concentration to generate a standard curve, this was deemed 
acceptable if r
2
>0.95 and duplicates of standards were accepted if they varied by <10%. 
Sample concentrations were then interpolated from the curve.  
2.6.6 Quantification of triglycerides 
Triglyceride was quantified in plasma and saponified liver samples using the Infinity 
Triglyceride Liquid Stable Reagent (Thermo Electron). The reagent contained substrates, 
cofactors and enzymes which break down triglycerides into glycerol and free fatty acids, 
these are then phosphorylated and reacted with oxygen to form H2O2; this was turned in to a 
chromophore, by peroxidase, which was measured spectrophotometrically. 
Serial dilutions of triglyceride standard (provided) were made (5.65-0.28mmol/L) in distilled 
water. Samples (2µl, in singlicate due to scarcity of plasma, duplicate for liver samples) and 
standards (2µl, duplicate) were added to a 96-well plate followed by 200µl reagent and 
incubated 37°C, 5min. Absorbance was read at 600nm (plate background) and 500nm 
(proportional to triglyceride concentration). Difference in absorbance readings (A500 – A600) 
was plotted against concentration to generate a standard curve, this was deemed acceptable if 
r
2
>0.95 and duplicates of standards were accepted if they varied by <10%. Sample 
concentrations were then interpolated from the curve. 
2.6.7 Quantification of Non-Esterified Fatty Acids (NEFAs) in plasma 
NEFAs were quantified using the HR Series NEFA-HR kit (Wako Diagnostics, VA, USA). 
The reagents contained substrates, cofactors and enzymes which converted NEFAs into fatty 
acyl-CoA esters, these were then reacted with oxygen forming H2O2; this was turned in to a 
chromophore, by peroxidase, which was measured spectrophotometrically. 
Serial dilutions of NEFA standard (provided) were made (2-0.1mmol/L) in distilled water. 
Samples (5µl, in singlicate due to scarcity of plasma) and standards (5µl, duplicate) were 
added to a 96-well plate followed by 150µl Reagent R1 and incubated 37°C, 10min. Reagent 
R2 was then added, 75µl incubated for a further minute and the absorbance read at 550nm 
(proportional to NEFA concentration) and 660nm (plate background). The difference in 
absorbance (A550 – A660) was calculated and plotted against concentration to generate a 
standard curve. This was deemed acceptable if r
2
>0.95 and duplicates of standards varied by 
<10%. 
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2.6.8 Quantification of corticosterone in plasma by radioimmunoassay 
(RIA) 
Plasma corticosterone was quantified using an in house assay samples collected at the peak 
and nadir of the diurnal variation (section 2.3.8). Plasma was diluted 10% (v/v) with borate 
buffer and incubated (80°C, 45min) to denature corticosteroid-binding globulin (CBG) and 
release corticosterone. Serial dilutions of corticosterone were prepared from a standard (320-
0.06nM) using borate buffer. Standards and samples (20µl) were added to a 96-well plate in 
duplicate. A mix of primary antibody (against corticosterone) and [
3
H]4-corticosterone was 
prepared; 3µl of [
3
H]4-corticosterone (62.2 Ci/mmol, GE Healthcare) was added to 6ml 
borate buffer and adjusted to 8,000cpm, followed by 60µl sheep anti-mouse primary 
antibody (pre-diluted 1:100, to give a final dilution of 1:10,000), a gift from Dr Christopher 
Kenyon, University of Edinburgh. The primary antibody mix (50µl) was added to each well 
followed by 50µl Scintillation proximity assay (SPA) beads (5mg/ml in borate buffer, GE 
Healthcare), coated with anti-sheep secondary antibody, the plate sealed, inverted to mix and 
incubated in the dark for 16 hours. 
Scintillation occurred when the SPA beads bound to primary antibody which was associated 
with [
3
H]4-corticosterone. The scintillation decreased as the concentration of unlabelled 
corticosterone increases, due to the increase in competition to bind the primary antibody. The 
scintillation was quantified using a liquid scintillation counter (Microbeta Plus, Wallac 1450, 
Turku, Finland), and data used to construct a semi-log standard curve (bound/bound at zero 
concentration against corticosterone concentration) on AssayZap software (Biosoft, 
Cambridgeshire, UK) (Figure 2.3). Plasma corticosterone in each sample was interpolated 
from the graph and the original dilution taken in to account. Duplicates of standards were 
deemed acceptable if they varied by <20%. 
2.7 Extraction of hepatic triglyceride 
To analyse hepatic triglyceride concentrations, lipids were extracted from tissues using a 
saponifcation method. This hydrolyses triglycerides under basic conditions to form glycerol 
and fatty acid salts, unwanted proteins are removed by salting out with MgCl2. Triglyceride 
content can be analysed by measuring the amount of glycerol produced in the hydrolysis. 
Liver tissue (~100mg) was digested at 55°C overnight in 10% (w/v) potassium hydroxide in 
ethanol; undigested tissue was removed by centrifugation at 10,000g 5min. Supernatant was  
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 Figure 2.3 Example corticosterone radioimmunoassay standard curve 
The proportion of bound [H] corticosterone (B/B0, y axis) decreases as it is displaced by 
increasing concentrations of unlablelled corticosterone (x-axis). Graph points were fitted 
with a sigmoidal concentration-response curve using AssayZap software. The corticosterone 
concentration of samples was determined from their B/B0 by interpolation from the standard 
curve. 
Unlabelled corticosterone (nmol/L) 
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removed and mixed with 1M magnesium chloride (1:1), samples were then vortexed, 
incubated on ice for 10min and centrifuged at 10,000g, 5min. The supernatant was used to 
measure triglyceride as in section 2.6.6. While the saponification generates glycerol the first 
step in the assay hydrolyses triglycerides into glycerol therefore the same assay can be used. 
2.8 Protein 
2.8.1 Tissue preparation for enzymatic activity assays 
To allow for enzyme activity analysis tissue homogenates of liver and adipose were made. In 
liver the homogenates were further processed to separate microsomes, the location of 11β-
HSD1, and cytosol as previously described (Livingstone et al., 2000; Livingstone et al., 
2005). 
2.8.1.1 Microsome and cystosol preparation 
Tissue (~100mg) was homogenised in 1.8ml homogenisation buffer (2.2.8), followed by 
centrifugation at 1000g ,4°C, 15 min to pellet heavy membranes. Supernatant was removed 
and subjected to ultra centrifugation using an Optima TLX, with a TLA100.3 rotor 
(Beckman Coulter, High Wycombe, UK) at 48,600rcf, 4°C, 30min to pellet membrane 
fraction. Supernatant was again removed and samples spun at 163,350rcf, 4°C, 1hr. 
Supernatant containing cytosol was aliquotted and stored at -80°C. The pellet containing 
microsomes was resuspended in 500µl Krebs buffer (2.2.9), aliquotted and stored at -80°C. 
2.8.1.2 Adipose tissue homogenates 
Tissue (~100mg) was homogenised in 1.8ml Krebs buffer (2.2.9) and centrifuged 1,000rcf, 
4°C, 5 min. The infranatant, a clear layer above the pellet and below the glycerol top 
containing the protein was removed, aliquotted and stored at -80°C. 
2.8.2 Enzymology 
2.8.2.1 11β-HSD1 activity 
11βHSD1 acts as a reductase in vivo, converting inactive 11-dehydrocorticosterone to 
corticosterone. However, in vitro, dehydrogenase activity predominates; therefore 11β-HSD1 
activity was quantified through conversion of corticosterone to 11-dehydrocorticosterone. 
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Enzyme kinetics were determined from hepatic microsomal fractions (section 2.8.1.1) and 
whole tissue homogenates from adipose (section 2.8.1.1). Tissue was incubated at 37°C in 
Krebs buffer containing glucose (1% w/v), NADP (2mM), 1,2,6,7-[
3
H]4-corticosterone (GE 
Healthcare) and unlabelled corticosterone. Protein concentration and time points were 
optimised for each tissue in each study to ensure first order enzyme kinetics; details are listed 
in relevant chapters. First order kinetics occurs when the rate of reaction is dependent on the 
concentration of only one reactant, such that if you double the amount of reactant the 
reaction velocity will also double. This linear relationship is only present up to a certain 
concentration, or time, after which the line starts to curve and flatten off. An example of a 
graph used during optimisation can be seen in Figure 2.4a, this shows the linear relationship 
between time and product formed is present. Other studies in our laboratory have shown the 
activity of 11β-HSD1 is in first order kinetics until 30% of substrate has been converted to 
product (Personal communication Dr R Andrews, University of Edinburgh).  
2.8.2.2 Steroid extraction and separation 
After incubations steroids were extracted into fresh tubes with 10x ethyl acetate, the organic 
phase was then evaporated under nitrogen at 60°C. The dried extracts were dissolved in 
500µl mobile phase (60% H2O, 15% Acetonitrile, 25% Methanol). Steroids were injected 
using a 717plus Autosampler (Waters Ltd., Hertfordshire, UK) and separated by high 
performance liquid chromatography (HPLC). Steroids were eluted (600 Controller pump, 
Waters Ltd.) with mobile phase (1.5ml/min, 45ºC) from a C18 Sunfire column (length 15cm; 
internal diameter, 4.6mm, pore size 5µm; Waters Ltd.) and quantified by on-line scintillation 
counting after mixing with Goldstar scintillation fluid (2ml/min; Meridian, Surrey, UK) 
using a scintillation pump (Berthold, Hertfordshire, UK). The proportion of corticosterone 
converted to metabolites was calculated by integrating the peak areas of the analytes in the 
chromatograms ( 
Figure 2.4) using Chromeleon software (Dionex, CA, USA). Specific activity was 
determined using the concentration of protein and substrate and time of incubation. Assays 
were performed in duplicate and deemed acceptable if they varied by <10%. Minimum peak 




Figure 2.4 Optimisation of first order kinetics for 11β-HSD1 assay and chromatogram showing separation of 11-dehydrocorticosterone 
(A) and corticosterone (B) by HPLC 
To ensure first order kinetics when determining activity of 11β-HSD1 product formed (pmols) from 2µM corticosterone was determined at 3 time points. 
3 samples from each group were used, in this case pre-pubertal animals investigated in chapter 4, and it shows the linear relationship was present over the 
range of incubation times used (a). Products of 11β-HSD1 assays were separated by HPLC and quantified using on-line scintillation counting. Standards 
were used to determine retention times (RT) of expected metabolites as is shown in (b). Enzyme activity was quantified by comparing the relative area of 
the substrate and product peaks following integration. 
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2.1 Imaging techniques 
2.1.1 Optical projection tomography (OPT) 
OPT is a relatively new 3D imaging technique which can be used to image murine 
neointimal lesions generated using the luminal wire injury model (section 2.3.5.4) (Kirkby et 
al., 2011). OPT provides images of a greater resolution to other methods available at a lower 
cost (Sharpe et al., 2002). While analysis by histology offers superior resolution than OPT, 
generating volumetric data by 3D reconstructions of 2D sections is lengthy, labour intensive 
and destructive. OPT can quickly provide 3D images of blood vessels, as well as leaving 
tissue intact allowing for further analysis with histology (Kirkby et al., 2011). 
The technique works by suspending the sample in a refractive index-matching solution and 
illuminating it with an ultraviolet source shone through a filter selective for a specific 
excitation wavelength. Photons emitted by endogenous fluorophores in the specimen are 
focussed through an emission filter to the detector. Multiple projections covering a 360° 
rotation of the sample are reconstructed using a modified computed tomography back-
projection algorithm to produce a 3D image. 
2.1.1.1  Tissue preparation 
Femoral arteries to be analysed by OPT were excised as described (2.3.4.2 & 2.3.4.3). Each 
femoral artery was suspended in 1.5% (w/v, 40ml) low melting point agarose which was 
cooled to 40-50°C and filtered through 113v Whatman paper (GE Healthcare). Arteries were 
suspended as straight as possible and agarose rapidly cooled. Gelled agarose blocks were 
fixed to magnetic mounts using cyanoacrylate adhesive (Henkel, Hertfordshire, UK) with the 
artery in the axis of the mount. The mounted blocks were trimmed into a conical shape to 
minimise back-reflection of light. Mounted samples were dehydrated in methanol (Fisher 
Scientific) for 24 hours then transferred to the refractive index matching solution BABB 
(2.2.4) and allowed to clear for >16 hours. 
2.1.1.2  Scanning and reconstruction 
Before scanning the optical projection tomograph (Bioptonics 3001, Bioptonics, Edinburgh, 
UK) was calibrated to the axis of rotation using the pin provided and applying an appropriate 
correction factor. Mounts with tissue attached were placed in the scanning chamber using the 
magnetic attachment. The sample position was adjusted until revolving around its own centre 
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of axis in the centre of the field of view. Magnification was set to 1pixel = 6µm, this was the 
maximum magnification possible to view the vessel. For scanning, samples were illuminated 
by a UV source with a 425/20nM band-pass excitation filter and 475nM low-pass emission 
filter (GFP filter) which strongly detects auto fluorescence. The exposure time was adjusted 
to maximise the resolution of the resulting image and the scanner focused by eye. Raw data 
was acquired by automated capture of images (1024 x 1024 pixels) at 0.9° rotation 
increments to give 400 images covering 360° rotation. After scanning the mounted femoral 
arteries were cleared of BABB in methanol >24hrs, detached from mounts and trimmed of 
excess agarose before processing for histology (section 2.2).  
Images were visually assessed for focus and rotation misalignment using appropriate 
software (Data Viewer, Sky Scan, Kontich, Belgium), before computed tomography 
reconstructions were calculated. A misalignment correction was applied to each dataset 
using NRecon Software (Skyscan) to compensate for defects in the axis of rotation. The 
compensation was calculated by manually viewing reconstructions of 2D planes at various 
points in the vessel.  
2.1.1.3  Quantification 
Reconstructed OPT data was quantified using CT data analysis software (CTan, SkyScan). 
In each vessel the region of interest, containing the intimal lesion, was defined. The border 
between the media and neointima (the internal elastic lamina) was estimated and traced 
~every 40 scans. This was possible due to the greater fluorescence emitted by the media. The 
intima/media border for the interleaved scans was interpolated by the software; this was 
checked and corrected where necessary. The defined volume, inside the internal elastic 
lamina, was subjected to a manually defined intensity threshold which produced a binary 
image with white pixels representing neointima and black pixels lumen. Volumes (µm
3
) of 
neointima and lumen were calculated from the stack of cross-section areas by the software. 
The volume of lesion was expressed according to the following equation 
 
As 3D volumetric data is calculated from a stack of 2D cross-section images, the maximum 
cross-sectional area of lesion can also be found in each vessel. The image with the largest 
neointima was selected as representative for each vessel. Stenotic ratio was calculated 
according to the following equation 
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2.2  Histological techniques 
2.2.1 Tissue preparation 
2.2.1.1  Preparation of vaginal smears 
Samples from vaginal smears (section 2.3.10) were air dried on to slides, to further fix the 
cells slides were immersed in 100% methanol (Fisher Scientific) for 2 minutes before 
staining. 
2.2.1.2  Preparation of femoral arteries 
To allow thin sections of tissues to be cut and analysed for morphology and composition 
samples were first processed. This removes water from the tissue and replaces it with 
paraffin wax which is solid at room temperature. The wax blocks containing tissue can then 
be cut and the wax is later removed when the tissue is stained. 
Femoral artery samples were processed in agarose due to prior OPT analysis (2.1.1). 
Samples were loaded into cassettes and processed to wax using a Tissue-Tek vacuum 
infiltration processor (Sakura Finetek Europe, Alphen aan den Rijn, The Netherlands) by the 
University of Edinburgh Histology Lab. Briefly, cassettes were dehydrated in increasing 
alcohol concentrations (50-100%), cleared in xylene and immersed in molten wax (Thermo-
Shandon, Cheshire, UK) at 60°C. This was performed under vacuum with agitation to ensure 
infiltration of solvent/wax. Samples were correctly positioned in molten paraffin embedding 
moulds and cooled on a Tissue-Tek Cryo-console (Sakura Finetek Europe) to solidify wax. 
Sequential 4µm sections were cut using a Leitz 1512 microtome (Leica Microsystems, 
Buckinghamshire, UK), then floated on a waterbath ~35°C to smooth the sections before 
being mounted 2 per slide (Superfrost Plus electrostatically-coated microscope slides, 
VWR). Slides were baked at 37°C overnight to fully adhere sections to slides. Femoral artery 
sections were mounted using the following pattern, 20 sections mounted then 20 sections 
(80µm) discarded, this was repeated until vessel morphology was normal, determined by 
microscopic analysis. Where possible OPT scans were used to determine the largest area of 
lesion and therefore when to stop sectioning. 
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2.2.2 Staining 
2.2.2.1  Grunewald-Giemsa staining 
Vaginal smears were stained with Grunewald-Giemsa, this visualises different cell types, 
specifically platelets and leukocytes which can be used to determine stage of estrus as 
previously described (Meziane et al., 2007).  
Fixed vaginal smears were immersed in 5%v/v Giemsa stain (stock 0.4% v/v, Sigma 
Aldrich) for 4 min, and washed in dH2O for 1 min. Smears were mounted in DPX mountant 
(BDH, Dorset, UK) and left to dry before microscopic analysis.  
2.2.2.2  United States Trichrome (UST) staining 
For morphological analysis the first femoral artery slide of each set was stained using a UST 
method (Hadoke et al., 1995). This stain uses a Gomori’s aldehyde Fucshin to stain Elastin, 
as well as Gomori’s trichrome which outlines collagen (blue-green), elastin (deep purple), 
and cells (cytoplasm – red, nuclei – black).  
Staining was carried out using an automated cytology stainer (Varistain Gemini, Thermo-
Shandon) as previously described (Hadoke et al., 1995). Briefly slides were deparaffinised in 
xylene (Fisher Scientific) and rehydrated through decreasing concentrations of alcohol 
(100%, 95% and 70%) to water. Sections were then bleached with potassium permanganate 
(2.2.3) followed by washing in 2% v/v oxalic acid. Sections were then stained with Gomori’s 
aldehyde fucshin (2.2.6), differentiated in 70% v/v alcohol and washed in running tap water. 
Nuclei were stained with Weigert’s iron haematoxylin (2.2.14), slides washed in distilled 
water then placed in 5% w/v phosphotungstic acid to de-stain collagen fibres. Slides were 
washed again then finally placed in Gomori’s trichrome reagent (2.2.7) to stain collagen and 
cytoplasm and rinsed in 0.2% v/v acetic acid. Sections were dehydrated through graded 
alcohols and cleared in xylene. Coverslips were mounted using Consulmount (Thermo-
Shandon) with an automated coverslipping device (Consul, Thermo-Shandon). The full 
staining protocol is detailed in Table 2.3. 
2.2.2.3  Photomicrograph acquisition 
Colour photomicrographs of stained tissue were taken to allow further analysis. Images were 
captured with a CoolSNAP colour camera (Photometrics, AZ, USA ) using 10x objective 
magnification (Axioskop stage microscope, Carl Zeiss Inc, Hertfordshire, UK) with a  
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Step Reagent  Duration 
1 Xylene 2 x 5min 
2 100% v/v ethanol 2 x 5min 
3 95% v/v ethanol 1 x 5min 
4 Running tap water 1 x 5min 
5 0.3% w/v potassium permanganate in 0.3% v/v sulphuric acid 1 x 1min 
6 Running tap water 1 x 1min 
7 2% oxalic acid 1 x 5s 
8 70% v/v ethanol  1x5min 
9 Gomori’s aldehyde fuchsin 1 x 5min 
10 70% v/v ethanol 1 x 2min 
11 Running tap water 1 x 5min 
12 Weigert’s iron haemotoxylin 1 x 5min 
13 5% w/v phosphotungstic acid 1 x 5min 
14 Running tap water 1 x 2min 
15 Gomori’s trichrome 1 x 20min 
16 0.2% v’v acetic acid 1 x 1min 
17 95% v/v ethanol 1 x 1min 
18 100% v/v ethanol 2 x 2min 
19 Xylene 2 x 2min 
 
Table 2.3 United States trichrome staining protocol 
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MicroColour liquid crystal RGB filter (Cambridge Research and Instrumentation Inc., MA, 
USA) using MCID basic 7.0 software (Interfocus Imaging Ltd., Cambridgeshire, UK).  
2.2.2.4  Analysis of vaginal smears 
Cell type/s present and abundance were determined on photomicrographs of smears. The 
stage of estrus was determined according to the details in Figure 2.5.  
2.2.2.5  Morphometric analysis of femoral artery  
UST staining allowed morphometric analysis of the femoral arteries. Both the external (EEL) 
and internal (IEL) elastic laminae could be seen in the sections and allowed measurements of 
medial area (between EEL and IEL), intimal lesion area (any cellular or thrombotic material 
between the IEL and lumen) and lumen (any empty space within IEL) to be made. 
Measurements were made using Photoshop CS3 software (Adobe systems, CA, USA) by 
tracing the lamina and areas calculated according to the scale 1 pixel = 0.5126µm
2
, 
determined by graticule slide. The section with the largest intimal area was chosen to 
represent each artery, and the stenotic ratio calculated as in section 2.1.1.3.   
2.3 Statistics 
Data are presented as mean ± SEM; statistical tests used are listed in individual chapters. 
Data were processed using Microsoft Office Excel 2007 (Microsoft, Berkshire, UK), graphs 
plotted using Prism 5.0 (GraphPad software, CA, USA) and statistical analysis carried out in 
Prism 5.0 or Statistica (Statsoft, Buckinghamshire, UK). In all studies n refers to the number 
of individual animals from which data were acquired. The numbers used in the studies were 
based on others in the published literature, where possible, which showed statistical 
differences in the parameters investigated. Our department has carried out and published 
many studies of metabolic function and glucocorticoid metabolism, similar to those in 
chapter 3, and found 8 animals per group provides adequate statistical power to find 
differences (Morton et al., 2005; Livingstone et al., 2009). Numbers used in studies of 
offspring metabolic and vascular physiology in chapters 5 and 6 were based on studies by 
Samuelsson et al. (Samuelsson et al., 2008) and Calvert et al. (Calvert et al., 2009). Studies 
investigating vascular function and remodelling numbers were based on the study by Molnar 




Figure 2.5 Analysis of vaginal smears using Giemsa staining 
Smear samples were obtained by vaginal lavage and stained using Giemsa. Stage of estrus 
cycle was determined by cell type, morphology and number as described in 
photomicrographs and text. Scale bar = 200µm. 
Stage of estrus cycle Details of cell histology 
Estrus Exclusively cornified epithelial cells, 
Diestrus Only leukocytes often few in number 
Metestrus Leukocytes in clumps, tendency to cluster around nucleated epithelial cells 
Proestrus Mostly nucleated epithelial cells with dispersed leukocytes 
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Chapter 3  
 
Sex differences in the response to 




There has been an increase in the prevalence of obesity over recent years, associated with an 
increase in cardiometabolic disorders such as type 2 diabetes, dyslipidemia and hypertension 
(Guh et al., 2009; WHO, 2011). Increasing evidence suggests the manifestation of obesity 
and associated metabolic disease is influenced by sex, with males at greater risk, and as a 
consequence the World Health Organisation is promoting gender specific research (Kautzky-
Willer A., 2009). 
Anatomical variations in the sites of deposition of adipose tissue have been suggested to play 
an important role in susceptibility to the metabolic sequelae of obesity. Men are prone to 
accumulate visceral adipose tissue, which is associated with metabolic abnormalities; 
whereas women tend to store fat in peripheral sites, such as subcutaneous and gluteal depots 
(Geer and Shen, 2009). Patients matched for the amount of subcutaneous adipose tissue, but 
with contrasting high or low visceral adipose accumulation, have very different insulin and 
glucose profiles (Ross et al., 2002a; Ross et al., 2002b). The sex-specific pattern of adipose 
distribution may be influenced by circulating androgens and estrogens. In men, post 
menopausal women, and ovariectomised animals, lower estrogen levels are associated with 
increased visceral adiposity and insulin resistance (Kotani et al., 1994; D'Eon et al., 2005). 
Exogenous estrogen treatment has been shown to be beneficial in reducing cardiovascular 
disease in observational studies of post-menopausal women (Stampfer et al., 1991) while 
randomised controlled trials found no benefit or, in fact, greater risk of disease (Herrington, 
1999). In males historical studies show estrogen increases coronary heart disease 
(Marmorston et al., 1962; CDPR Group, 1973). Changes in the concentrations of one sex 
steroid are unlikely to occur in isolation, as estrogen can be synthesised from testosterone 
(section 1.3.1) and an association between lower testosterone concentrations and increased 
cardiovascular disease risk in men has been found in some human and animal studies 
(reviewed in (Alexandersen et al., 1996), while women suffering from polycystic ovary 
syndrome with elevated testosterone concentrations are at increased risk (Talbott et al., 
1995). Additionally the balance of free androgens and estrogens can be controlled by sex 
hormone binding globulin (SHBG) in humans, which has itself been proposed to play a role 
in cardiovascular disease risk (Pugeat et al., 1995). 
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The reasons for increased susceptibility to obesity and the associated metabolic dysfunction 
in certain individuals are unclear. However, similarities between some of the clinical features 
associated with glucocorticoid excess as a consequence of Cushing’s syndrome and those 
found in the metabolic syndrome suggest a potential role for glucocorticoids. Increased 
peripheral glucocorticoid regeneration is found in the adipose tissue of obese humans (Rask 
et al., 2001; Rask et al., 2002; Wake et al., 2003) and rats (Livingstone et al., 2000a; 
Livingstone et al., 2000b), and transgenic over-expression of 11β-HSD1 in adipose tissue of 
mice causes obesity and metabolic dysfunction (Masuzaki et al., 2001). Interestingly male 
mouse models of dietary obesity have decreased 11β-HSD1 expression and activity in 
adipose tissue (Morton et al., 2004). This has been proposed to be a protective mechanism as 
mice with a targeted disruption of the gene show improved insulin sensitivity when fed a 
high fat diet (Kotelevtsev et al., 1997; Morton et al., 2001). Glucocorticoid metabolism in 
obese females has not been explored in mouse models. 
To allow further studies of the mechanisms involved in the progression of obesity and 
metabolic dysfunction, animal models have been extensively used. Although models of 
monogenic obesity are useful in studying the control of energy expenditure, only a very 
small percentage of the human population have similar loss of function mutations (Farooqi 
and O'Rahilly, 2005). More relevant to the modern obesity epidemic, which is believed to be 
polygenic in origin, are models of diet-induced obesity (DIO). Studies in rats (Pagliassotti et 
al., 1994; Pagliassotti et al., 1996; Levin et al., 1997) and mice (West et al., 1992; Surwit et 
al., 1995) have shown that induction of obesity is possible using high fat and/or sugar 
feeding, although the time taken for obesity and metabolic consequences to become manifest 
varies between strains. The C57BL/6 mouse strain is susceptible to the development of 
obesity and its metabolic consequences on a high fat and sugar diet (Surwit et al., 1988; 
West et al., 1992; Surwit et al., 1995) and was therefore chosen for the studies in this thesis. 
Generating the model in mice also gives the possibility for genetic manipulation in future 
studies to dissect potential mechanisms. However, few studies have investigated the effects 
of gender in models of rodent obesity. Studies in two genetic models of obesity and diabetes 
in rats suggest that there are sex-specific differences in the response to high fat diet (Maher 
et al., 1996; Corsetti et al., 2000) and studies in mouse models of dietary obesity suggest 
male animals are more prone to weight gain (Noonan and Banks, 2000; Nishikawa et al., 
2007) and metabolic dysfunction (Hwang et al., 2010) than females. Although the 
mechanisms controlling the sex-specific responses to diet-induced obesity in rodent models 
are unclear, studies showing that ovariectomised females gain more weight than males 
(Hong et al., 2009) suggest an important role for estrogen.  
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3.1.1 Hypothesis 
This chapter explores the hypothesis that the metabolic effects of consuming a high fat diet 
are more profound in male than female mice. 
 
3.1.2 Aims 
To investigate this hypothesis a model of dietary obesity in C57BL/6 mice was used to 
answer the following questions; 
 Does consumption of a high fat diet cause comparable increases in body weight and 
adipose deposition in male and female mice? 
 Presuming comparable increases in adipose tissue; do plasma lipid, glucose, insulin 
and corticosterone concentrations increase to a greater extent in male mice? 
 Does consumption of a high fat diet cause hepatic lipid accumulation in both sexes? 
 Does a high fat diet alter the mRNA abundance of genes involved in glucose and 
lipid metabolism in a sex specific manner? 
 Does a high fat diet alter the mRNA abundance and/or activity of glucocorticoid 
metabolising enzymes in the liver and adipose in a sex specific manner? 
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3.2 Methods 
3.2.1 Experimental Outline 
The experimental outline is presented in Figure 3.1. Blood pressure measurements are 
reported in chapter 6. 
3.2.2 Animal Maintenance and terminal procedures 
Male and female C57BL/6 mice (n=8/group from 8 litters) were fed control (CON, research 
diets D12328) or obesogenic (DIO, research diets D12331) diets ad libitum from 5 weeks of 
age and maintained as described (2.3.2). Five days prior to glucose tolerance testing animals 
were individually housed to allow for acclimatisation. 
Mice were killed by CO2 asphyxiation between 2-5pm, following a 6 hour fast, and tissues 
collected as described (0). Female mice were killed during estrus, as determined by vaginal 
smear (2.3.10) and Giemsa staining (2.2.2.1). The purpose of fasting and controlling for 
estrus cycle stage was to minimise variability in mRNA abundance and enzyme activity 
measured in tissues post mortem. 
3.2.3 Metabolic tests 
Male and female mice underwent a glucose tolerance test (2.3.7) at least 5 days after being 
individually housed and one week later diurnal blood samples were taken in line with the 
changing of the lights (2.3.8). 
3.2.4 Quantification of nutrients and hormones in plasma and hepatic 
triglycerides 
Levels of glucose (2.6.4) and insulin (2.6.2) were measured in plasma samples taken during 
the glucose tolerance test. Non-esterified fatty acids (NEFAs) were measured (2.6.7) in the 
first two glucose tolerance test samples. Plasma triglycerides were measured (2.6.6) in the 
fasting plasma sample. Corticosterone concentrations were measured (2.6.8) in diurnal blood 
samples, and cholesterol (2.6.5) in the nadir sample. Liver triglyceride was extracted using a 
saponfication method (2.7) and quantified using a colourimetric assay as in plasma.  
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Figure 3.1 Schematic of experimental outline 
Male and female C57BL/6 mice were fed control (CON, Research Diets D12328) or obesogenic (DIO, Research Diets D12331) diets from 5 weeks of 




3.2.5 Quantification of mRNA abundance 
RNA was isolated from liver (2.5.1.1) and subcutaneous adipose tissue (2.5.1.2), quantified 
(0) and used for cDNA synthesis (2.5.1.6). RNA was also extracted from the mesenteric 
adipose tissue, however the quality was not deemed high enough for use in quantitative PCR 
due to presence of degradation products despite several attempts. The abundance of mRNA 
encoding 5α-reductase type1 (5αR), 5β-reductase (5βR), 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1), estrogen receptor-α (ERα), fatty acid synthase (FAS), glucocorticoid 
receptor (GR), hormone-sensitive lipase (HSL), lipoprotein lipase (LPL), 
phosphenolpyruvate carboxykinase (PEPCK), peroxisome proliferator receptor α (PPARα) 
and peroxisome proliferator receptor γ (PPARγ) were determined as appropriate using qPCR 
(2.5.1.7). Due to the large sex differences in the abundance of mRNA encoding ER, separate 
standard curves of cDNA were made for males and females and the mRNA abundance 
analysed in the two sexes separately. In liver, mRNA transcript levels were normalised to the 
abundance of cyclophilin mRNA and in adipose tissue mRNA was normalised to β-actin 
mRNA abundance. 
3.2.6 Enzymology 
11β-HSD1 reductase activity was measured as described (2.8.2). Conditions were optimised 
for each tissue individually to ensure kinetics were in the first order (Table 3.1). While 5αR 
is active in both the liver and adipose, its activity is unstable ex-vivo and therefore 5αR 
activity could not determined. The activity of 5βR has been measured in previous studies 
(Livingstone et al., 2000b; Drake et al., 2005a; Barat et al., 2007; Livingstone et al., 2009) 
but conditions to produce reproducible results, with first order kinetics, could not be 
ascertained in this study.  
3.2.7 Statistics  
Data are presented as mean ± SEM and were analysed using two-way analysis of variance 
(ANOVA) or repeated measures ANOVA as appropriate to assess the overall effects of the 
obesogenic diet and sex. Fisher’s least squares difference post-hoc testing was used when 
appropriate to determine differences between individual groups. When applicable (i.e. in 
epididymal adipose tissue and for ER mRNA abundance), data were analysed in each sex 
separately using Student’s unpaired t test. 
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Table 3.1 Conditions for quantification of 11β-HSD1 activity 
Activity of 11β-HSD1 was quantified using radiolabelled corticosterone. The substrate and 










2 – ♂ 




0.025 - CON ♂ 
0.05 - CON ♀ 
0.1 – DIO ♂ & ♀ 
16 - CON ♂ 
20 - CON ♀ 
24 - DIO ♂ & ♀ 
Mesenteric adipose 
homogenate 9 
0.1 - CON 





3.3.1 The effects of diet-induced obesity and sex on physiology 
3.3.1.1 Body and Tissue Weights 
DIO caused a significant increase in weight gain between 5 and 13 weeks age in both sexes 
(Figure 3.2). At culling male DIO mice were 19.7% and females 14.4% heavier than their 
respective CON groups (Table 3.2). 
DIO increased the wet weights of subcutaneous, mesenteric, retroperitoneal and, for males 
only, epididymal adipose tissue (Table 3.2), this was also seen when tissue weights were 
expressed as a percentage of body weight (Figure 3.3). Female mice had smaller adipose 
depots than male mice (Table 3.2), though relative to body weight this was only true for 
mesenteric adipose (Figure 3.3). No interaction between the effects of diet and sex were 
found in wet (Table 3.2) or relative (Figure 3.3) adipose tissue weights.  
Liver and kidneys were smaller in females than males, DIO increased liver and kidney 
weight in both sexes (Table 3.2). When organ weights were expressed relative to body 
weight, only reduced liver size in females remained significant (Table 3.3). DIO and sex did 
not affect the wet weights of the adrenal glands or spleen (Table 3.2), however both were 
found to be larger in females when expressed relative to body weight (Table 3.3). 
3.3.1.2 Glucose Tolerance Test 
DIO caused an increase in plasma glucose and insulin concentrations during a glucose 
tolerance test (Figure 3.4A & B). A striking sex difference was found in that females had 
lower concentrations of both glucose and insulin, and only a small upwards shift of the 
response curve following DIO (Figure 3.4A & B). In contrast male DIO mice had elevated 
fasting plasma insulin concentrations and neither the plasma glucose nor insulin returned to 
baseline during the 90 minutes of the test. 
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Figure 3.2 Consumption of an obesogenic diet increases weight gain 
Male (blue) and female (pink) mice fed control (CON, open circles) or obesogenic (DIO, 
closed squares) diet from 5 weeks of age were weighed at regular intervals. a: effect of DIO 
to cause increased weight gain. b: effect of sex, such that females weighed less than males. 





Table 3.2 Body, adipose and organ weights from obese (DIO) and control (CON) mice 
Male and female mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age and killed at 16 weeks of age. Wet tissue weights were 
recorded at culling. DIO increased the weight of subcutaneous (SC.), mesenteric (Mes.), retroperitoneal (Ret.) and epididymal (Epi) adipose as well as liver 
and kidney. The wet weights of the same adipose depots and organs were smaller in females. There was no significant interaction between the effects of diet 
and sex. Adrenal gland and spleen weight were not altered as a result of DIO or sex. Data are mean ± SEM, analysed by 2 way ANOVA. Epididymal (Epi.) 
adipose weight was analysed by Student’s unpaired t-test. n=8/group. 
 Body, adipose and organ weights 
 Males Females Effect of diet Effect of sex Interaction 
 CON DIO CON DIO P value P value P value 
Cull weights (g) 27.4 ± 0.6 32.8 ± 1.0 22.2 ± 0.6 25.4 ±0.7 <0.001 <0.001 0.19 
SC. adipose (mg) 231 ± 17 404 ± 17 141 ± 14 267 ± 29 <0.001 <0.001 0.25 
Mes. adipose (mg) 198 ± 11 256 ± 19 106 ± 10 171 ± 23 <0.001 <0.001 0.86 
Ret. adipose (mg) 68 ± 9 129 ± 13 48  ± 5 80 ± 14 <0.001 <0.01 0.18 
Epi. adipose (mg) 186 ± 25 414 ± 42   <0.001   
Liver (g) 1.21 ± 0.07 1.30 ± 0.05 0.90 ± 0.02 1.13 ± 0.02 <0.01 <0.001 0.16 
Kidney (mg) 148 ± 20 195 ± 10 128 ± 04 142 ± 04 <0.05 <0.01 0.16 
Adrenal (mg) 3.6 ± 0.7 2.5 ± 0.3 4.1 ± 0.8 4.2 ± 0.7 0.43 0.11 0.38 
Spleen (mg) 96 ± 6 89 ± 6 96 ± 10 101 ± 2 0.41 0.41 0.83 
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Figure 3.3 Consumption of an obesogenic diet increased adiposity 
Male (blue) and female (pink) mice were fed control (CON, open bars) or 
obesogenic (DIO, closed bars) diet from 5 weeks age and killed at 16 weeks of age. 
Wet weights of; subcutaneous (SC.), mesenteric (Mes.), retroperitoneal (Ret.) and 
epididymal (Epi) adipose were recorded, and are expressed as a percentage of 
bodyweight. a: effect of DIO to increase percent of body weight contained in 
adipose tissue. b: effect of sex on the size of mesenteric adipose depots. Data are 
mean ± SEM, analysed by 2 way-ANOVA. Epididymal (Epi.) adipose weight was 
analysed by Student’s unpaired t-test. n=8/group, *p<0.05, ***p<0.001. 
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Table 3.3 Relative organ weights from obese (DIO) and control (CON) mice 
Male and female mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age and killed at 16 weeks of age. Wet tissue weights were 
recorded at culling and are expressed as a percentage of body weight. DIO did not affect the relative weights of the organs measured. Data are mean ± SEM, 
analysed by 2 way ANOVA n=8/group.  
 
 Relative organ weights 
 Males Females Effect of diet Effect of sex Interaction  
 CON DIO CON DIO P value P value P value 
Liver (%bw) 4.5 ± 0.1 4.4 ± 0.3 3.8 ± 0.1 3.9 ± 0.1 0.88 <0.001 0.62 
Kidney (%bw) 0.57 ± 0.07 0.70 ± 0.04 0.64 ± 0.01 0.68 ± 0.03 0.12 0.36 0.54 
Adrenal (%bw) 0.014 ± 0.003 0.009 ± 0.001 0.021 ± 0.004 0.020 ± 0.003 0.33 <0.01 0.47 
Spleen (% bw) 0.34 ± 0.03 0.33 ± 0.02 0.48 ± 0.04 0.48 ± 0.01 0.90 <0.001 0.80 
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Figure 3.4 Obesogenic diet has profound effects on plasma glucose and insulin 
in males 
Male (blue) and female (pink) mice were fed control (CON, open circles) or obesogenic 
(DIO, closed squares) diet from 5 weeks of age and underwent a glucose tolerance test at 13 
weeks of age. Glucose (A), insulin (B) and non-esterified fatty acids (NEFAs) (C) were 
measured in plasma samples collected during a glucose tolerance test. a: the effect of DIO to 
increase plasma glucose and insulin concentrations. b: effect of sex to decrease parameters 





Table 3.4 Concentrations of lipids and corticosterone in obese (DIO) and control (CON) mice 
Male and female mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age. Plasma lipid and corticosterone levels were measured in 
samples taken during metabolic tests. Hepatic triglyceride was analysed in post-mortem tissue. DIO increased lipid levels and decreased peak corticosterone 
concentrations. There were sex differences in plasma triglyceride and corticosterone concentrations. Data are mean ± SEM, analysed by 2 way ANOVA 
n=8/group. 
  
Lipid and hormone concentrations 
 Males Females Effect of diet Effect of sex Interaction of 
effects 
 CON DIO CON DIO P value P value P value 
Fasting plasma 
triglyceride (mmol/L) 
0.57 ± 0.03 0.78 ± 0.05 0.41 ± 0.03 0.54 ± 0.02 <0.001 <0.001 0.21 
Total plasma 
cholesterol (mmol/L) 
1.71 ± 0.13 2.67 ± 0.23 1.53 ± 0.17 2.86 ± 0.16 <0.001 0.55 0.56 
Hepatic triglyceride 
(nmol/mg) 
27.5 ± 3.7 60.6 ± 8.6 26.5 ± 3.0 58.5 ± 3.8 <0.001 0.77 0.93 
Nadir plasma 
corticosterone (nM) 
64.8 ± 8.0 70.8 ± 7.6 66.6 ± 14.3 62.1 ± 10.0 0.94 0.74 0.60 
Peak plasma 
corticosterone (nM) 
282.0 ± 43.0 177.0 ± 26.2 457.3 ± 62.0 375.0 ± 33.1 0.03 <0.001 0.79 
 
94 
3.3.1.3 Lipid Concentrations 
Neither sex nor diet had an effect on NEFA concentrations following a glucose bolus (Figure 
3.4C). DIO was associated with an increase in the plasma concentrations of triglycerides and 
total cholesterol as well as hepatic triglycerides in both sexes (Table 3.4). Plasma triglyceride 
concentrations were lower in females than males (Table 3.4). 
3.3.1.4 Corticosterone Concentrations 
The expected rise in corticosterone concentration over the dark phase, when mice are active, 
was seen in all groups. Neither obesity nor sex had an effect on nadir concentrations of 
corticosterone. However, at the peak of the circadian rhythm DIO was associated with a 
decrease in circulating corticosterone concentrations (Table 3.4). Females had higher peak 
plasma corticosterone concentrations than males (Table 3.4). 
3.3.1.5 Plasma concentrations of sex steroids 
An ELISA for measuring murine plasma estradiol, proposed to be the most accurate of those 
commercially available (Haisenleder et al. 2011) was used. However, in all samples, 
estradiol levels from both sexes were below the limit of detection and therefore the data are 
not presented in this thesis. Due to the lack of plasma and assay cost this was not repeated. 
Testosterone was measured in plasma from female mice, but the values obtained were below 
the limit of detection of the assay and therefore these data are not presented. Testosterone 
concentrations were measured in a group of comparable male animals and the data are 
presented and discussed in chapter 4. 
3.3.2 The effects of diet-induced obesity and sex on mRNA transcript 
abundance 
3.3.2.1 Glucose and lipid metabolising genes 
DIO did not affect the hepatic abundance of mRNAs encoding PEPCK, LPL, HSL or 
PPARα (Figure 3.5A). The abundance of mRNA encoding PPARα was higher in females 
than males (Figure 3.5B) and there was an interaction between the effects of DIO and sex on 
PEPCK, LPL and PPARα mRNA levels such that DIO was associated with an increase in 
males but either reduced or unaltered transcript abundance in females (Figure 3.5A). 
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Figure 3.5 Obesity and sex influence hepatic mRNA abundance 
Male (blue) and female (pink) mice were fed control (CON, open bars) or obesogenic (DIO, 
closed bars) diet from 5 weeks of age and killed at 16 weeks of age. Abundance of mRNA 
encoding proteins involved in (A) glucose and lipid metabolism and (B) glucocorticoid 
metabolism was quantified in liver and normalised to the abundance of mRNA encoding 
cyclophilin using qPCR. a: effect of DIO to increase mRNA abundance of 11β-HSD1 and 
GR. b:effect of sex on mRNA abundance of PPARα, 5αR and 5βR. c: interaction between 
the effects of diet and sex to affect the transcript levels of PEPCK, LPL, PPARα and 11β-




DIO was associated with a decrease in subcutaneous adipose abundance of mRNAs 
encoding PEPCK, LPL and PPARγ but did not affect HSL (Figure 3.6A). mRNA levels of 
both PEPCK and HSL were lower in females than males (Figure 3.6A) and additionally, 
there was an interaction between DIO 
and sex so that DIO caused a large decrease in PEPCK mRNA levels in males but had a very 
small effect on females (Figure 3.6A). 
3.3.2.2 Glucocorticoid metabolising genes 
In the liver DIO was associated with increased levels of mRNA encoding 11β-HSD1 and GR 
(Figure 3.5B) but did not affect the abundance of 5αR or 5βr mRNA. Females had lower 
transcript levels of 5αR mRNA and higher transcript levels of 5βR mRNA than males 
(Figure 3.5B). There was an interaction between the effects of DIO and sex on the 
abundance of 11β-HSD1 mRNA; whilst DIO increased abundance in both sexes, the effect 
was much greater in males than females. As glucocorticoid metabolism was a focus of this 
chapter further post-hoc analysis of 11β-HSD1 and GR mRNA abundance was carried out 
using Fisher’s least squares difference. This revealed higher levels of mRNA encoding 11β-
HSD1 in lean females than lean males (p<0.05) but no difference in GR. 
In the subcutaneous adipose DIO caused a significant reduction in the mRNA abundance of 
11β-HSD1 in both sexes but did not affect levels of mRNA encoding GR (Figure 3.6B) and 
there were no differences between sexes. Additional post-hoc analysis did not find any 
difference between male and female control animals. 5βR is not expressed in adipose and 
additionally, the abundance of 5αR mRNA could not be reliably determined in subcutaneous 
adipose tissue as transcript levels were very low. 
3.3.2.3 Estrogen receptor α 
mRNA encoding ERα was not detectable in male liver, but in female liver DIO did not alter 
its abundance (Figure 3.7A). There was no effect of DIO on mRNA abundacne of ERα in 
subcutaneous adipose tissue in either sex (Figure 3.7B & C), mRNA encoding ERβ was not 
detectable in subcutaneous adipose in either sex. 
3.3.3 The effects of diet-induced obesity and sex on 11β-HSD1 activity 
There was an interaction between DIO and sex such that DIO was associated with a trend to 
decreased hepatic 11β-HSD1 activity in males and increased activity in females (Figure 
3.8A).
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Figure 3.6 Obesity and sex influence mRNA abundance in subcutaneous adipose 
tissue 
Male (blue) and female (pink) mice were fed control (CON, open bars) or obesogenic (DIO, 
closed bars) diet from 5 weeks of age and killed at 16 weeks of age. Abundance of mRNA 
encoding proteins involved in (A) glucose and lipid metabolism and (B) glucocorticoid 
metabolism was quantified in subcutaneous adipose tissue and normalised to the abundance 
of β-actin using qPCR. a: effect of DIO to decrease abundance of mRNA encoding PEPCK, 
LPL, PPARγ and 11β-HSD1. b:effect of sex on abundance of mRNA encoding PEPCK and 
HSL. c: interaction between the effects of diet and sex to affect the transcript levels of 
PEPCK. Data are mean ± SEM, analysed by 2 way ANOVA; a: effect of diet, b: effect of 




Figure 3.7 Obesity does not affect mRNA abundance of estrogen receptor α 
Male (blue) and female (pink) mice were fed control (CON, open bars) or obesogenic (DIO, 
closed bars) diet from 5 weeks age and killed at 16 weeks of age. Abundance of estrogen-
receptor α (ERα) mRNA was quantified in female liver, normalised to cyclophilin mRNA 
(A), and male (B) and female (C) subcutaneous adipose tissue, normalised to β-actin mRNA, 
using qPCR. DIO did not cause any significant differences in abundance of mRNA encoding 
ERα. Data are mean ± SEM analysed using Student’s unpaired t-test; n=8/group in liver (A), 
5/CON group, 7/DIO group in subcutaneous adipose (B & C). 
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Figure 3.8 Obesity and sex influence 11β-HSD1 activity in the liver and adipose 
tissue 
Male (blue) and female (pink) mice were fed control (CON, open bars) or obesogenic (DIO, 
closed bars) diet from 5 weeks of age and killed at 16 weeks of age. The activity of 11β-
HSD1 was quantified using a radio-labelled tracer in hepatic microsomes (A), subcutaneous 
(B) and mesenteric (C) adipose tissue. a: effect of DIO to decrease 11β-HSD1 activity. b: 
effect of sex to lower 11β-HSD1 activity in females. c: interaction between the effects of diet 
and sex to affect 11β-HSD1 activity. Data are mean ± SEM, analysed by 2 way ANOVA; 
n=8/group, **p<0.01, ***p<0.001. 
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DIO caused a decrease in activity of 11β-HSD1 in subcutaneous (Figure 3.8B) and 
mesenteric (Figure 3.8C) adipose tissue. 11β-HSD1 activity was lower in adipose tissue in 
females (Figure 3.8B & C). The interaction between the effects of DIO and sex showed the 
relative reduction in activity was much larger in males (Figure 3.8B & C). 
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3.4 Discussion 
The results presented in this chapter demonstrate consumption of a high fat diet causes 
comparable increases in adipose deposition in both sexes as well as raised plasma and 
hepatic concentrations of lipids. However, the effects on glucose-insulin homeostasis were 
more profound in males such that they demonstrated fasting hyperinsulinaemia, glucose 
intolerance and insulin resistance during a glucose tolerance test. Further sex specific 
responses to a high fat diet were found in the hepatic and adipose mRNA abundance of 
genes involved in glucose, lipid and glucocorticoid metabolism. The activity of 11β-HSD1 in 
adipose tissue was found to be sexually dimorphic, with lower activity in lean females than 
males and reduced activity in response to DIO in both sexes. These results suggest that the 
sex differences reported in human obesity and rates of related cardiovascular disorders may 
also be apparent in mice. They also suggest a role for reduced adipose glucocorticoid 
regeneration in the apparent protection of glucose-insulin homeostasis in females. 
3.4.1 Body weight and adiposity 
Female mice are lighter than males and the difference in body weight following consumption 
of an obesogenic diet was less obvious in females. Female mice consuming an obesogenic 
diet were significantly heavier than controls although the increase was less than that seen in 
males. While few studies use female mice, slower weight gain when exposed to obesogenic 
diets is consistently reported (Noonan and Banks, 2000; Hong et al., 2009; Hwang et al., 
2010) despite comparable food intake between sexes (Noonan and Banks, 2000; Nishikawa 
et al., 2007; Hwang et al., 2010). It would have been beneficial to measure food intake and 
energy balance in this study to explore this sex difference. Whilst body weight is a useful 
measure of obesity, adipose depot weights may give a better indication of metabolic health 
as adiposity is associated with insulin resistance (Kaye et al., 1991) and coronary heart 
disease (Casassus et al., 1992) independently of body weight in humans. There was a similar 
increase in the percentage of body weight stored in adipose in both males and females on the 
obesogenic diet. In humans, females have a greater total body fat mass, with more 
subcutaneous adipose than males, although hepatic and intra-abdominal adipose are 
comparable between the sexes (Westerbacka et al., 2004). These patterns of deposition were 
not detected in the mice, though DIO females did have less mesenteric adipose tissue than 
males. Interestingly mesenteric adipose is the part of the visceral depot which is most 
correlated with metabolic disease both in humans (Fox et al., 2007) and mice (Rebuffe-
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Scrive et al., 1993). The differences in metabolism between males and females could reflect 
both the less severe weight gain and/or reduced amount of mesenteric adipose with DIO in 
females. 
3.4.2 Lipid concentrations 
DIO caused an increase in plasma and hepatic lipid concentrations consistent with previous 
studies (Gallou-Kabani et al., 2007; Oosterveer et al., 2009; de Meijer et al., 2010; Fraulob 
et al., 2010). DIO increased plasma triglyceride concentrations in both sexes but these were 
lower in control females than in males and the response to diet was also smaller in females. 
Interestingly this pattern was not seen with hepatic triglyceride or plasma cholesterol 
concentrations suggesting sex-specific lipid metabolism may be molecule and location 
specific. In normal physiology, NEFA concentrations fall in the fed state due to increased 
lipogenesis and reduced lipolysis (Kahn and Flier, 2000). Analysis of plasma NEFA 
concentrations did not reveal a clear effect of DIO or sex. Another study has reported lack of 
NEFA suppression in obese male mice (Burcelin et al., 2002). The reason this was not 
apparent in this chapter is probably due to the variation in results between mice. The mean 
values for male DIO mice were above all other groups, different statistical analysis, such as 
separating the sexes may demonstrate a lack of NEFA suppression. Insulin induces the 
switch from lipolysis to lipogenesis in response to feeding (Kahn and Flier, 2000) and lack 
of NEFA suppression is suggestive of insulin resistance. 
3.4.3 Glucose and insulin homeostasis 
Evidence for insulin resistance was noted in male DIO animals in the form of fasting 
hyperinsulinemia, as well as raised glucose and insulin concentrations throughout a 90 
minute glucose tolerance test, consistent with previous studies (Surwit et al., 1988; Surwit et 
al., 1991; Rebuffe-Scrive et al., 1993; Surwit et al., 1995; Collins et al., 2004). A striking 
effect of sex was noted in response to an endogenous glucose bolus: whilst obesity caused 
increased glucose and insulin concentrations in females the difference was much smaller 
than in males, and both parameters returned to baseline during the test. This is consistent 
with the few other studies investigating obesity in both sexes of mice (Noonan and Banks, 
2000; Gallou-Kabani et al., 2007; Hwang et al., 2010). The results in this chapter suggest 
females are more insulin sensitive than males when fed a control diet, and maintain 
sensitivity when fed an obesogenic diet, as has been demonstrated in human studies with pre-
menopausal women (Nuutila et al., 1995; Donahue et al., 1996; Ross et al., 2002b; Cnop et 
al., 2003; Moran et al., 2008).  
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The mechanism behind the greater insulin sensitivity in females, regardless of body weight, 
is unclear. As mentioned, human females have a greater percentage of body fat than males 
(Westerbacka et al., 2004) though this was not found in either the CON or DIO mice 
investigated in this chapter.  In fact all mice had comparable sized adipose depots when 
expressed relative to body weight, with the exception of a smaller mesenteric deposition in 
DIO females. The differences in mesenteric adipose may a play a role in the glucose-insulin 
homeostasis as visceral adipose has been associated with insulin resistance (Pouliot et al., 
1992; Fox et al., 2007; Despres et al., 2008). It has been suggested that the pattern of adipose 
deposition which occurs during and following puberty is a factor in insulin sensitivity, with 
females primarily accumulating peripheral adipose and males developing a more central 
pattern of adipose deposition (Kissebah and Krakower, 1994). The differences in the relative 
concentrations of sex steroids following puberty may account for these sex differences in 
adipose distribution and the associated insulin sensitivity seen in human and animal models. 
Estrogen, acting through the ERα receptor, has been shown to increase insulin sensitivity 
through inhibition of hepatic glucose production and increased glucose transport to muscle in 
mice (Bryzgalova et al., 2006), which would predict a healthier metabolic phenotype in 
obese females if estrogen concentrations are maintained. The sex differences found in this 
study resemble the maintenance of insulin sensitivity despite increase in adiposity in human 
females and support the use of female as well as male mice in studies of obesity and insulin 
resistance. 
3.4.4 mRNA abundance of glucose and lipid metabolising genes 
In male mice DIO caused an increase in hepatic mRNA abundance of glucose and lipid 
metabolising genes, but no changes were observed in females. This may reflect the more 
marked changes in glucose homeostasis in males. In contrast DIO affected mRNA transcript 
levels in the adipose tissue of both sexes, consistent with increased lipid levels and 
expansion of adipose. 
Levels of hepatic PEPCK are decreased in the fed state as a response to insulin release, and 
induced in the fasting state by glucagon to increase gluconeogenesis in liver (O'Brien et al., 
1990). The increase in hepatic PEPCK mRNA levels despite fasting hyperglycaemia 
suggests the males have hepatic insulin resistance resulting in a failure to suppress 
gluconeogenesis. Sex differences in PEPCK activity have been reported in rat liver 
(Wimmer, 1989a), as activity was not quantified in this study it is currently unclear if this is 
also found in mice. The same author reports anatomical differences in PEPCK activity 
throughout the liver with highest activity in the periportal zone declining towards the 
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perivenous zone (Wimmer, 1989b). While a sample of the left lobe was always used to 
extract RNA for the studies in this thesis the specific area within the lobe was not kept 
consistent and may explain why the mRNA abundance was quite variable. 
In adipose tissue PEPCK is regulated by the same hormones as in the liver, though 
glucocorticoids have the opposite effect. PEPCK catalyses glyceroneogenesis in adipose 
tissue, generating glycerol 3-phosphate and promoting fatty acid re-esterification (Pilkis and 
Granner, 1992). DIO males had fasting hyperinsulinaemia which would be predicted to 
decrease PEPCK mRNA as was found in the subcuaneous adipose. Transgenic over-
expression of PEPCK in adipose tissue results in increased lipid storage with the 
maintenance of insulin sensitivity (Franckhauser et al., 2002). However, when the same 
transgenic mice are fed an obesogenic diet they become more obese and are metabolically 
impaired compared with controls (Franckhauser et al., 2006), suggesting that lower adipose 
PEPCK expression may be beneficial when animals are exposed to an obesogenic diet. The 
female mice in this chapter had much lower subcutaneous adipose abundance of mRNA 
encoding PEPCK, regardless of diet. As the females have a preferable metabolic state and 
response to diet, this further suggests the change seen in obese males may be an attempt to 
compensate for, or reduce the consequences of, an obesogenic diet. 
In the liver the role of HSL is believed to be small (Reid et al., 2008), though the enzyme 
can hydrolyse cholesterol as well as intracellular triglyceride, as in adipose tissue (its 
primary site of action) (reviewed in (Holm et al., 2000)). The induction of hepatic HSL 
mRNA with fasting in DIO males may increase rates of lipolysis and direct free fatty acids to 
β-oxidation or back in to the circulation to be stored in a ‘metabolically safe’ manner in 
adipose, as is seen in HSL hepatic over-expressing mice (Reid et al., 2008). Interestingly, no 
increase of HSL mRNA abundance was found in DIO female mice, even though they have 
comparable hepatic triglyceride accumulation to males. Sex differences in HSL have been 
reported in human adipose tissue (Kolehmainen et al., 2002), consistent with the sex-specific 
expression in adipose tissue reported here. The activity of HSL is controlled by 
phosphorylation which is induced by catecholamines and insulin (Holm et al., 2000) so that 
hormone-induced phosphorylation may have a more important role in controlling tissue 
activity than mRNA abundance. 
LPL also hydrolyses triglycerides to release free fatty acids, though unlike HSL it acts on the 
lipid rich core of lipoproteins rather than intracellular triglycerides (Wang and Eckel, 2009). 
The enzyme is most abundant in muscle and adipose tissue, and on the epithelial cells of the 
blood vessels where it controls the uptake of fatty acids into tissues (Wang and Eckel, 2009). 
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Hepatic synthesis of LPL is low in adult compared to neonatal rat (Burgaya et al., 1989) and 
mouse (Yacoub et al., 1990) livers and its presence is believed to be mainly due to uptake 
from the circulation (Vilaro et al., 1988; Camps et al., 1991), which may explain why low 
levels of hepatic mRNA encoding LPL were detected in this study. Given that LPL is 
normally synthesised at low levels in the liver it is intriguing that DIO in male mice caused 
an increase in mRNA levels; predicting an increase in tissue fatty acid levels, which could 
then be incorporated into triglycerides for storage. Hepatic over-expression of LPL causes 
lipid accumulation and insulin resistance (Kim et al., 2001) which suggests the increase in 
mRNA in male DIO mice could be contributing to the metabolic phenotype seen. 
LPL synthesised in adipose tissue is transported to the capillary endothelial cells where it 
hydrolyses circulating lipoproteins to allow for uptake by the adipocytes. Studies have 
shown that LPL expression increases in adipose in line with triglyceride accumulation (Amri 
et al., 1996) and is induced in response to insulin (Picard et al., 2002). The decrease in LPL 
mRNA observed here would seem counterintuitive as it predicts a decrease in lipid uptake in 
adipocytes which would potentially contribute to lipid accumulation in other tissues such as 
liver. The transcription of LPL is controlled by many regulatory elements binding to its 5’ 
region (Preiss-Landl et al., 2002) and, in addition, LPL is under post-transcriptional, 
translational and post-translational regulation (reviewed in (Wang and Eckel, 2009), so that 
the differences found in mRNA may not be indicative of activity. 
Activation of PPARα induces transcription of genes involved in lipid oxidation (Gulick et 
al., 1994), and in the clinic agonists of this receptor are used as lipid lowering agents 
(reviewed in (Fruchart, 2009)). Increased mRNA abundance of PPARα in DIO males, along 
with increased concentrations of its endogenous ligand, free fatty acids, may represent a 
compensatory mechanism to increase fatty acid oxidation and reduce hepatic accumulation 
of triglycerides. The higher abundance of mRNA encoding PPARα in females, regardless of 
diet, is consistent with the literature, suggesting its control is sexually dimorphic (Yoon, 
2009) and indeed, receptor agonists are only effective in treating dyslipidemia in male mice 
(Yoon et al., 2002) or female mice following ovariectomy (Jeong et al., 2004). This implies 
an interaction between PPARα and estrogen; so that higher PPARα expression in females 
may be protective from some effects of obesity, resulting in higher basal oxidation of fatty 
acids. It therefore follows that the increase in mRNA abundance in response to DIO may be 
beneficial in males but the already higher levels in females cannot, or need not, be further 
modulated. 
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Adipose tissue PPARγ activation causes an increase in the transcription of molecules 
involved in lipid uptake and storage and modulates glucose metabolism (reviewed in (Lehrke 
and Lazar, 2005). Agonists of PPARγ are used clinically as insulin sensitising agents 
(Kintscher and Law, 2005) and were originally shown to have similar effects on insulin 
sensitivity in obese rodents (Chang et al., 1983a; Chang et al., 1983b; Chang et al., 1983c). 
Although there is an effect of an obesogenic diet to reduce PPARγ transcript levels, the 
difference is obviously greater in female mice. This reduction in PPARγ in response to DIO 
would predict a reduction in adipose lipid uptake and increased insulin resistance. However, 
contradictory results have been reported from two PPARγ knock-out models when fed a high 
fat diet; one study reported reduced adipose deposition and maintenance of insulin sensitivity 
(Jones et al., 2005), whilst the other reported insulin resistance in fat and liver (He et al., 
2003). It is, therefore, unclear whether the reduction in mRNA abundance seen in female 
mice following DIO, and the lower levels in males would have an adverse or beneficial 
effect in obesity. 
3.4.5 Hepatic glucocorticoid metabolism 
Studies in humans and mice have shown decreased or comparable hepatic 11β-HSD1 
expression and activity in obesity (Rask et al., 2001; Rask et al., 2002; Morton et al., 2004; 
Livingstone et al., 2009). However the results of this chapter show increased mRNA 
abundance in response to DIO, particularly in male mice. Whilst this may reflect a 
compensatory response to the lower circulating corticosterone concentrations found in the 
plasma, increased expression may be deleterious, as hepatic over-expression of 11β-HSD1 
results in fatty liver and insulin resistance (Paterson et al., 2004). Changes in enzyme activity 
differed from those in mRNA abundance, suggesting either post-transcriptional mechanisms 
of regulation or enzyme inhibition. Biochemical studies of 11β-HSD1 show it to be folded 
and glycosylated in the ER (Ozols, 1995) and it is possible that alterations in this ER 
processing could underlie the differences between mRNA abundance and activity. Levels of 
circulating androgens, estrogens and/or growth hormone may underlie the sex differences in 
11β-HSD1 in CON animals. An inhibitory effect of pharmacological levels of estrogen on 
transcription of 11β-HSD1 has been found in rats (Low et al., 1994; Jamieson et al., 1999; 
Andersson et al., 2010) although mRNA abundance was higher in female than male mice. 
Conversely, one study showed that testosterone treatment in gonadectomised rats caused up-
regulation of 11β-HSD1 mRNA and activity (Liu et al., 1998); although another study found 
no effect of androgen treatment in intact animals (Nwe et al., 2000).  
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Whilst the diet-induced changes seen in 11β-HSD1 were sex specific, GR mRNA abundance 
increased in DIO in all mice. This may reflect a compensatory response to decreased 
circulating corticosterone concentrations. However, the consistency in both sexes, despite 
potential differences in glucocorticoid regeneration by 11β-HSD1, suggests it may be a 
response to increasing adiposity or other metabolic parameters occurring in both male and 
female mice. 
Increased metabolism of glucocorticoids by 5αR has also been reported in human (Andrew 
et al., 1998) and rodent obesity (Livingstone et al., 2005; Livingstone et al., 2009). In this 
study obesity did not affect the abundance mRNA encoding 5αR but was associated with 
increased levels of 5βR mRNA in males. This may be important as 5α-reduced metabolites 
can still activate the glucocorticoid receptor (McInnes et al., 2004). Therefore increased 
metabolism specifically through the 5β-pathway would be predicted to reduce local 
glucocorticoid concentrations and signalling. Thus, the higher baseline abundance of 5βR 
mRNA in females may be protective and the increase seen in DIO males may be a 
compensatory mechanism. Changes in metabolism may also reflect the dual function of the 
liver to maintain circulating corticosterone concentrations as a consequence of increased 
regeneration by 11β-HSD1, whilst reducing local concentrations by increased degradation by 
5βR (Mayes and Watson, 2004). Sex differences have been reported in rat 5αR expression 
(Normington and Russell, 1992) with much higher expression in female livers. However the 
opposite was found in the results of this chapter. Whether the species differences are due to 
the nutritional state in which the animals were killed, as is seen with PEPCK expression 
(Wimmer, 1989b), is unclear. Interestingly, in lean humans, disproportionally low 
concentrations of 5α-reduced metabolites are found in urine of females compared with males 
(Finken et al., 1999), which suggests the metabolism in the female mice shares some 
similarities to that seen in humans. 
3.4.6 Adipose glucocorticoid metabolism  
The results of this chapter support previous studies demonstrating that male mice fed an 
obesogenic diet have reduced subcutaneous adipose expression and activity of 11β-HSD1 
(Morton et al., 2004) and this may be a protective mechanism to reduce local glucocorticoid 
signalling. Additionally, the results here demonstrate that subcutaneous adipose 11β-HSD1 
mRNA abundance and mesenteric and subcutaneous adipose activity are lower in females 
than in males, consistent with data in humans (Paulsen et al., 2007). These results suggest a 
new hypothesis; that a lower level of adipose glucocorticoid regeneration in females may be 
advantageous, reducing the metabolic complications associated with obesity. Evidence 
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suggests that both estrogen and testosterone can modulate the transcription and activity of 
11β-HSD1 in the adipose of humans (Zhu et al., 2010) and rodents (Paulsen et al., 2008; 
Tagawa et al., 2009). These observations suggesting interactions between sex hormones, 
obesity and 11β-HSD1 will be explored further in the next chapter. 
The activity of 11β-HSD1 was much lower in mesenteric than subcutaneous adipose but the 
sex-specific and diet-induced changes were maintained across both depots. Changes in 11β-
HSD1 following obesity have been shown to be specific to the particular adipose depot 
studied in some rodent models (Livingstone et al., 2000a; Livingstone et al., 2009). However 
a study comparing subcutaneous and visceral adipose tissue from humans found no 
differences in mRNA abundance between depots (Paulsen et al., 2007). Depot-specific 
glucocorticoid metabolism may be important in the development of the obesity-related 
metabolic syndrome. If increased local glucocorticoid regeneration causes fat accumulation 
and insulin resistance, the effects on metabolism may be less marked if this occurs in 
subcutaneous rather than visceral adipose. Given the sex differences in adipose distribution, 
depot specific differences in glucocorticoid metabolism could be important in the sexually 
dimorphic effects seen in obesity. 
3.4.7 Study limitations 
Although there was a significant increase in adipose tissue weight in the DIO mice of both 
sexes the increase in body weight was less profound in females. A greater difference in 
bodyweight was found in another cohort of female mice used to study the effects of maternal 
obesity (Chapter 5). The animals were a similar age to those studied in this chapter but had 
not undergone any metabolic studies at this point. This may suggest the female DIO mice 
were highly affected by the inevitable stress of the procedures, studies of food intake would 
help to address this issue. In addition the levels of obesity achieved in these studies were 
modest in comparison to others investigating metabolism (Black et al., 1998; Surwit et al., 
1995) and glucocorticoid metabolism (Morton et al., 2004), primarily due to longer feeding 
periods. Extending the feeding time in future experiments may allow for easier comparison 
to the published data. This is of particular importance in female mice; if the increase in body 
weight could be comparable to that found in males greater interpretation of sex differences 
could be made. 
While many interesting changes in response to DIO and due to sex were found in the 
abundance of mRNAs whether this translates to protein levels is unknown. Many 
mechanisms can alter the amount of mRNA which is translated to protein. Additionally post-
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translational modifications can affect protein structure and function and enzyme activity. In 
order to determine if the differences found in mRNA are playing a role in the metabolic 
response to obesity more investigations are required. Overall protein concentrations could be 
determined using western blotting and more specific cellular location by 
immunohistochemistry. Where enzymes are concerned activity assays should also be 
completed. In addition experiments investigating the abundance of mRNAs in subcutaneous 
adipose tissue may have been statistically under powered. Whilst 8 animals were used in 
each group good quality RNA could not be extracted from all of them, therefore reducing the 
n numbers from what was planned. This may lead to type 2 errors; failing to reject a false 
null hypothesis. Using a larger cohort of animals would ensure the investigations would be 
adequately powered even if some samples were not useable. 
3.4.8 Conclusions 
In summary, exposure to an obesogenic diet is associated with weight gain and increased 
adipose deposition in both sexes. The accompanying changes in metabolism are sex specific, 
with males becoming insulin resistant whilst females remain insulin sensitive. The 
differences in physiology may be influenced by sexually dimorphic changes in genes 
involved in glucose and lipid metabolism. Furthermore, the sex specific profiles of 
glucocorticoid metabolising enzymes, specifically lower activity of 11β-HSD1 in females, 
may play a role in determining the metabolic response to a high fat and sugar diet. 
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Chapter 4  
 
Effects of estradiol on the response 




The work described in chapter 3 shows that the physiological response to obesity in mice 
differs between the sexes, with females maintaining insulin sensitivity despite diet-induced 
increases in adiposity. Many studies have proposed that estrogen may play an important role 
in protecting females from the deleterious effects of obesity (reviewed in (Mayes and 
Watson, 2004; Meyer et al., 2011)). The risk of developing obesity and the metabolic 
syndrome increases after the menopause (Poehlman et al., 1995) or ovariectomy (Hong et 
al., 2009) and this effect is reversed after treatment with exogenous estrogen (McElroy and 
Wade, 1987). In addition, estrogen regulates body fat distribution, energy balance, insulin 
synthesis, hepatic glucose production and lipid deposition (reviewed in (Meyer et al., 2011)). 
However, many of the pathways through which estrogen elicits these effects remain to be 
discovered. The findings in transgenic mouse models lacking estrogen or its receptor suggest 
that estrogen may also have a role in male adipose tissue deposition. Male mice lacking 
aromatase (Fisher et al., 1998) or estrogen receptor (ER) (Heine et al., 2000) have increased 
adipose depots and develop insulin resistance, although both models are also associated with 
elevations in testosterone concentrations. Whilst these studies have described the deleterious 
effects of removing estrogen signalling on adiposity and metabolism, the effects of increased 
estrogen levels in male animals have been less well characterised. 
The changes in circulating sex steroids as a consequence of sexual maturation are associated 
with the development of obesity in male ERα KO mice (Ohlsson et al., 2000). Since these 
mice lack estrogen action through ERα receptor, this suggests that estrogen action may be 
associated with protection from the development of obesity following the maturational 
changes which occur at puberty. In addition to the changes in circulating steroids occurring 
during puberty, in rats the sexually dimorphic expression of some liver enzymes is 
programmed by sex steroid exposure during early life, with reinforcement of these 
differences occurring at puberty (Gustafsson et al., 1977). The sex differences in mRNA 
abundance and enzyme activity reported in chapter 3 may, therefore, occur as a result of 
exposure to sex steroids during prenatal or early postnatal development or as a consequence 
of the changes in sex steroids following puberty. 
As discussed in chapter 3, the lower activity of 11β-HSD1 in adipose tissue of lean females 
may be one mechanism protecting females from the deleterious effects of exposure to an 
obesogenic diet. Although the pathways underlying the sexually dimorphic transcript levels 
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and activity of 11β-HSD1 in the mouse are not known, in rats estradiol inhibits the 
transcription of hepatic 11β-HSD1 (Low et al., 1994; Jamieson et al., 2000) and acts as a 
non-competitive inhibitor in adipose tissue (Tagawa et al., 2009). Additionally, 11β-HSD1 
activity in subcutaneous adipose increases following estrogen depletion at the menopause in 
humans (Andersson et al., 2009). This evidence suggests a role for estrogen in mediating the 
sex differences in local glucocorticoid regeneration. 
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4.1.1 Hypothesis 
Estrogen exerts a protective effect against the metabolic consequences associated with diet-
induced obesity in C57BL/6 adult mice. This is mediated in part through effects on 
peripheral glucocorticoid metabolism. 
 
4.1.2 Aims 
To investigate this hypothesis two groups of mice were used. The first cohort was killed pre-
puberty to answer the following questions: 
 Are sex differences in glucose, lipid and glucocorticoid metabolising genes already 
present before puberty? 
The second group used obese and lean male mice generated as described in chapter 3, with 
the addition of continuous estradiol treatment from a slow-release pellet to answer the 
following questions: 
Does administration of estradiol: 
 Alter body weight and adiposity caused by DIO in male mice? 
 Modulate the development of obesity-associated insulin resistance? 
 Modify the increases in plasma and hepatic lipids seen in DIO? 
 Alter the mRNA abundance of genes involved in glucose and lipid metabolism? 
 Alter the mRNA abundance and/or activity of glucocorticoid metabolising enzymes 




4.2.1 Experimental outline 
C57BL/6 mice (n=8/group from 8 litters) of both sexes used in the pre-pubertal experiments 
were culled between 3 and 4 weeks of age, following a physical examination for signs of 
puberty. Female mice were assessed for vaginal opening and male mice assessed for balano-
preputial separation. If either characteristic was detected the animal was deemed to be in 
puberty and not used in this cohort. Onset of puberty varies between strain and animal 
facility: in our animal facility puberty in C57BL/6 mice has been found to begin at 33.1 ± 0.8 
days in both sexes (Personal communication Dr Caitlin Wyrwoll, University of Edinburgh 
and University of Western Australia).  
The experimental outline for adult mice used in this chapter can be seen in Figure 4.1. 
4.2.2 Animal Maintenance and terminal procedures 
Male C57BL/6 mice were fed control (CON, research diets D12328) or obesogenic (DIO, 
research diets D12331) diets ad libitum from 5 weeks and maintained as described (2.3.1). 
At 6 weeks mice underwent estradiol pellet implantation surgery (see below) providing four 
groups (Sham CON n=11, Sham DIO n=11, Estradiol CON n=12, Estradiol DIO n=12). 5 
days prior to glucose tolerance testing animals were individually housed to allow for 
acclimatisation. 
Mice were killed by CO2 asphyxiation and tissues collected as described (0). Pre-pubertal 
mice were killed between 2-4pm following a 2 hour fast and adult mice between 2-5pm, 
following a 6 hour fast. The purpose of fasting was to minimise variability in gene 
expression and enzyme activity measured in tissues post mortem. 
4.2.3 Estradiol pellet implantation surgery 
Ninety-day release, 0.25mg 17β-estradiol pellets were implanted in male mice at 6 weeks 
age (2.3.5.3), to consistently release the hormone for the remainder of the study (Estradiol 
CON n=12, Estradiol DIO n=12). A control group underwent sham surgery (Sham CON 
n=11, Sham DIO n=11), which involved all surgical procedures with the exception of the 
pellet being implanted. Animals were left to recover as described (2.3.5.2) before being  
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Figure 4.1 Schematic of experimental outline 
Male C57BL/6 mice were fed control (CON, Research diets D12328) or obesogenic (DIO, 
Research diets D12331 diets from 5 weeks of age. One week later mice underwent surgical 
implantation of an estradiol pellet, or sham surgery giving 4 groups; Sham CON n=11, Sham 
DIO n=11, Estradiol CON n=12, Estradiol DIO n=12. At 12 weeks of age mice were 
individually housed and underwent metabolic tests. Animals were then killed and tissues 
weighed and collected. 
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returned to the home cage with the relevant experimental diet. Cages housed a mixture of 
estradiol and sham treated animals on the same experimental diet. 
4.2.4 Metabolic tests 
Mice underwent a glucose tolerance test (2.3.7) at least 5 days following individual housing; 
a week later diurnal blood samples were taken in line with the light cycle (2.3.8). 
4.2.5 Quantification of nutrients and hormones in plasma and hepatic 
triglycerides 
Levels of glucose (2.6.4) and insulin (2.6.2) were measured in plasma samples taken during 
the glucose tolerance test. Non-esterified fatty acids (NEFAs) were measured (2.6.7) in the 
first two glucose tolerance test samples. Plasma triglycerides were measured (2.6.6) in the 
fasting plasma sample. Corticosterone concentrations were measured (2.6.8) in diurnal blood 
samples, and cholesterol (2.6.5) in the nadir sample. Liver triglyceride was extracted using a 
saponification method (2.7) and quantified using a colourimetric assay as in plasma. 
Testosterone was measured (2.6.3) in blood samples collected at post-mortem; estradiol 
could not be quantified. For further discussion see sections 3.3.1.3 & 4.4.6. 
4.2.6 Quantification of mRNA abundance 
RNA was isolated from liver (2.5.1.1) and subcutaneous adipose tissue (2.5.1.2), quantified 
(0) and cDNA synthesised using RT-PCR (2.5.1.6). The abundance of mRNA encoding 5α-
reductase type 1 (5αR), 5β-reductase (5βR), 11β-hydroxysteroid dehydrogenase (11β-
HSD1), androgen receptor (AR), estrogen receptor-α (ERα), fatty acid synthase (FAS), 
glucocorticoid receptor (GR), hormone-sensitive lipase (HSL), lipoprotein lipase (LPL), 
phosphoenolpyruvate carboxykinase (PEPCK), peroxisome proliferator receptor α (PPARα) 
and peroxisome proliferator receptor γ (PPARγ) were determined using qPCR (2.5.1.7). In 
adult mice hepatic and adipose mRNA abundance were normalised to the average abundance 
of mRNAs encoding cyclophilin and β-actin. In pre-pubertal mice hepatic and adipose 
mRNA transcript levels were normalised to the abundance of cyclophilin mRNA. 
4.2.7 Enzymology 
11βHSD1 reductase activity was measured as described (2.8.2). Conditions are shown in 














0.025 – Estradiol 
CON & DIO, Sham 
DIO 
0.05 – Sham CON 
0.05 - Pre-pubertal 
20 – Estradiol & 
Sham 
 
24 – Pre-pubertal 
Table 4.1 Conditions for quantification of 11β-HSD1 activity 
Activity of 11β-HSD1 was quantified using a radiolabelled substrate. The substrate and 
protein concentration as well as incubation time were optimised to give first order kinetics in 
each tissue. 
 
4.2.8 Statistics  
Data are presented as mean ± SEM. Differences between males and females pre-puberty 
were assessed using unpaired Student’s t-test. For the adult study, 2-way analysis of variance 
(ANOVA) or repeated measures 2-way ANOVA was used to analyse the effects of the 




4.3.1 Sex differences in mRNA abundance and enzyme activity pre-
puberty 
4.3.1.1 Glucose and lipid metabolism 
There were no differences between males and females in the hepatic mRNA levels of 
PEPCK, LPL or HSL, while PPARα transcript levels were higher in females (Figure 4.2A). 
In subcutaneous adipose tissue, there were no differences between the sexes in the 
abundance of mRNA encoding PEPCK, LPL, FAS or PPARγ, however females had higher 
transcript levels of HSL (Figure 4.3A). 
4.3.1.2 Glucocorticoid metabolism 
There were no differences between males and females in the hepatic abundance of mRNA 
encoding 11β-HSD1, 5αR or 5βR, but females had greater abundance of GR (Figure 4.2B). 
In subcutaneous adipose tissue, sex did not affect the transcript levels of GR or 11β-HSD1 
(Figure 4.3B). In addition there were no sex differences in the activity of 11β-HSD1 in the 
liver (Figure 4.4A) or subcutaneous adipose (Figure 4.4B). 
 
4.3.2 The effects of estradiol treatment and diet-induced obesity on 
physiology in adulthood 
4.3.2.1 Body and tissue weights 
DIO caused a significant increase in weight gain over the duration of the study (Figure 4.5). 
Estradiol administration reduced weight gain regardless of diet (Figure 4.5) and at culling 
sham DIO mice were 27% heavier than CON while estradiol-treated DIO mice were only 
8.8% heavier than their controls (Table 4.2). 
Estradiol treatment had a striking effect on adipose weight such that it blocked the majority 
of the DIO induced increase in adipose tissue seen in sham animals when expressed either as 
wet tissue weight (Table 4.2) or relative to body weight (Figure 4.6). DIO increased wet liver 
weight (Table 4.2), but caused a reduction relative to body weight (Table 4.3). In addition  
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Figure 4.2 Sex determines hepatic abundance of mRNA encoding PPARα and 
GR in mice pre-puberty 
Male (blue bars) and female (pink bars) mice were killed before the onset of puberty, 
between 21-28 days. Abundance of mRNAs encoding proteins involved in (A) glucose and 
lipid metabolism and (B) glucocorticoid metabolism were quantified in liver and normalised 
to mRNA levels of cyclophilin using qPCR. Females had greater abundance of PPARα and 
GR mRNA. Data are mean ± SEM, analysed by Student’s t-test; n=8/group, *p<0.05. 
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Figure 4.3 Sex determines subcutaneous adipose mRNA abundance of HSL in 
mice pre-puberty 
Male (blue bars) and female (pink bars) mice were killed before the onset of puberty. 
Abundance of mRNAs encoding proteins involved in (A) glucose and lipid metabolism and 
(B) glucocorticoid metabolism were quantified in subcutaneous adipose and normalised to 
mRNA levels of cyclophilin using qPCR. Females had a greater abundance of mRNA 
encoding HSL. Data are mean ± SEM, analysed by Student’s t-test; n=8/group, *p<0.05. 
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Figure 4.4 Sex does not affect 11β-HSD1 activity in mice pre-puberty 
Male (blue bars) and female (pink bars) mice were killed before the onset of puberty. The 
activity of 11β-HSD1 was quantified in liver (A) and subcutaneous adipose (B) tissue 




Figure 4.5 Continuous estradiol treatment ameliorates DIO-induced weight gain 
in male mice 
Male mice were fed control (CON, open symbols) or obesogenic (DIO, closed symbols) 
diets from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous 
release 17β-estradiol pellet (Estradiol, purple symbols) or sham surgery (sham, green 
symbols). Mice were weighed weekly. a: effect of DIO to increase weight gain, b: effect of 
estradiol to reduce body weight. Data are mean ± SEM, analysed by repeated measures 2-




Table 4.2 Body, adipose and organ weights from male obese (DIO) and control (CON) mice treated with estradiol 
Male mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 17β-
estradiol pellet (Estradiol) or sham surgery (sham). Mice were killed at 16 weeks of age and wet tissue weights recorded. DIO mice were heavier than 
controls, and had larger adipose depots, livers and kidneys. Additionally estradiol affected body weight, and wet weights of adipose tissue, liver, kidney and 
testis. There was an interaction of the effects of DIO and estradiol on body and adipose tissue weight. Data are mean ± SEM, analysed by 2 way ANOVA 
n=11/Sham group, 12/Estradiol group.  
 Body, adipose and organ weights 
 Sham Estradiol Effect of diet Effect of estradiol Interaction  
 CON DIO CON DIO P value P value P value 
Cull weights (g) 26.3 ± 0.4 33.4 ± 1.0 23.8 ± 0.3 25.9 ±2.1 <0.001 <0.001 <0.001 
SC. Adipose (mg) 205 ± 15 579 ± 58 169 ± 15 225 ± 22 <0.001 <0.001 <0.001 
Mes. Adipose (mg) 151 ± 19 389 ± 33 130 ± 58 191 ± 19 <0.001 <0.001 <0.01 
Ret. Adipose (mg) 52 ± 6  218 ± 21 33 ± 3 64 ± 7 <0.001 <0.001 <0.001 
Epi Adipose (mg) 189 ± 12  750 ± 50 120 ± 12 224 ± 32 <0.001 <0.001 <0.001 
Liver (g) 1.00 ± 0.03 1.17 ± 0.05 0.97 ± 0.03 1.02 ± 0.04 <0.01 <0.05 0.11 
Kidney (mg) 153 ± 4 171 ± 10 139 ± 3 159 ± 6 <0.01 <0.05 0.80 
Adrenal (mg) 3.3 ± 0.05 4.6 ± 0.08 3.5 ± 0.03 4.7 ± 0.08 0.06 0.84 0.93 
Testis (mg) 101 ± 4 112 ± 3 66 ± 5 71 ± 8 0.13 <0.001 0.57 
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Figure 4.6 Continuous estradiol treatment attenuates obesity-associated adipose 
deposition 
Male mice were fed control (CON, hatched bars) or obesogenic (DIO, closed bars) diets 
from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 
17β-estradiol pellet (Estradiol, purple bars) or sham surgery (sham, green bars). Mice were 
killed at 16 weeks of age and wet weights of; subcutaneous (SC.), mesenteric (Mes.), 
retroperitoneal (Ret.) and epididymal (Epi) adipose recorded. a: effect of DIO to increase 
percent of body weight contained in adipose tissue, b: effect of estradiol to reduce adipose 
deposition, c: interaction between the effects of diet and estradiol. Data are expressed as a 
percentage of bodyweight. Graph shows mean ± SEM, analysed by 2 way-ANOVA; 
n=11/Sham group, 12/Estradiol group ***p<0.001. 
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Table 4.3 Relative organ weights from male obese (DIO) and control (CON) mice treated with estradiol  
Male mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 17β-
estradiol pellet (Estradiol) or sham surgery (sham). Mice were killed at 16 weeks of age and wet tissue weights were recorded; these are expressed as a 
percentage of body weight. DIO mice had relatively larger livers and estradiol affected liver, kidney and testis size. Data are mean ± SEM, analysed by 2 way 
ANOVA n=11/Sham group, 12/Estradiol group.  
 Body and Organ weights  




 CON DIO CON DIO P value P value P value 
Liver (%bw) 3.8 ± 0.1 3.5 ± 0.1 4.1 ± 0.1 3.9 ± 0.1 <0.05 <0.01 0.69 
Kidney (%bw) 0.59 ± 0.01 0.51 ± 0.03 0.58 ± 0.01 0.62 ± 0.03 0.44 <0.05 <0.05 
Adrenal (%bw) 0.013 ± 0.002 0.014 ± 0.003 0.015 ± 0.002 0.018 ± 0.003 0.33 0.18 0.63 
Testis (% bw) 0.38 ± 0.02 0.34 ± 0.01 0.28 ± 0.02 0.27 ± 0.03 0.20 <0.001 0.34 
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estradiol reduced liver weight but increased it relative to body weight. Estradiol caused a 
reduction in actual and relative testes size (Table 4.2 & Table 4.3). 
4.3.2.2 Glucose tolerance test 
DIO was associated with an increase in plasma glucose and insulin during glucose tolerance 
testing in all mice (Figure 4.7A & B). Estradiol-treated mice had lower glucose and insulin 
concentrations when compared with sham animals. Estradiol treatment reduced the increase 
in plasma insulin and glucose associated with DIO (Figure 4.7A & B). 
4.3.2.3 Lipid concentrations 
Neither diet nor estradiol-treatment affected the suppression of NEFAs in the plasma 
following a glucose bolus (Figure 4.7C). DIO caused an increase in the concentrations of 
plasma triglycerides and total cholesterol as well as hepatic triglycerides (Table 4.4). 
Estradiol did not affect any of these parameters in CON mice, but reduced the DIO 
associated increase in hepatic triglycerides (Table 4.4). 
4.3.2.4 Corticosterone concentrations 
DIO did not affect the concentrations of corticosterone at the peak or nadir of the circadian 
rhythm (Table 4.4). Estradiol treatment increased nadir corticosterone concentrations in 
CON and DIO mice but did not alter peak levels (Table 4.4). 
4.3.2.5 Testosterone concentrations 
Estradiol caused a reduction in plasma testosterone concentrations in CON and DIO mice. 
DIO was not associated with any effect on plasma testosterone concentrations (Table 4.4). 
4.3.3 The effects of estradiol and diet-induced obesity on mRNA 
abundance 
4.3.3.1 Glucose and lipid metabolising genes 
DIO and estradiol both increased hepatic abundance of mRNA encoding PPARα such that 
estradiol DIO mice had the greatest abundance (Figure 4.8A). Estradiol decreased levels of 




Figure 4.7 Continuous estradiol treatment ameliorates the obesity-associated 
increases in plasma glucose and insulin 
Male mice were fed control (CON, open/hatched symbols) or obesogenic (DIO, closed 
symbols) diets from 5 weeks of age and at 6 weeks of age underwent implantation of a 
continuous release 17β-estradiol pellet (Estradiol, purple symbols) or sham surgery (sham, 
green symbols). Glucose (A), insulin (B) and non-esterified fatty acids (NEFAs) (C) were 
measured in plasma samples collected during a glucose tolerance test. a: the effect of DIO to 
increase plasma glucose and insulin, b: effect of estradiol to decrease glucose and insulin, c: 
interaction between the effects of diet and estradiol. Data are mean ± SEM, analysed by 




Table 4.4 Concentrations of lipids, corticosterone and testosterone in male obese (DIO) and control (CON) mice treated with estradiol 
Male mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 17β-
estradiol pellet (Estradiol) or sham surgery (sham). Plasma lipid and corticosterone levels were measured in samples taken during metabolic tests. Hepatic 
triglyceride was analysed in post-mortem tissue. DIO increased lipid levels in mice, whereas estradiol caused an increase in nadir corticosterone concentration 
and decrease in testosterone concentration. Data are mean ± SEM, analysed by 2 way ANOVA, plasma testosterone concentrations were log transformed 
before analysis as the variance within groups was not comparable. n=11/Sham group, 12/Estradiol group. 
 
Lipid and hormone concentrations  
 Sham Estradiol Effect of diet Effect of 
estradiol 
Interaction  
 CON DIO CON DIO P value P value P value 
Fasting plasma 
triglyceride (mmol/L) 
0.55 ± 0.05 0.94 ± 0.09 0.59 ± 0.06 0.81 ± 0.06 <0.001 0.49 0.20 
Total plasma 
cholesterol (mmol/L) 
2.19 ± 0.31 3.59 ± 0.44 2.05 ± 0.22 3.16 ± 0.21 <0.001 0.34 0.62 
Hepatic triglyceride 
(nmol/mg) 
19.0 ± 2.7 48.8 ± 6.9 25.9 ± 2.8 27.9 ± 3.3 <0.001 0.10 <0.01 
Nadir plasma 
corticosterone (nM) 
15.3 ± 3.5 17.0 ± 2.9 50.0 ± 11.7 39.6 ± 6.0 0.55 <0.001 0.41 
Peak plasma 
corticosterone (nM) 
148.7 ± 18.1 178.9 ± 24.5 240.2 ± 35.5 173.1 ± 30.6 0.52 0.14 0.09 
Plasma testosterone 
(ng/ml) 
2.5 ± 1.3 2.2 ± 1.4 0.4 ± 0.1 0.5 ± 0.2 0.70 <0.05 0.95 
 
129 
Figure 4.8 Continuous estradiol treatment affects hepatic abundance of mRNAs 
encoding proteins involved in glucose, lipid and glucocorticoid metabolism 
Male mice were fed control (CON, hatched bars) or obesogenic (DIO, closed bars) diets 
from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 
17β-estradiol pellet (Estradiol, purple bars) or sham surgery (sham, green bars). Mice were 
killed at 16 weeks of age and abundance of mRNAs encoding proteins involved in (A) 
glucose and lipid metabolism and (B) glucocorticoid metabolism was quantified in liver 
using qPCR. Abundance was normalised to the average abundance of cyclophilin and β-actin 
mRNA. a: effect of DIO to increase abudance of PPARα and 5βR mRNA. b:effect of 
estradiol on mRNA abundance of PEPCK, PPARα, 11β-HSD1 5αR, 5βR and GR. c: 
interaction between the effects of diet and estradiol to affect the transcript levels of GR. Data 
are mean ± SEM, analysed by 2 way ANOVA; n=11/Sham group, 12/Estradiol group, 
*p<0.05, **p<0.01, ***p<0.001. 
 
130 
In subcutaneous adipose tissue DIO increased mRNA abundance of LPL and PPARγ, and 
decreased that of FAS (Figure 4.9A). Estradiol administration reduced the abundance of 
mRNA encoding PEPCK, LPL and HSL (Figure 4.9A) in CON and DIO mice. Estradiol 
increased FAS transcript levels in the adipose of CON mice, but DIO reduced it to levels 
comparable to those seen in sham DIO animals (Figure 4.9A).  
4.3.3.2 Glucocorticoid metabolising genes  
DIO increased mRNA abundance of hepatic 5βR regardless of estradiol treatment but did not 
affect transcript levels of the other glucocorticoid metabolising genes (Figure 4.8B). 
Estradiol caused an increase in hepatic 11β-HSD1 and 5βR mRNAs and a decrease in 5αR 
and GR mRNAs (Figure 4.8B). There was an interaction between the effects of diet and 
estradiol on GR mRNA such that DIO did not affect the transcript level in sham animals, but 
increased it in the estradiol group. 
In subcutaneous adipose both high fat diet and estradiol caused a reduction in mRNA 
abundance of 11β-HSD1, there was also an interaction between the effects, as the reduction 
induced by DIO was much smaller in estradiol treated mice than sham animals (Figure 
4.9B). Neither diet nor estradiol altered abundance of mRNA encoding GR in adipose 
(Figure 4.9B). 
4.3.3.3 Androgen and estrogen receptors 
mRNAs encoding AR and ERα could not be detected in the liver using tissues from this 
study. In subcutaneous adipose tissue DIO caused an increase in mRNA abundance of AR, 
while estradiol had no effect (Figure 4.10A). Neither diet nor estradiol-treatment altered 
transcript levels of ERα (Figure 4.10B). 
4.3.4 The effects of diet and estradiol on 11β-HSD1 activity  
No significant effect of diet or estradiol on hepatic 11β-HSD1 was found (Figure 4.11A). In 
subcutaneous adipose tissue, both DIO and estradiol reduced the activity of 11β-HSD1. 
There was also an interaction between DIO and estradiol such that the DIO induced-
reduction in 11β-HSD1 activity was large in sham animals and much smaller in the estradiol 




Figure 4.9 Continuous estradiol treatment affects subcutaneous adipose 
abundance of mRNAs encoding proteins involved in glucose, lipid and 
glucocorticoid metabolism 
Male mice were fed control (CON, hatched bars) or obesogenic (DIO, closed bars) diets 
from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 
17β-estradiol pellet (Estradiol, purple bars) or sham surgery (sham, green bars). Mice were 
killed at 16 weeks of age and abundance of mRNAs encoding proteins involved in (A) 
glucose and lipid metabolism and (B) glucocorticoid metabolism was quantified in 
subcutaneous adipose using qPCR. Abundance was normalised to the average abundance of 
cyclophilin and β-actin mRNA. a: effect of DIO on levels of mRNAs encoding LPL, FAS, 
PPARγ and 11β-HSD1. b:effect of estradiol on mRNA abundance of PEPCK, LPL, HSL, 
FAS and 11β-HSD1, c: interaction between the effects of diet and estradiol to affect the 
transcript levels of FAS and 11β-HSD1. Data are mean ± SEM, analysed by 2 way ANOVA; 




Figure 4.10 Continuous estradiol treatment does not alter levels of mRNAs 
encoding androgen or estrogen receptor-α in subcutaneous adipose tissue 
Male mice were fed control (CON, hatched bars) or obesogenic (DIO, closed bars) diets 
from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 
17β-estradiol pellet (Estradiol, purple bars) or sham surgery (sham, green bars). Mice were 
killed at 16 weeks of age and abundance of mRNAs encoding (A) androgen receptor (AR) 
and (B) estrogen receptor-α (ERα) quantified in subcutaneous adipose using qPCR. 
Abundance was normalised to the average abundance of cyclophilin and β-actin mRNA. a: 
effect of DIO to increase abundance of mRNA encoding AR. Data are mean ± SEM, 
analysed by 2 way ANOVA; n=11/Sham group, 12/Estradiol group, *p<0.05. 
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Figure 4.11 Continuous estradiol treatment and DIO reduces 11β-HSD1 
activity in adipose tissue but not liver 
Male mice were fed control (CON, hatched bars) or obesogenic (DIO, closed bars) 
diets from 5 weeks of age and at 6 weeks of age underwent implantation of a 
continuous release 17β-estradiol pellet (Estradiol, purple bars) or sham surgery 
(sham, green bars). Mice were killed at 16 weeks of age and the activity of 11β-
HSD1 was quantified in liver (A) and subcutaneous adipose (B) using a radio-
labelled tracer. a: effect of DIO to decrease 11β-HSD1 activity in adipose. b: effect 
of estradiol to lower 11β-HSD1 activity, c: interaction between the effects of diet 





The results of this chapter support the hypothesis that estradiol treatment in male mice alters 
the response to an obesogenic diet and affects glucocorticoid metabolism. These data will be 
discussed with reference to chapter 3, which demonstrated sex differences in the response to 
obesity and glucocorticoid metabolism, providing the hypothesis for these experiments. Sex 
differences in the transcript levels of some genes are evident before puberty, and are likely to 
be ‘programmed’ during early-life. Continuous administration of estradiol to male mice 
reduced weight gain, adipose deposition and changes in glucose-insulin homeostasis 
associated with obesity. Additionally, estradiol exposure altered glucocorticoid metabolism 
in the liver and adipose tissue, resulting in mRNA levels and enzyme activity profiles similar 
to those found in females (chapter 3). These data support the hypothesis that sexually 
dimorphic patterns of glucocorticoid metabolism play a role in the sex specific response to 
an obesogenic diet. 
4.4.1 Body weight, adiposity and organ size 
Estradiol-treated mice did not gain weight at the same rate as sham mice, regardless of diet. 
This difference in body weight may be due to the reduction in adipose tissue induced by 
alterations in appetite or metabolism and energy expenditure. The differences in body weight 
could also reflect a lack of linear growth, though no visible phenotype was recorded at post-
mortem; measurements of body length and muscle size would provide useful information in 
future studies to eliminate this possibility. To date, there have been no reports of the effect of 
estradiol on diet-induced obesity in male animals although daily injections of estradiol for 
one week decreased body weight and adipocyte size in male rats, presumably fed chow 
though not reported (Pedersen et al., 1991). Conversely, deletion of ERα (Heine et al., 2000) 
or aromatase (Jones et al., 2001), and therefore ablation of estrogen signalling or synthesis, 
increases weight gain and adipose deposition in male mice fed a normal diet. In ERα KO 
mice this increase in weight was due to reduced energy expenditure rather than increased 
food consumption (Heine et al., 2000), as well as adipocyte hypertrophy and hyperplasia, 
parameters which were not examined in this thesis. Estrogen concentrations also have an 
impact on energy balance in females, as ovariectomy in mice leads to increased weight gain 
and adiposity without increased food intake (Witte et al., 2010). The alterations in energy 
balance induced by estrogen are likely to be, at least in part, controlled by the brain. Direct 
injections of estradiol into the paraventricular nucleus result in a reduction in food intake, 
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body weight and increased wheel running (Butera and Czaja, 1984), whereas brain specific 
deletion of ERα leads to hyperphagia and abdominal obesity (Xu et al., 2011). The receptor-
interacting protein 140 (RIP140) is a negative transcriptional regulator of nuclear receptors 
required for maintainence of energy homeostasis, including ER (Cavailles et al., 1995). 
RIP140 is involved in fat accumulation and mice deficient in the protein are lean and 
resistant to diet-induced obesity (Leonardsson et al., 2004). Interestingly estrogen has been 
shown to increase the expression of RIP140 (Augereau et al., 2006) therefore investigating 
its expression of would be of interest in future studies.  
Effects of estradiol were also seen on liver and testis weights. The reason for a decrease in 
liver weight relative to body weight following DIO is unclear. This was not seen in the 
previous chapter using the same model (chapter 3), but is consistent with another study from 
our group (Personal communication Dr. Vicky King, University of Edinburgh). The reason 
for this is unclear since liver weight would be expected to increase in obesity as a 
consequence of lipid accumulation. The reduction in testicular size is as expected since 
estrogen will suppress the HPG axis by negative feedback mechanisms; this will reduce the 
synthesis and release of gonadotrophins so both Leydig cell and spermatogenesis function is 
reduced and the testes shrink.  
4.4.2 Glucose and insulin homeostasis 
Maintenance of normal glucose tolerance and insulin sensitivity in estradiol-treated males 
may be a consequence of the reduction in adipose tissue, since adipose tissue releases FFAs 
and adipokines into the circulation which can lead to insulin resistance (Boden, 1999; Rabe 
et al., 2008). Male ERα (Heine et al., 2000) and aromatase (Jones et al., 2001) KO mice 
have moderate insulin resistance which may be due to the increase in adiposity associated 
with models lacking estrogen signalling. Additionally, females subjected to ovariectomy 
(Riant et al., 2009) also develop moderate insulin resistance and glucose intolerance which 
can be reversed with estrogen treatment (Riant et al., 2009), and this is also seen with 
hormone replacement therapy in post-menopausal women (Tchernof et al., 1998). Estrogen 
can alter glucose metabolism and insulin sensitivity in many tissues including liver, muscle 
and adipose tissue. Estrogen treatment in rats up-regulates ERα mRNA abundance and 
protein levels in the liver (Koritnik et al., 1995), and in mice ER binding domains are found 
in hepatic genes which control metabolism and maintain insulin sensitivity (Gao et al., 
2008). Estrogen treatment increases hepatic insulin sensitivity by decreasing 
gluconeogenesis and glycogenolysis in female rats (Matute and Kalkhoff, 1973) and 
ovariectomised mice (Ahmed-Sorour and Bailey, 1981). In this study, the decreased levels of 
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mRNA encoding PEPCK in the estradiol treated males suggests reduced gluconeogenesis. 
Exogenous estrogen treatment in post-menopausal women suppresses lipolysis and free-fatty 
acid release in adipose, which also helps maintain insulin sensitivity (O'Sullivan and Ho, 
1995). In models of reduced estrogen signalling, reduced glucose uptake into skeletal muscle 
(Puah and Bailey, 1985), increased hepatic expression of genes involved in lipid synthesis 
(Bryzgalova et al., 2006), hepatic lipid accumulation (Takeda et al., 2003) and loss of 
insulin-mediated suppression of glucose production (Bryzgalova et al., 2006) have all been 
proposed to play a role in the development of insulin resistance and may warrant further 
investigation in the model used in this chapter. 
Estradiol can also affect insulin synthesis and secretion in the pancreas (Wong et al., 2010). 
Diabetes can be induced in mice by injection of streptozotocin (STZ) which enters beta-cells 
and causes oxidative stress, DNA damage and cell death. STZ treatment is much more 
effective in male mice and exogenous estrogen treatment reduces its effectiveness (Paik et 
al., 1982). Other models of diabetes are more severe in males than females (Corsetti et al., 
2000; Geisler et al., 2002), suggesting a role for estradiol in protecting the pancreas. In vitro, 
estradiol can protect isolated pancreatic islets from apoptosis, and this effect is partially 
reversed by ER antagonists (Contreras et al., 2002) suggesting a direct role of estradiol in 
preserving islet function. 
4.4.3 Lipid concentrations 
Consistent with the data presented in chapter 3 (Table 3.4), DIO increased plasma and 
hepatic lipid concentrations. Although estradiol-treated mice had less adipose tissue and a 
reduction in hepatic triglyceride levels, estradiol treatment had no effect on plasma lipid 
concentrations. While no changes in total cholesterol were found, estradiol may be athero-
protective through its effects on LDL and HDL (Kushwaha and Hazzard, 1981; Tang et al., 
1991), which were not measured independently in this study. 
Estradiol-treated male mice, like female mice, maintained insulin sensitivity despite 
increased plasma lipid concentrations following consumption of an obesogenic diet. The 
results of this chapter suggest the lower plasma triglyceride concentrations in females, 
despite consumption of an obesogenic diet (chapter 3); cannot be induced in males by 
estradiol treatment used in this chapter, and may be due to a non er-dependent mechanism. 
However, in male humans estrogen treatment can correct the dyslipidemia resulting from 
mutations in ER or aromatase (Grumbach and Auchus, 1999) suggesting some ER pathways 
play a role in controlling plasma lipids in humans. 
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4.4.4 mRNA abundance of glucose and lipid metabolising genes 
The abundance of mRNAs encoding PPARα and PPAR was sexually dimorphic before 
puberty, in the same pattern as found in adults (chapter 3), suggesting that this difference is 
programmed during early development as has been reported for other genes in the rat 
(Gustafsson et al., 1977). A number of studies have suggested that there is cross talk 
between ER and PPARs (Keller et al., 1995; Ma et al., 1998; Wang and Kilgore, 2002) and 
the results of this chapter suggest that estradiol can increase abundance of mRNAs encoding 
the PPARs in adult mice. Thus, the surge in sex steroids at puberty could exaggerate the 
differences seen earlier in life or, alternatively, the mechanisms which induced changes in 
early life can still be activated by high concentrations of estradiol in adulthood. 
The increase in hepatic PPARα mRNA levels induced by DIO is consistent with the results 
previously reported in males (chapter 3). As this response was not found in females, it may 
be mediated by other pathways specific to male mice that are not affected by estradiol 
treatment. An increase in adipose PPARγ mRNA following DIO was not found in the 
previous study (chapter 3) and the reasons for this are unclear as the same protocol was used. 
Increasing PPARγ enhances lipid storage and promotes insulin sensitivity, suggesting the 
increase in DIO sham males may be an attempt to compensate for the effects of obesogenic 
diet. 
The sex difference in adipose HSL mRNA levels before puberty is opposite to that seen in 
adults (chapter 3). Estradiol treatment of males resulted in mRNA levels comparable to adult 
females suggesting that this sex difference is induced following increases in estrogen at 
puberty. The lack of an effect of DIO is consistent with the previous chapter and suggests 
HSL is not a primary target in modulating metabolism following consumption of an 
obesogenic diet. 
Although estradiol treatment reduced abundance of hepatic PEPCK mRNA in males, there 
were no sex differences identified in chapter 3. This suggests that pepck mRNA might be 
modulated by high concentrations of estrogen and/or that other hormones such as 
glucocorticoids, glucagon and insulin may have a greater effect on PEPCK mRNA in normal 
physiology. In the adipose tissue the lower PEPCK transcript levels in estradiol-treated 
males is consistent with the results found in females (chapter 3). This supports the hypothesis 
that reduced PEPCK mRNA abundance and the consequent reduction in glyceroneogenesis 
may be one mechanism protecting females from the deleterious metabolic consequences of 
DIO. Sex differences in transcript levels of PEPCK mRNA were not present before puberty, 
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suggesting that the changes in hormone concentrations in females following puberty are 
responsible for the differences in adulthood. Interestingly the diet-induced change in adipose 
PEPCK mRNA levels found in chapter 3 was not found in this experiment. Given the 
similarity of the metabolic results in the male animals in chapter 3 and sham male animals in 
this chapter, and the use of the same protocols, the reasons for this difference are unclear. 
Due to technical issues mRNA encoding FAS could not be measured in subcutaneous 
adipose tissue chapter 3, which would have been of interest given the large increase in levels 
seen following estradiol treatment. The increased mRNA abundance in the estradiol-treated 
CON mice may reflect the relative lack of adipose tissue and the need to synthesise fatty 
acids to be released into circulation and oxidized in the liver to generate energy. Despite the 
high transcript levels of FAS in estradiol CON mice, DIO reduced FAS transcript abundance 
to lower levels than those found in sham CON mice with similar amounts of adipose tissue. 
The resultant reduction in fatty acid synthesis may be a key pathway targeted by estradiol, in 
response to increased dietary lipids, to reduce lipogenesis and utilise stored and circulating 
FFAs. 
4.4.5 Glucocorticoid metabolism 
4.4.5.1 Estradiol and hepatic glucocorticoid metabolism in lean animals 
The sexually dimorphic patterns of hepatic 11β-HSD1 mRNA abundance found in chapter 3 
were not present before puberty. Alterations in transcript levels of 11β-HSD1 were induced 
by estradiol treatment, suggesting the differences seen in adults are induced by changes in 
sex steroids following puberty. Sex differences in mRNA and activity of 11β-HSD1 have 
been reported in rats (Low et al., 1994), though the differences are thought to be partly 
induced by sex differences in growth hormone (GH) secretion during early life (Low et al., 
1994). The results of this chapter propose a role for this to occur after puberty coinciding 
with a dramatic increase in estrogen concentrations. 
5αR plays a key role in sexual differentiation by converting testosterone into 
dihydrotestosterone (DHT) and, while this is mainly catalysed by the type 2 isozyme, the 
type 1 enzyme measured in this study can also bind this substrate (Normington and Russell, 
1992). No significant difference in mRNA levels of hepatic 5αR was found in pre-pubertal 
animals, although a trend for lower levels in females was present as was found in adulthood 
(Chapter 3). It is likely this difference did not reach significance because of the large 
variability between animals and because the experiment was under powered. No studies have 
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investigated sex differences prepuberty, and therefore n numbers were based on those used 
in adult studies. In future experiments with young animals a larger cohort should be used to 
ensure adequate power. Additionally, estrogen-treated males had lower 5αR mRNA levels. 
The difference may be programmed in utero due to the local milieu of hormones involved in 
sexual development with the difference becoming more evident in adulthood, following the 
increase in estrogen concentrations in females. The decreased transcript levels of mRNA 
encoding 5αR type 1 in females may result in the preferential metabolism of glucocorticoids 
by 5βR. This hypothesis is supported by the sex differences in 5βR induced following 
increases in estrogen post puberty and by estrogen treatment in males. Tipping the balance in 
favour of 5βR metabolism may reduce GR activation by metabolising 11-
dehydrocorticosterone, the substrate for 11β-HSD1 and also reducing the local levels of 5α-
metabolites which are still active at the receptor (McInnes et al., 2004). 
Hepatic abundance of mRNA encoding GR was higher in females than males before puberty, 
this difference was no longer apparent in adults and estradiol exposure reduced abundance in 
males. This suggests a role for estradiol in the regulation of GR, reducing mRNA levels at 
puberty in females. This is consistent with data showing treatment of human breast cancer 
cells with estrogen reduces GR expression (Krishnan et al., 2001). 
4.4.5.2 Estradiol and adipose tissue glucocorticoid metabolism in lean animals 
Activity of 11β-HSD1 was not affected by sex prepuberty as was found in adulthood 
(chapter 3). Additionally, adipose 11β-HSD1 mRNA and activity was reduced in males by 
estradiol treatment. This suggests that the sex differences in 11β-HSD1 mRNA abundance 
are due to the changes in circulating concentrations of estrogen which occur following 
puberty. The abundance of mRNA encoding GR was not sexually dimorphic before puberty 
or in adulthood (chapter 3) and consistent with these results estradiol treatment did not affect 
GR mRNA. This suggests that the estradiol-induced reduction in glucocorticoid regeneration 
by 11β-HSD1 does not result in a compensatory increase in gr mRNA abundance. 
4.4.5.3 Obesity, estradiol and hepatic glucocorticoid metabolism 
As in females (chapter 3), the mRNA abundance of 11β-HSD1 and 5αR in liver was not 
affected by DIO in estradiol-treated males however DIO did increase the abundance of 5βR, 
in addition to the induction by estradiol, consistent with the data from male animals in the 
previous chapter. This may reflect a physiological response to dietary composition, such that 
increased glucose and/or lipid intake increases 5βR mRNA levels in males regardless of the 
circulating concentrations of sex steroids, as is the case for adipose ApoE expression in 
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response to cholesterol (Laffitte et al., 2001). Changes in 5βR may also be a compensatory 
mechanism to increase local glucocorticoid metabolism or decrease circulating 
corticosterone concentrations, though the circulating concentrations were not different from 
CON mice. 
4.4.5.4 Obesity, estradiol and adipose tissue glucocorticoid metabolism 
DIO and estradiol reduced mRNA abundance of 11β-HSD1 in adipose tissue. The activity of 
11β-HSD1 was also reduced by estradiol treatment, but there was little additional effect of 
combining these interventions. These results suggest a similar level of glucocorticoid 
regeneration in sham DIO and all estradiol-treated males, in addition to comparable GR 
mRNA abundance. Due to the differences in adiposity and glucose-insulin homeostasis 
between groups these results support the published hypothesis that the reduction of adipose 
11β-HSD1 in male mice is a compensatory mechanism in response to obesity (Morton et al., 
2004). The results also support the hypothesis for the chapter that reduced glucocorticoid 
regeneration, mediated by estradiol, is associated with protection from some of the effects of 
exposure to an obesogenic diet.  
4.4.5.5 Potential mechanisms for estradiol regulation of 11β-HSD1 
Interestingly, the mRNA abundance of hepatic 11β-HSD1 did not correlate with activity of 
the enzyme in adult mice, in this or the previous chapter. This disparity becomes apparent 
post-puberty suggesting that sex steroids may play a role in controlling activity as well as 
gene expression in mice. Although the sexually dimorphic expression of 11β-HSD1is 
affected by GH secretion in rats (Low et al., 1994), estradiol can also repress transcription 
(Low et al., 1993; Andersson et al., 2010). Estrogen can still down regulate 11β-HSD1 in 
adrenalectomised rats (Jamieson et al., 1999) suggesting the effect of estrogen is not 
mediated by changes in glucocorticoid synthesis in the adrenals. Furthermore, whilst GH 
secretion patterns affect 11β-HSD1 expression and activity, in hypophysectomised rats 
estrogen still has a suppressive effect (Low et al., 1994), suggesting it is not mediated by the 
pituitary. Other hormones and inflammatory factors have been shown to regulate 11β-HSD1, 
and estrogen may be acting with or upon such molecules. In the mouse, leptin increases 
hepatic 11β-HSD1 activity (Liu et al., 2003), and estradiol may be activating leptin 
expression with a consequent increase in 11β-HSD1. Increasing leptin would also be 
expected to protect against the metabolic complications of obesity due to its effects on 
adipose mass and appetite regulation through receptors in the brain (Campfield et al., 1996). 
In primary cultures from rat mesenteric adipose, estradiol acts as a non-competitive inhibitor 
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of 11β-HSD1 (Tagawa et al., 2009). Removal of estradiol production in vivo by ovariectomy 
increases 11β-HSD1 in rat visceral adipose tissue and the enzyme can then be repressed by 
estrogen treatment (Andersson et al., 2010). Adiposity and adipocyte hyperplasia has been 
proposed as the most likely explanation for estradiol regulation of 11β-HSD1 in rats. In pair-
fed female rats, changes in 11β-HSD1 following ovariectomy and estrogen treatment were 
due to the lack of adipose rather than increases in estradiol (Paulsen et al., 2008). 
Complementary to this study, Andersson et al. reported that estradiol induced a decrease in 
visceral, but not subcutaneous, adipose deposition in female rats in addition to a decrease in 
mesenteric, but not subcutaneous adipose tissue, 11β-HSD1 expression and activity 
(Andersson et al., 2010). In contrast to the findings in DIO females in which a significant 
increase in adipose deposition was associated with a reduction in 11β-HSD1 (chapter 3), 
estradiol-treated male mice had very small increases in adipose when fed the obesogenic diet 
and no change in 11β-HSD1 activity compared to their respective controls. Consistent with 
the rat data this implies that diet or adipose expansion can alter 11β-HSD1 despite 
differences caused by estradiol in lean animals. It is possible the differences are induced by 
estradiol if its local production by aromatase is amplified in obesity as has been suggested in 
humans due to adipocyte hyperplasia (Cleland et al., 1985). 
4.4.6 The androgen-estrogen balance 
Due to the technical issues described in chapter 3 (3.3.1.3) the plasma concentrations of 
estradiol in the sham group could not be determined. The concentrations obtained with 
plasma from the estradiol-treated group were not adequate for presentation or analysis as 
some samples fell below the limits of detection and those that did not were hugely variable. 
In female mice plasma estradiol concentrations vary throughout the estrus cycle reaching 
their maximum during proestrus (Saito et al., 2009). Other groups have reported inconsistent 
plasma estradiol concentrations following implantation of pellets from the same source as 
used in this experiment. One group using 0.1mg, 21-day (~ 4.7µg/day) pellets in females, 
reported plasma estradiol concentrations in the range of 115-148pg/ml stating it as a dose 
that restored physiological levels (Karas et al., 2001), presumably those in proestrus. While 
another group reported plasma estradiol concentrations of 323pg/ml from pellets 
administering ~2µg/day in male mice and 13.8pg/ml in the vehicle treated group (Geisler et 
al., 2002), comparable to other reports in WT males (Couse and Korach, 1999; Saito et al., 
2009). One potential reason for the disparity in results is the time the plasma used to measure 
estradiol was collected from the mice. The study in female mice collected plasma at the end 
of the 21-day release period of the pellet (Karas et al., 2001); whereas that of Geisler et al. 
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analysed estradiol concentrations in plasma collected 28 days into a 90-day release period 
(Geisler et al., 2002). The pellets do not actively pump the hormone in to the circulation and 
therefore the concentrations are likely to reduce towards the end of the release period. In 
addition the groups used different commercially available assays to measure plasma estradiol 
which have been shown to be highly variable (Haisenleder et al., 2011). The lack of plasma 
estradiol measurements in this chapter is a current weakness in this study. The results of 
other studies discussed above suggest the plasma concentrations are likely to exceed those 
found physiologically in female mice, though at present this cannot be confirmed.  
Whilst plasma testosterone concentrations were variable, as has been reported in rodents 
(Bartke et al., 1973), a decrease occurred in response to estradiol treatment as has been 
previously demonstrated (Akingbemi et al., 2003). This is likely to be due to increased 
negative feedback on the HPG axis, which decreases GnRH and gonadotrophin secretion and 
therefore reduces testosterone production. ERs are found in the hypothalamus where they 
can regulate the transcription of gonadotrophin genes (Gharib et al., 1990; Shughrue et al., 
1997) such that reduced negative feedback in er KO mice increases testosterone 
concentrations (Akingbemi et al., 2003). DIO did not alter plasma testosterone 
concentrations in either estradiol-treated or sham mice, in contrast to studies of morbidly 
obese human males (reviewed in (Cohen, 1999)). In fact, morbidly obese male humans 
suffer from low testosterone and high estradiol (Kley et al., 1979; Cohen, 1999), similar to 
the hormonal environment in the model used in this chapter, though in the mouse this was 
associated with resistance, rather than propensity, to obesity. 
The changes in testosterone found in this model should not be neglected when discussing the 
phenotype induced by estradiol treatment. Treatment of men with testosterone reduces 
waist/hip ratio (Marin et al., 1992) and visceral fat mass (Marin et al., 1993) and male AR 
KO mice have smaller adipose depots, with fewer and smaller adipocytes when young (Yeh 
et al., 2002) but develop obesity with age (Sato et al., 2003). Global AR KO mice maintain 
insulin sensitivity despite obesity (Fan et al., 2005), while an adipose specific AR KO model 
has hyperinsulinemia without obesity (McInnes, 2010). The relative estrogen concentrations 
in these models were not reported, but the phenotypes of AR KOs propose a role for 
androgens in adiposity and insulin sensitivity. Additionally, in ER and aromatase KO mice 
obesity and the associated metabolic complications are confounded by increased testosterone 
concentrations as well as the lack of estrogen signalling. Data from all of these transgenic 
mouse models suggest that the relative concentrations of estrogen and testosterone may be 
important in normal physiology, such that the changes in adiposity and insulin sensitivity 
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presented in this chapter may have been a consequence of the alterations in either sex 
hormone or a change in the androgen-estrogen balance. The effects of altering the balance 
have rarely been addressed but one study found treatment of ovariectomised mice with 
dihydro-testosterone caused greater weight gain and adipose deposition than is seen with 
physiological testosterone concentrations (McInnes et al., 2006). Further studies are required 
to investigate the importance of the androgen-estrogen balance in males.  
The alteration in the androgen-estrogen balance of the estradiol-exposed males may have 
also affected glucocorticoid metabolism and, therefore, the changes in physiology. 
Testosterone increases the expression and activity of 11β-HSD1 in omental adipose tissue 
from pre-pubescent boys (Zhu et al., 2010). Therefore the decrease in testosterone following 
estradiol treatment could account for the reduced activity. However, the decrease in adipose 
11β-HSD1 following DIO in sham mice was not accompanied by a change in testosterone 
suggesting this is unlikely. Additionally, adipose tissue aromatase can modulate levels of 
testosterone and estrogen, and, therefore, the balance of the two may control the sexual 
dimorphism of 11β-HSD1 and the changes seen in enzyme activity in obesity and following 
the menopause. 
4.4.7 Sex steroid receptors 
Whilst transcript levels of mRNA encoding AR in subcutaneous adipose were increased by 
DIO, no changes were found in response to estradiol or the reduction in testosterone. This 
suggests the receptor may be responsive to the metabolic environment rather than changes in 
sex steroids. This may be tissue specific as a study in the reproductive tract suggests 
increasing estrogen reduces AR protein levels (Rivas et al., 2002). As discussed above data 
from transgenic AR KO mice suggest a role for androgens in metabolism. The increase in 
AR mRNA abundance with DIO in this study may be a compensatory mechanism to 
maintain insulin sensitivity, or to decrease adipose deposition as is seen in humans given 
endogenous testosterone (Marin et al., 1992). The lack of change in abundance of mRNA in 
estradiol treated males which do not have impaired metabolism or increased adipose 
deposition, supports the idea of a compensatory mechanism. Interestingly global AR deletion 
leads to obesity in adulthood in male but not female mice (Sato et al., 2003) which further 
indicates the importance of the balance of sex steroids. Local adipose levels of estrogen are 
increased in obesity due to adipocyte hyperplasia increasing the abundance of aromatase 
(Cleland et al., 1985). Increased tissue concentrations of estrogen may affect receptor 
expression, with one study showing the steroid upregulates AR mRNA in human 
preadipocytes (Dieudonne et al., 2006).  
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The abundance of mRNA encoding ERα was altered in response to diet but the direction of 
change was dependent on estradiol treatment. mRNA encoding ERβ could not be quantified 
in this study; this is likely due to the lower expression than α isoforms, and additionally the 
reduced mRNA in males compared to female animals. Tissue specific concentrations of 
estrogen and testosterone in adipose tissue may modulate ER expression (Rodriguez-Cuenca 
et al., 2005) and the response to sex steroids in different adipose depots may play a role in 
the metabolic consequences of obesity (Rodriguez-Cuenca et al., 2005). It would be of 
interest to determine mRNA levels of ER and AR in other adipose depots in this study given 
greater time. The results of this chapter support studies showing there is sufficient ER to be 
quantified in adipose tissue of male mice, and to play a role in normal physiology (Heine et 
al., 2000; Cooke et al., 2001). 
4.4.8 Study limitations 
The estradiol treatment obviously had a profound effect on weight gain and adiposity such 
that the DIO estradiol mice were comparable in weight to sham CON mice. It is therefore 
unclear if the relative lack of changes in metabolism are due to low food intake and reduced 
adipose tissue in estradiol mice or changes in basal physiology. Studies of food intake and 
pair feeding sham mice would provide a more strigent control phenotype and allow for 
greater interpretation of the data. As discussed in section 4.4.6 the concentrations of plasma 
estradiol in the mice has not been measured to date. This information is vital for full 
interpretation of the results and comparison to the concentrations found in females. Reducing 
the concentration of estradiol used may lead to a greater degree of obesity being achieved in 
the mice. This would also help address the issue of whether the differences found are based 
on adiposity, estradiol or a combination of both.  
The differences in mRNA abundance should also be investigated on a protein level (see 
section 3.4.7). The effects of estradiol on 11β-HSD1 have been proposed to be depot specific 
(Andersson et al., 2010), therefore studying the enzyme in visceral adipose would allow for 
further comparisons to published literature.  
4.4.9 Conclusions 
In summary, estradiol-treatment of male mice consuming an obesogenic diet blocked the 
adipose tissue deposition and insulin resistance found in controls. Indeed, the physiology of 
male mice treated with estradiol resembled that of female mice presented in the previous 
chapter with the exception that the obese females accumulated a comparable amount of 
adipose to males, whereas estradiol-treated males did not. Treatment with estradiol induced 
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changes in many genes involved in glucose, lipid and glucocorticoid metabolism and, 
consistent with the hypotheses for this study; estradiol-treated mice had reduced 
glucocorticoid regeneration in adipose tissue, suggesting that this may be part of the 
mechanism determining the metabolic response to an obesogenic diet. These results support 
the use of pharmacological inhibition of 11β-HSD1 as a potential insulin sensitising strategy 
in men, and suggest further investigations into their efficacy in females. The results 
presented in this chapter also highlight the need to increase the understanding of the 





The effects of maternal obesity on 
offspring metabolism 
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5.1  Introduction 
Many epidemiological studies have demonstrated a link between the environment in early-
life and long term risk of cardiovascular disease (Barker et al., 1989; Barker et al., 1993b; 
Ravelli et al., 1998; Doyle et al., 2000; Shiell et al., 2000; Gillman et al., 2003; Martin-
Gronert and Ozanne). In recent times there has been an explosion in the rates of obesity, 
including in women of child bearing age (Kanagalingam et al., 2005; Guelinckx et al., 
2008). This has led to a plethora of studies suggesting links between exposure to obesity in 
utero and during suckling (referred to as early-life) and long term health (Laitinen et al., 
2001; Ogden et al., 2006; Gale et al., 2007; Koupil and Toivanen, 2008; Catalano et al., 
2009a). Due to the limited opportunities for experimental manipulations and time required to 
study this link in humans, animal models have proved useful experimental tools. In rodent 
models, exposure to maternal obesity induces a variety of adverse metabolic changes in the 
offspring, including increased rates of obesity, insulin resistance and hyperlipidemia (Guo 
and Jen, 1995; Bayol et al., 2008; Samuelsson et al., 2008; Howie et al., 2009; McCurdy et 
al., 2009; Nivoit et al., 2009). Furthermore some groups have demonstrated maternal obesity 
can cause long-term alterations in tissue structure or function (Cerf et al., 2005; Ford et al., 
2009, Armitage et al., 2005a; Calvert et al., 2009 ) and signalling pathways (Rodrigues et 
al., 2009, Bruce et al., 2009; Martin-Gronert et al., 2010) of the offspring. These data 
suggest that exposure to obesity during development and suckling can program the offspring, 
though the mechanisms controlling this are still unclear. 
To investigate potential mechanisms of programming a model of early life programming by 
obesity was required. Studies have suggested that over feeding dams post conception is 
enough to program changes in offspring adiposity (Khan et al., 2005; Bayol et al., 2008) 
(Tamashiro et al., 2009) whilst others show obesity pre-conception is also required (White et 
al., 2009). The model chosen for this study used pre-existing obesity before conception, to 
replicate the problem of increasing levels of obesity in women of child bearing age which 
occurs before and not just during pregnancy. C57BL/6 mice are known to be predisposed to 
the effects of high fat and sugar diets (Surwit et al., 1988; West et al., 1992; Surwit et al., 
1995), and therefore provide a good representation of the human condition (see section 
1.1.5.4). Generating the model in mice gives the potential for genetic manipulation in future 
studies to dissect mechanisms. 
In chapter 3 the effects of an obesogenic diet on C57BL/6 mice were described. To allow for 
comparison of the effects of exposure to maternal obesity or post natal obesity the same diet 
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and time points were used in this study. The results of chapter 3 showed female C57BL/6 
mice given an obesogenic diet have increased adiposity and mild elevations of glucose and 
insulin during a glucose tolerance test, but no fasting hyperglycaemia or hyperinsulinemia. 
While females become more insulin resistant during pregnancy (Catalano et al., 1991), the 
results of chapter 3 suggest the dams would start with comparable insulin and therefore 
provide a model of the effects of maternal obesity and not maternal diabetes. The second 
reason for using this model and experimental design was to allow for the comparison of the 
vascular effects of post-natal obesity, with those induced by exposure to maternal obesity 




This chapter explores the hypothesis that exposure to maternal obesity during development 
and suckling adversely programmes offspring metabolism in later life. 
 
5.1.2 Aims 
To investigate this hypothesis we generated a murine model of maternal obesity and studied 
male offspring to answer the following questions: 
 Does exposure to maternal obesity increase weight gain and adiposity?  
 Does maternal obesity increase plasma concentrations of glucose, insulin, lipids and 
corticosterone in the offspring? 
 Does exposure to maternal obesity alter the mRNA abundance of genes involved in 





5.2.1  Experimental protocol 
The experimental outline can be seen in Figure 5.1. Only male offspring were used, one from 
each litter. 
5.2.2 Animal maintenance and terminal procedures 
Male offspring of obese (DIOoff) or control (CONoff) dams, first time mothers, were 
generated as described in chapter 2 (2.3.3). All offspring were fed a standard diet (RMI 
801002; Special Diet Services, Witham, UK) ad libitum following weaning and 
maintained as described (2.3.1). For subsequent experiments one offspring per litter was 
used. Offspring were individually housed at 3 months (n=8/group) and 6 months (n=10 
CONoff, 6 DIOoff) and left to acclimatise for at least 5 days before metabolic experiments 
commenced.  
Animals were killed ~ 10 days after diurnal blood sampling; their blood pressure was 
measured during this time (see chapter 6 for results). All mice were killed using CO2 
asphyxiation and tissues were collected and stored as described (0). Offspring aged 3 months 
were killed between 8-10am, whilst those aged 6 months were killed between 2-5pm 
following a 6 hour fast. Although ideally all mice would have been killed in the fasted state 
and at the same time of day to minimise variability in mRNA levels, the 3 month offspring 
were killed in the morning to allow for the analysis of vascular function in newly dissected 
vessels (see chapter 6). 
5.2.3 Metabolic tests 
Offspring aged 3 and 6 months underwent a glucose tolerance test (2.3.7) at least 5 days after 
individual housing. One week later diurnal blood samples were taken in line with the light 
cycle (2.3.8). 
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Figure 5.1 Schematic of Experimental Protocol 
C57BL/6 females fed control (CON, Research diets D12328) or obese (DIO, Research diets D12331) diets were bred with C57BL/6 males (maintained 
on chow diet) at ~17 weeks and dams remained on experimental diet during gestation and suckling. All litters were reduced to 6 pups on postnatal day 1 
and at 3 weeks age offspring of control (CONoff) and obese (DIOoff) dams were weaned and housed in single sex groups 3-5/cage,. Two cohorts of 
offspring were studied, one at 3 months and one at 6 months. At the ages specified mice were individually housed and underwent metabolic tests. 
Animals were then killed and tissues weighed and collected. 
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5.2.4 Quantification of plasma nutrients and hormones and hepatic 
triglycerides 
Concentrations of glucose (2.6.4) and insulin (2.6.2) were measured in plasma samples taken 
during the glucose tolerance test. Non-esterified fatty acids (NEFAs) were measured (2.6.7) 
in the first two glucose tolerance test samples. Plasma triglycerides were measured (2.6.6) in 
the fasting plasma sample. Corticosterone concentrations were measured (2.6.8) in diurnal 
blood samples, and cholesterol (2.6.5) in the nadir sample. Liver triglyceride was extracted 
using a saponfication method (2.7) and quantified using a colourimetric assay as in plasma 
5.2.5 Quantification of mRNA levels 
RNA was isolated from liver (2.5.1.1) and subcutaneous adipose tissue (2.5.1.2), quantified 
(0) and cDNA synthesised using RT-PCR (2.5.1.6). The abundance of mRNAs encoding; 
5α-reductase type1 (5αR), 5β-reductase (5βR), 11β-hydroxysteroid dehydrogenase (11β-
HSD1), fatty acid synthase (FAS), glucocorticoid receptor (GR), hormone-sensitive lipase 
(HSL), lipoprotein lipase (LPL), phosphoenolpyruvate carboxykinase (PEPCK), peroxisome 
proliferator receptor α (PPARα) and peroxisome proliferator receptor γ (PPARγ) were 
determined using qPCR (2.5.1.7) and normalised to the abundance of cyclophilin. 
5.2.6 Statistics  
Data are presented as mean ± SEM, where n numbers represent the number of offspring 
used. Data was analysed by unpaired Student’s t-test or repeated-measures analysis of 
variance (ANOVA) as appropriate. 
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5.3 Results 
5.3.1 The effects of maternal obesity on offspring physiology 
5.3.1.1 Maternal Charateristics 
DIO female mice were heavier than controls and had hyperglycaemia during a glucose 
tolerance test (IPGTT) pre-mating, this weight difference was maintained at e18 (Table 5.1). 
DIO females had less pups per litter but the birth weights were comparable (Table 5.1). Over 
all the studies set-up by Dr V. King the plug rate for both CON and DIO females was found 
to be 90% and the rate of successful pregnancies was 70% (Personal communication Dr V. 
King). 
5.3.1.2 Body and tissue weights 
At weaning, 3 weeks of age, DIOoff were heavier than controls (13.1 ± 0.64 vs 8.9 ± 0.56 g, 
p<0.001 n=27CONoff, 19 DIOoff each from different litters). Repeated measures ANOVA 
showed maternal diet did not affect body weight over time (Figure 5.2); weights were not 
taken once animals were individually housed. 
At 3 and 6 months liver, kidney, adrenal, subcutaneous, mesenteric, retroperitoneal and 
epidydimal adipose weights were all comparable to controls (Table 5.22). 
5.3.1.3 Glucose tolerance test 
Concentrations of plasma glucose and insulin during a glucose tolerance test were 
comparable in DIOoff and CONoff at both 3 months (Figure 5.3a & c) and 6 months (Figure 
5.3 b & d). Both parameters increased with age in line with previous literature (Bailey et al, 
1982). 
5.3.1.4 Lipid concentrations 
There were no differences in plasma NEFAs on fasting or in response to a glucose bolus in 
either age group (Figure 5.3 e & f). At 3 months of age fasting plasma triglyceride 
concentrations were lower in DIOoff (3), whereas hepatic triglycerides were comparable to 
controls (3). There was no difference in total plasma cholesterol (3) between groups at 3 
months. At 6 months of age DIOoff and CONoff had  
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 CON DIO P value 
Weight at mating (g) 22.2 ± 0.4 (6) 30.2 ± 0.9 (6) <0.001 
Plasma glucose during 
IPGTT (area under curve 
-mmol/l/min) 
45.8 ± 3.1 (6) 64.0 ± 4.0 (6) 0.004 
Weight at e18 (g) 33.9 ± 0.4 (7) 38.3 ± 1.1 (7) <0.001 
Number of pups per litter 6.5 ± 0.5 (21 litters) 5.0 ± 0.4 (22 litters) 0.033 
Offspring birth weights 1.32 ± 0.02 (7 litters) 1.28 ± 0.03 (6 litters) 0.25 
 
Table 5.1 Maternal characteristics and offspring statistics 
Female C57BL/6 mice were fed con (CON) or obesogenic diets (DIO) from 5 weeks age. 
Mice underwent an intraperitoneal glucose tolerance test (IPGTT) at 15 weeks pre-mating. 
Data are mean ± SEM analysed by Student’s unpaired t-test, n numbers shown in brackets. 
All data in table provided by Dr V. King, University of Edinburgh.  
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Figure 5.2 Exposure to maternal obesity causes increased weight at 3 weeks of 
age, but does not affect body weight after weaning 
Offspring of obese (DIOoff, squares) and control (CONoff, circles) dams were weighed at 
regular intervals. Exposure to maternal obesity did not alter offspring body weights over the 
duration of the study (3-25 weeks age). Data are mean ± SEM, analysed by repeated 




Table 5.2 Body and tissue weights from offspring of control (CONoff) and obese 
(DIOoff) dams  
Offspring were killed aged 3 or 6 months and wet tissue and organ weights recorded. No 
differences in organ or adipose weights were observed. Data are mean ± SEM, n= 6-
10/group. Comparisons between groups analysed using Student’s unpaired t-test. 
 
Body, organ and adipose weights 
 
Tissue 3 months 6 months 
 CONoff DIOoff p Value CONoff DIOoff p Value 
Final body 
weight (g) 
28.0 ± 0.5 28.4 ± 0.5 0.57 33.7 ± 0.8 31.1 ± 1.9 0.17 
Liver (g) 1.43 ± 0.09 1.49 ±0.08 0.63 1.36 ±0.05 1.25 ± 0.07 0.21 
Kidney (mg) 183 ± 15 203 ± 6 0.21 182 ± 8 168 ± 9 0.28 
Adrenal (mg) 2.8 ± 0.5 2.6 ± 0.04 0.75 3.9 ± 0.9 3.3 ± 0.2 0.60 
Subcutaneous 
adipose (mg) 
195 ± 22 154 ± 16 0.39 298 ± 50 269 ± 60 0.72 
Mesenteric 
adipose (mg) 
163 ± 27 221 ± 19 0.08 323 ± 29 284 ± 60 0.52 
Retroperitoneal 
adipose (mg) 
51 ± 7 48 ± 6 0.74 180 ± 23 122 ± 20 0.09 
Epididymal 
adipose (mg) 




Figure 5.3 Exposure to maternal obesity does not affect glucose, insulin or free 
fatty acids during a glucose tolerance test 
Offspring of obese (DIOoff, squares) or control (CONoff, circles) dams underwent a glucose 
tolerance test at 3 (filled symbols) or 6 months (open symbols) of age. Glucose (a & b), 
insulin (c & d) and non-esterified fatty acids (NEFAs) (d & f) were measured in plasma 
samples collected at times indicated. No differences were found in any of the parameters. 
Data are mean ± SEM, n=6-10/group, data were analysed using repeated-measures ANOVA. 
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Table 5.3 Lipid and corticosterone concentrations in offspring from obese (DIOoff) and control (CONoff) dams 
Fasting plasma and hepatic triglycerides, total cholesterol and basal and peak corticosterone concentrations were analysed at 3 and 6 months. 
Data are mean ± SEM, n=6-10/group, values compared using Student’s unpaired t test. 
 
Lipid and Corticosterone levels  
 3 months 6 months 
 CONoff DIOoff p Value CONoff DIOoff p Value 
Fasting plasma triglyceride 
(mmol/L) 
0.62± 0.06 0.46 ± 0.02 0.04 1.10 ±0.02 1.03±0.07 0.23 
Total plasma cholesterol 
(mmol/L) 
1.25 ± 0.13 1.04 ±0.07 0.19 2.22 ± 0.14 2.14 ± 0.24 0.78 
Hepatic triglyceride 
(nmol/mg) 
15.0 ± 0.20 21.0 ± 2.7 0.09 29.5 ± 1.8 32.1 ± 5.8 0.61 
Nadir plasma 
corticosterone (nM) 
26.7 ± 2.2 44.7 ± 7.0 0.04 35.3 ± 5.7 27.3 ± 5.0 0.35 
Peak plasma corticosterone 
(nM) 
217.4 ± 21.5 259.7 ± 14.6 0.12 222.1 ± 16.5 196.4 ± 17.0 0.31 
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comparable concentrations of plasma triglycerides, cholesterol and hepatic triglycerides (3), 
though an increase due to age was noted. 
5.3.1.5 Plasma corticosterone 
The expected difference in corticosterone during the active and inactive phase was seen in all 
offspring. At 3 months of age DIOoff had higher concentrations of plasma corticosterone 
than CONoff at the diurnal nadir; however, there was no difference at the peak time point 
(3). At 6 months of age, the concentrations of plasma corticosterone were comparable at both 
the peak and nadir of the circadian rhythm (3).  
5.3.2 The effects of exposure to maternal obesity on mRNA abundance 
5.3.2.1 Hepatic mRNA levels 
At 3 months of age DIOoff had higher transcript levels of mRNAs encoding LPL, HSL and 
PPARα than CONoff and comparable FAS mRNA (Figure 5.4a). These differences were not 
maintained at 6 months (Figure 5.4c). The mRNA levels of PEPCK was not affected by 
exposure to maternal obesity at either time point (Figure 5.4a & c). Note that the assays to 
measure abundance of HSL and FAS mRNAs were not deemed acceptable for use at the 6 
month time point due to high variability between replicates both of samples and standards.  
Analysis of glucocorticoid metabolising genes showed an increase in transcript levels of 5αR 
and 5βR in DIOoff at 3 months (Figure 5.4b). However, at 6 months there was no difference 
in 5αR or 5βR mRNA levels (Figure 5.4d). The abundance of 11β-HSD1 and GR mRNA 
was not changed by early-life exposure to obesity in either age group studied (Figure 5.4b & 
d). 
5.3.2.2 Subcutaneous adipose mRNA levels 
Maternal obesity caused a decrease in transcript levels of mRNA encoding PPARγ in 
subcutaneous adipose but did not alter the transcript levels of PEPCK, LPL or HSL at 3 
months (Figure 5.5a). However, at 6 months DIOoff had increased mRNA levels of LPL and 
HSL, but mRNA abundance of PEPCK, FAS and PPARγ were comparable to controls 
(Figure 5.5c). The abundance of FAS could not be quantified at 3 months due to problems 
with the assay, specifically large variability between replicates. 
The mRNA levels of 11β-HSD1 and GR were comparable in DIOoff and CONoff at 3 
months age (Figure 5.5b). This remained the case for both genes at 6 months (Figure 5.5d). 
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Figure 5.4 Exposure to maternal obesity causes changes in hepatic mRNA 
abundance at 3 months 
Hepatic mRNA levels were analysed by qPCR in offspring of obese (DIOoff) and control 
(CONoff) dams at 3 (solid bars) and 6 (hatched bars) months. Abundance was normalised to 
the abundance of cyclophilin mRNA. At 3 months DIOoff had a significant increase in 
abundance of mRNAs encoding LPL, HSL, PPARα, 5αR and 5βR. At 6 months mRNA 
abundance was comparable for all genes quantified. Data are mean ± SEM, n=6-10/group, 
groups compared using Student’s unpaired t test *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.5 Exposure to maternal obesity causes alterations in subcutaneous 
adipose mRNA abundance 
Subcutaneous adipose mRNA levels were analysed by qPCR in offspring of obese (DIOoff) 
and control (CONoff) dams at 3 (solid bars) and 6 (hatched bars) months. Abundance was 
normalised to the abundance of cyclophilin mRNA. At 3months DIOoff had a significant 
decrease in abundance of mRNA encoding PPARγ. At 6months maternal obesity caused 
increased transcript levels of LPL and HSL. Data are mean ± SEM, n=6-10/group, groups 
compared using Student’s unpaired t test, *p<0.05, **p<0.01. 
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5.4 Discussion 
The experiments in this chapter addressed the hypothesis that exposure to maternal obesity 
during development and suckling adversely programmes offspring metabolism in later life. 
The results show that this model of maternal obesity does not programme alterations in 
offspring body weight, adiposity or plasma concentrations of glucose, insulin or lipids but 
does induce changes in mRNA levels at both 3 and 6 months of age. This suggests in some 
circumstances an obesogenic developmental environment can be tolerated by mice, without 
causing long term changes in metabolism. 
5.4.1 Offspring body and tissue weights 
The difference in body weight developed during the first 3 weeks of life has been shown in 
other models of maternal obesity (Samuelsson et al., 2008; Guo and Jen, 1995; Rodrigues et 
al., 2009; Tamashiro et al., 2009) though not all (Srinivasan et al., 2006; Calvert et al., 
2009). This is likely to be due to suckling milk from an obese mother still consuming an 
obesogenic diet, since maternal diet during the suckling period has a large effect on milk 
composition, so that it contains less protein and more fat, altering the overall energy density 
(Rolls et al., 1986). As the birth weights of both groups were comparable this suggests an 
increased growth rate in DIOoff in the first 3 weeks of life. Although accelerated growth has 
been suggested to have negative effects on insulin sensitivity in neonates that are light for 
gestational age (Rotteveel et al., 2008; Hermann et al., 2009), the same findings have not 
been described in ‘normal’ weight neonates, and the lack of difference in weight, adiposity 
or glucose-insulin homeostasis of the offspring later in life suggests this initial period of 
rapid growth may not be of great significance.  
The results show maternal diet did not affect offspring body weight between 3-25 weeks, 
despite the difference seen at weaning. Some studies of maternal obesity suggest offspring of 
obese dams are heavier, divergences occurring at 12 weeks in males (Samuelsson et al., 
2008) and transiently from 5 weeks (Samuelsson et al., 2008) or permenantly from 10 weeks 
in females (Srinivasan et al., 2006), others report no differences (Khan et al., 2005; Khan et 
al., 2003; Han et al., 2005; Bruce et al., 2009; Calvert et al., 2009). Increased adiposity has 
also been reported in offspring of obese mothers (Buckley et al., 2005; Khan et al., 2005; 
Bayol et al., 2008) though body weight was not reported. Larger adipose depots suggest 
greater lipid storage and a propensity for obesity and its related metabolic consequences in 
later life, however in this study no significant differences in adipose size were found. 
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5.4.2 Offspring plasma hormone and lipid concentrations 
Maternal obesity did not cause a difference in fasting plasma glucose or insulin 
concentrations, or response to an intraperitoneal glucose tolerance test in offspring, in 
agreement with a number of other studies (Han et al., 2005; Bayol et al., 2008). Those that 
do report increases in glucose and insulin (Tamashiro et al., 2009) or insulin alone (Buckley 
et al., 2005; Khan et al., 2005; Srinivasan et al., 2006), as a result of exposure to maternal 
obesity, also report increases in body weight and/or adiposity. The results of previous 
chapters (3 & 4) demonstrate changes in glucose-insulin homeostasis normally occur 
alongside increases in weight gain and adiposity, with smaller increases in weight correlating 
with less severe metabolic disturbance. This suggests that alterations in glucose and insulin 
concentrations in offspring of obese dams may occur as a consequence of weight gain, rather 
than specific programming of individual pathways. 
Exposure to maternal obesity reduced plasma triglyceride concentrations but did not alter 
hepatic triglycerides in offspring aged 3 months. These results may suggest an altered lipid 
flux and deposition pattern in the offspring. Diet consumption and physical activity of 
offspring were not monitored in this study. It is possible that the DIOoff did not eat as much 
as CONoff, and/or they were more metabolically active. However, in fasting, plasma 
triglyceride is mainly determined by liver VLDL secretion and is not very sensitive to food 
intake. Short term adaptations may be the consequence of adjustment from the obese 
environment in early life to the standard diet post weaning. Increased hepatic lipid content in 
older offspring of obese mothers has been reported (Bruce et al., 2009) in association with 
changes in the inflammatory marker CD44, hepatic mitochondria and genes involved in 
oxidative stress (Bruce et al., 2009).  
Plasma concentrations of glucose, insulin and lipids increased with age in our study, age 
related increases in these parameters are well established (Bailey and Flatt, 1982). Early-life 
exposure to obesity may worsen metabolic health by programming accelerated aging in the 
offspring as has been hypothesised in other models of early-life programming (Sayer et al., 
1997; Entringer et al.,2011). 
5.4.3 Offspring mRNA levels 
The increases in abundance of LPL, HSL and PPARα mRNAs at 3 months, if translated to 
protein levels, could increase fatty acid hydrolysis and increase β-oxidation of stored 
triglyceride. This may result in reducing hepatic lipid storage and plasma lipid 
concentrations which correlates with maintaining insulin sensitivity (Hansen et al., 1997; 
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Griffin et al., 1999). These changes in mRNA abundance are transient and may cause the 
decreased plasma triglyceride concentrations found at 3 months. In the study suggesting 
priming of steatohepatitis by maternal obesity (Bruce et al., 2009) a microarray was used to 
evaluate hepatic expression of many genes. In comparison to the results shown here Bruce et 
al. report offspring of obese dams have a 2.6 fold increase in mRNA levels of FAS (Bruce et 
al., 2009), the only gene investigated in common to this study. There was no evidence for 
hepatic lipid accumulation at this time point in the Bruce study. However, at 30 weeks when 
steatosis was present they report a 1.6 fold increase in FAS expression a reduction from the 
earlier time point (Bruce et al., 2009). Again this supports the observation that mRNA levels 
are highly dynamic, can react to changes in physiology and are, therefore, unlikely to be the 
sole mechanism behind programming. 
More temporal changes were found in mRNA levels in the subcutaneous adipose tissue. At 3 
months there was an increase in PPARγ mRNA. This transcription factor increases 
adipogenesis and, therefore, provides storage for lipid molecules (Medina-Gomez et al., 
2007). It is an important drug target in humans with agonists to the receptor prescribed to 
help maintain insulin sensitivity (Yki-Jarvinen, 2004). While adipose weights in the DIOoff 
were not increased, the increase in abundance of mRNA encoding PPARγ at 3months may 
be an attempt to provide more metabolically ‘safe’ storage if the excess hepatic lipids were 
to be hydrolysed. This change in transcript level is again lost with age and by 6 months 
DIOoff have increased transcript levels of mRNA encoding LPL and HSL in subcutaneous 
adipose. As in the liver these lipases are responsible for hydrolysing lipids and generating 
free fatty acids from stored sources which may be beneficial in times of starvation. The mice 
were killed in a fasted state which may have caused an increase in the mRNA abundance of 
these genes, though why it would be greater in the DIOoff compared with CONoff is 
unclear. If this is maintained long term it may have adverse affects on the animals’ 
metabolism by raising circulating free fatty acids. 
It is possible other changes in mRNA levels found at 3 months age and not 6 months are due 
to nutritional state and timing of killing. Offspring were killed un-fasted in the morning 
when 3 months of age to allow for vascular function analysis (Chapter 6), but killed fasted in 
the afternoon when 6 months of age. Although fasting would be expected to have the same 
effect on both CON and DIO offspring, it is possible the response may have been 
programmed in utero.  
As in the other chapters to further investigate the functional relevance of changes in mRNA 
protein levels and enzyme activities should be determined. 
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5.4.4 Plasma corticosterone and glucocorticoid metabolism in offspring 
The 3 month DIOoff offspring had higher concentrations of corticosterone at the nadir but 
not at the peak of the circadian cycle, in agreement with other studies (Boullu-Ciocca et al., 
2005). The reason for this increase is unclear but could include differing stress responses, an 
alteration in the circadian rhythm potentially due to the transcription factor ‘clock’ ( Kino 
and Chrousos, 2011a; Kino and Chrousos, 2011b), or changes in corticosteroid binding 
globulin (CBG) (Breuner and Orchinik, 2002). As with most of the differences seen in the 3 
month offspring the difference in corticosterone concentrations was lost by 6 months, 
suggesting the adaptations in early life are enough to return physiology to normal by 6 
months. The DIO offspring had increased levels of mRNA encoding the metabolising 
enzymes 5αR and 5βR which would lower hepatic glucocorticoid concentrations. This may 
be a compensatory mechanism to reduce the increased circulating corticosterone though it 
should be noted that 5α-metabolites can activate the glucocorticoid receptor (McInnes et al., 
2004). It may also be a mechanism to protect from the development of obesity as several 
animal models have shown that reducing glucocorticoid concentrations helps protect against 
the effects of diet-induced obesity (Morton et al., 2001; Morton et al., 2004). An alternative 
explanation for changes in these enzymes is the potential for these offspring to have been 
exposed to elevated glucocorticoids in utero as this is known to affect the HPA axis in other 
models of programming (Levitt et al., 1996; Nyirenda et al., 1998). Concentrations of 
glucocorticoids greatly increase in maternal blood towards the end of pregnancy (Nolten et 
al., 1980; Montano et al., 1991), but no differences were found between control and obese 
dams used in this study (personal communication Dr. V King). Additionally, maternal diet is 
known to affect the activity of the enzyme 11β-HSD type 2 (11β-HSD2) in the placenta 
(Bertram et al., 2001, Langley-Evans et al., 1996); this enzyme inactivates maternal 
corticosterone and alterations in its activity can affect fetal glucocorticoid exposure (Lindsay 
et al., 1996; Holmes et al., 2006). It would be possible to test the integrity of this barrier 
using radio-labelled tracers in future studies. 
At 6 months there was no difference in GR mRNA levels in adipose tissue, although 
increased expression has been seen in a study of perinatal overfeeding in rats (Boullu-Ciocca 
et al., 2005). This would be predicted to increase glucocorticoid signalling in the adipose 
which has been shown to have a negative impact on metabolism, specifically insulin 
sensitivity and hyperlipidemia (Masuzaki et al., 2001). One proposed mechanism to explain 
long term alterations in gene expression, and increased risk of cardiovascular disease, is 
epigenetic modification of the genome (Handy et al., 2011). Epigenetic marks are laid down 
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in development and persist throughout the life of an animal and include methylation of DNA, 
histone modification and non-coding RNAs (Handy et al., 2011). The GR has been proposed 
as a target of epigenetic modification in models of early-life under-nutrition (Lillycrop et al., 
2005; Lillycrop et al., 2007), altered maternal behaviour (Weaver et al., 2004) and maternal 
stress (Szyf et al., 2005). Investigating possible epigenetic modifications of the 
glucocorticoid receptor gene in the adipose tissue of DIOoff would be interesting. 
Nevertheless, this study found no major effects of maternal obesity on whole body 
physiology; suggesting any epigenetic changes may not be having an influence or may only 
cause effects with ageing. 
5.4.5 Models of maternal obesity 
Overall, this study shows that maternal obesity in C57BL/6 mice does not have major effects 
on offspring physiology at 3 or 6 months age, contrary to other published work (Samuelsson 
et al., 2008; Bruce et al., 2009; Elahi et al., 2009). Many of the changes reported in other 
studies are reported in older offspring and do not affect all the parameters studied. Sex 
specific affects of maternal obesity have been reported with suggestions of more metabolic 
dysfunction in females (Han et al., 2005; Bayol et al., 2008; Samuelsson et al., 2008; Elahi 
et al., 2009), suggesting programming of alterations in sex steroids as well as, or instead of, 
metabolic parameters. Studying female offspring may provide a physiological phenotype as 
a consequence of maternal obesity; published data would also suggest aging the offspring 
further would bring about changes in metabolism.  
Other major differences between this study and others, which may explain the variation in 
outcomes, is the model of maternal obesity used. Some studies have utilised genetic models 
of obesity (Han et al., 2005; Calvert et al., 2009), an obesogenic diet very briefly before 
pregnancy (Guo and Jen, 1995; Khan et al., 2005) or just during pregnancy and suckling 
(Bayol et al., 2007; Tamashiro et al., 2009) and also postnatal over-nutrition by reducing 
litter size (Rodrigues et al., 2009). These models will not generate the same extent of obesity 
in females, and some may be more likely to promote alterations in insulin signalling giving a 
phenotype of gestational diabetes, not maternal obesity. Not only does the type and ‘length’ 
of obesity vary but also the age of female rodents used to become mothers. Some studies 
begin high fat feeding at weaning (Howie et al., 2009), another at 100 days age (Samuelsson 
et al., 2008). However the weights of the dams in this study are comparable to those reported 
in two others (Samuelsson et al., 2008; Bruce et al., 2009) that effected offspring 
physiology. Finally the composition of obesogenic diets used in other studies is varied; some 
having just increased fat content as lard (Howie et al., 2009) or palm oil (Ferezou-Viala et 
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al., 2007) with no change in sucrose content, whilst other studies use diets supplemented 
with human foods (Bayol et al., 2007; Samuelsson et al., 2008). The biggest problem with 
these diets is the choice of control, it is extremely important, particularly when looking at 
programming effects, to consider the content of all other micro and macronutrients in the 
control diet. If increased fat intake occurs at the expense of protein, the widely accepted 
programming effects of prenatal exposure to a low protein diet (reviewed in (Barker, 1998)) 
may occur. Secondly, in comparison to refined diets, cereal based chow diets (often used as 
controls) contain plant-derived ingredients, which may vary throughout the year (Barnard et 
al., 2009). They also contain markedly different micronutrients and phytoestrogens not 
found in refined diets which affect physiology and behaviour (as reviewed in (Warden and 
Fisler, 2008)). These variables were minimised in this study by using two matched refined 
diets from the same supplier. This suggests that some of the programming effects reported in 
other studies may be due to differences in other micro- or macronutrient content between 
obesogenic and control diets.  
Another important difference between the study in this thesis and others is the use of first 
time mothers. The study by Samuelsson et al. (Samuelsson et al., 2008) used proven 
breeders which improved the success rate of pregnancy (Personal communication Professor 
L. Poston, King’s College, London). Multiparity itself is an independent risk factor for 
obesity in humans (Gunderson et al., 2009) and was recently shown to increase adiposity in 
female mice and their male offspring (Rebholz et al., 2011). Therefore using proven breeders 
may amplify the effects of maternal obesity alone.    
5.4.6 Conclusions 
In summary we did not find any marked changes in offspring physiology as a result of 
maternal obesity. We did see some changes in mRNA abundance, though these were not 
consistent at 3 and 6 months. Plasticity in programmed changes may allow for a transitional 
period early in life to minimise the effects of the maternal physiology which are not required 





The effects of maternal and 
postnatal obesity on vascular 
function and remodelling
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6.1 Introduction  
Obesity is associated with hypertension (Berchtold et al., 1981), atherosclerosis (McGill et 
al., 2002) and coronary artery disease (Jousilahti et al., 1999). Recent data suggest the risk of 
cardiovascular disease is also increased in those whose mother was obese (reviewed in 
(Drake and Reynolds, 2010)). The exact link between obesity and CVD is not fully 
understood, but evidence suggests a role for vascular dysfunction (Drexler and Hornig, 1999; 
Cai and Harrison, 2000; Bonetti et al., 2003; Caballero, 2003). This includes alterations in 
vascular tone, which can increase peripheral resistance, and modified vascular remodelling 
following injury such as is seen in atherosclerosis. The Barker hypothesis, supported by 
many clinical studies, proposes a link between adverse fetal environment and risk of adult 
hypertension and cardiac events (Barker et al., 1989; Barker et al., 1990; Barker et al., 
1993a), however, this work is centred around maternal under-nutrition and intrauterine 
growth restriction rather than maternal obesity. 
Many animal models have been used to explore the relationship between obesity and 
cardiovascular disease but the results generated are not consistent. Increased blood pressure 
has been shown in some rat (Kurtz et al., 1989; Dobrian et al., 2001) and mouse (Noronha et 
al., 2005; Rahmouni et al., 2005; Symons et al., 2009) models of dietary and genetic obesity, 
but not in others (Mark et al., 1999; Monassier et al., 2006). Vascular dysfunction as a result 
of obesity has been shown in many relevant animal models (Bourgoin et al., 2008) some 
suggesting it even precedes the metabolic manifestation (Kim et al., 2008). However, in 
rodent models discrepancies exist with some suggesting only certain arteries are affected 
(Oltman et al., 2006; Bhattacharya et al., 2008), or receptor specific effects (Molnar et al., 
2005; Mundy et al., 2007). Vascular remodelling and lesion formation have also been 
studied in rodent models of obesity; in Zucker fatty rats neointima formation following 
arterial injury was greater than in controls (Desouza et al., 2006), however, in genetic mouse 
models of obesity lesion formation was decreased (Schafer et al., 2004). Furthermore murine 
models of dietary obesity have reported both increased (Schafer et al., 2004) and comparable 
(Molnar et al., 2005) lesion formation following arterial injury. 
Recently, with the explosion in rates of obesity, models investigating the long term effects of 
exposure to maternal obesity have been generated, discussed in chapter 5. Some models 
produce increased blood pressure in rodent offspring exposed to maternal obesity during 
development and suckling (Khan et al., 2005; Samuelsson et al., 2008; Elahi et al., 2009). 
However, the offspring in these studies were also shown to have increased adiposity or 
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plasma lipid concentrations, making it difficult to distinguish between the effects of exposure 
to maternal obesity, versus the consequences of postnatal obesity. Rabbit (Napoli et al., 
2000) and mouse (Napoli et al., 2002) models of maternal hypercholesterolaemia produce 
offspring with an increased risk of atherogenesis, suggesting programming of vascular 
remodelling can occur in utero, though no models investigating response to arterial injury 
have been published to date. 
Obesity is associated with insulin resistance both in humans and in animals (Kahn and Flier, 
2000). Insulin has a role in controlling vascular tone, and therefore blood pressure, via the 
synthesis and release of nitric oxide in the endothelial cells, which causes vasodilation 
(Muniyappa et al., 2007). Endothelial dysfunction is a common occurrence in diabetic 
patients (Steinberg et al., 1996), but whether the same mechanisms are affected in obesity is 
unclear. It has also been demonstrated that plasma lipid concentrations can affect vascular 
function (Jayakody et al., 1987; Liao, 1994). Overall these studies indicate obesity may 
affect the vasculature directly through unknown mechanisms, as well as through changes in 
metabolic or endocrine state. 
The experimental models of postnatal and maternal obesity presented in this thesis (chapter 3 





This chapter explores the following hypothesis: exposure to high fat diet either (a) in utero 
and throughout suckling, or (b) in postnatal life, causes arterial dysfunction and an increase 
in lesion formation following arterial injury. 
 
6.1.2 Aims 
To investigate the proposal that either postnatal obesity or exposure to maternal obesity 
during development and suckling adversely affects the vascular system, the following 
questions were addressed;  
 Does exposure to obesity alter systolic blood pressure? 
 Can exposure to obesity cause changes in vasoconstriction and relaxation?  
 Does exposure to obesity cause changes in arterial smooth muscle or endothelial cell 
function? 
 Does exposure to obesity alter the extent of vascular remodelling following intra-
luminal injury? 
 
Mice do not spontaneously develop atherosclerosis on a high fat or high cholesterol diet 
without transgenic alteration such as deletion of the gene coding for apolipoprotein E (ApoE) 
(Zhang et al., 1992; Zhang et al., 1994a) or the LDL-receptor (Ishibashi et al., 1993). 
Atherosclerosis is a physiological response to vascular injury, as is re-stenosis that can occur 
in humans following stent implantation, an event more common in obese subjects (Piatti et 
al., 2003; Nikolsky et al., 2005). Therefore a model of femoral artery intra-luminal injury 
(Sata et al., 2000; Dover et al., 2007) was used to assess vascular remodelling in the mice. 
The response to intra-luminal injury is a cellular proliferation resulting in a smooth muscle 
rich neointima, similar to that seen in re-stenosis. 
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6.2  Methods 
6.2.1 Experimental Outline 
Mice were exposed to either: 
1. Postnatal obesity, induced by a high fat and sugar diet administered (to male and 
female mice) from 5 weeks of age. 
2. Maternal obesity, in the form of obese mothers maintained on a high fat and sugar 
diet prior to pregnancy, during gestation and suckling. The effects on male offspring 
were studied 
One cohort of animals underwent blood pressure measurements when aged 15 weeks 
(following the metabolic tests presented in chapters 3 and 5) and were killed the following 
week. Femoral arteries were removed for ex vivo functional analysis which was performed 
on the same day. For studies of post-natal obesity n= 8/group, and studies of exposure to 
maternal obesity n= 10 CONoff and 8DIOoff all from different litters also used for studies of 
metabolism reported in chapter 5. However, due to technical difficulties in successfully 
mounting and denuding arteries on myographs the number of animals used in each 
experiment is stated in the figure legend. Additional cohorts of animals (not used for 
metabolic studies and therefore group housed) underwent intra-luminal wire injury surgery at 
15 weeks of age, were left to recover for 4 weeks and were then killed to allow collection of 
femoral arteries for analysis. For studies of post-natal obesity n=7/group were fed 
experimental diets, however 2 animals did not survive the surgical procedure meaning the 
number of animals available for analysis was as follows; n=6 CON males and DIO females, 
n=7 DIO males and CON females. All offspring of dams fed control or high fat diet survived 
the surgical procedure, n=8 CONoff and 6 DIOoff. 
6.2.2 Animal maintenance and terminal procedures 
In the study of post-natal obesity, mice were fed either control (CON, Research Diets 
D12328) or obesogenic (DIO, Research Diets D12331) diets from 5 weeks of age (2.3.2). 
The vascular impact of maternal obesity was addressed using male offspring of obese 
(DIOoff) or control (CONoff) dams which were first time mothers, generated as described 
(2.3.3), and fed a standard diet (RMI 801002; Special Diet Services, Witham, UK) from 
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weaning ad libitum. One animal from each litter was used in experiments. All animals were 
maintained as described (2.3.1). 
For functional analysis of the femoral artery, mice were killed using CO2 asphyxiation 
(2.3.4.1) between 8-10am, femoral arteries were removed and placed into PSS. To analyse 
response to intra-luminal wire injury mice were killed by perfusion fixation (2.3.4.2) with 
neutral buffered formalin 28 days post surgery. Perfusion fixation was used as it preserved a 
patent lumen, allowing for easier and more informative image analysis. After fixation, 
femoral arteries were removed and stored in formalin for a further 24 hours before transfer to 
70% ethanol. 
6.2.3 Blood pressure measurements 
Systolic blood pressure was measured by tail cuff plethysmography on 3 consecutive days 
and an average of the three readings was taken (2.3.9). As mice must be restrained for this 
procedure it is known to be stressful and therefore the results were interpreted as such. 
Wherever possible, serial measurements were taken at the same time of day, to reduce 
extraneous sources of variability. 
6.2.4 Intra-luminal wire injury surgery 
To induce intra-luminal injury the femoral artery was isolated and an angioplasty guidewire 
(0.015” diameter) advanced into the lumen through an arteriotomy in the popliteal branch, 
left for 1 minute, removed, and the artery ligated just above the arteriotomy (2.3.5.4). 
Animals were killed 28 days post-injury by perfusion fixation (see section 6.2.2) and femoral 
arteries collected. This is the optimal time point for the maximal stable lesion size following 
intra-luminal wire injury (Sata et al., 2000; Dover et al., 2007) and in a similar model of 
mouse carotid artery ligation (Kumar and Lindner, 1997, Godin et al., 2000).  
6.2.5 Ex vivo functional analysis of femoral arteries 
Vascular function was investigated by wire myography (section 2.4) using ~2mm long 
arterial rings taken from a point immediately proximal to the femoropopliteal bifurcation. 
Two rings cleaned of peri-adventitial material (which is known to alter vascular 
responsiveness (Lohn et al., 2002; Verlohren et al., 2004), were prepared from each artery; 
one ring was left intact, and the second denuded of endothelium by rubbing the lumen with a 
human hair. This allowed for the effects of obesity on endothelial cell function to be 
explored. 
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All vessels were stimulated with three successive exposures to high (125mM) potassium PSS 
(KPSS) to check viability and reproducibility of contraction. This was followed by 









) (2.4.2). Two vasoconstrictors 
were chosen as they agonise different receptors; PE working primarily through α1-
adrenergic receptors and 5-HT acting on 5-HT1 and 5-HT2-receptors, but both activate G-
proteins and similar downstream signalling pathways. The sensitivity to the vasodilators 
acetylcholine (ACh) and sodium nitroprusside (SNP) (following pre-constriction with 3x10
-
7
M 5-HT, to give 80% of the maximal response,) was also analysed (2.4.2). ACh is an 
endothelium-dependent vasodilator acting on muscarinic receptors to induce release of 
vasodilators including nitric oxide (Furchgott and Zawadzki, 1980) whereas SNP is an 
endothelium-independent vasodilator causing activation of guanylate cyclase in smooth 
muscle cells (Schultz and Schultz, 1977). 
6.2.6 Quantification of lesion formation using optical projection 
tomography 
Injured femoral arteries were imaged using optical projection tomography (OPT). This 
recently published technique (Kirkby et al., 2011) scans the femoral artery in 0.9° 
increments and individual scans are then reconstructed to form a 3-dimensional 
representation of the vessel. The position of the intima/media border, the internal elastic 
lamina (IEL), was traced on scans at regular intervals from the remaining ligature and the 
position interpolated for the regions in between. The neointima and lumen were 
distinguished using image segmentation and the absolute size of the neointima was 
expressed as total volume or 2D area for each scan line. The largest area of neointima at a 
single scan line was used as a measure of 2D neointimal area in the section and this allowed 
for comparison with histological analysis (2.1.1). 
6.2.7 Quantification of lesion formation using histology 
Following OPT, femoral arteries were processed and embedded in paraffin wax for 
histology. Sequential 4µm sections were cut in a repeating pattern where 20 sections were 
kept (2 per slide) then 20 discarded (2.2.1.2). The first slide from each set was stained with 
United States Trichrome (UST) (2.2.2.2) to distinguish between the different layers of the 
vessel, particularly the elastic laminae which border the media and intima. The slide with the 
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largest neointima was identified to represent the arterial sample, and the area of the vessel 
layers was measured to allow for calculation of the stenotic ratio, as described (2.2.2.5). 
6.2.8 Statistics 
Concentration-response curves were created using non-linear regression and compared by 2-
way ANOVA followed by Bonferroni’s post-hoc analysis. Myography summary data were 
generated using a least squares fit model (2.4.3). Other comparisons in this chapter were 
performed using unpaired Student’s t-test, with adult males and females and offspring 
analysed separately. Data shown are mean ± SEM. 
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6.3 Results 
6.3.1 Systolic blood pressure 
Systolic blood pressure was not altered following induction of diet-induced obesity in male 
or female mice, nor in male offspring following exposure to maternal obesity (Table 6.1).  
6.3.2  Femoral artery function 
Vessel viability was confirmed using KPSS in all groups; there were no differences in basal 
responses of intact or denuded vessels in mice subjected to postnatal or maternal DIO (Table 
6.2, Table 6.3, Table 6.4). Lumen diameter was not measured in arteries used for 
myography. However, no differences were found when measurements were made in 
comparable cohorts of animals which underwent the intraluminal femoral artery injury 
surgery (Table 6.5 & 6.6). Functional data are expressed as a percentage of KPSS response 
to minimise variability due to unavoidable damage caused by removal of the endothelium 
and mounting on myographs. Arteries from all groups elicited concentration-dependent 
contractions to PE and 5-HT, and relaxation with SNP. Denuding the vessels of endothelium 
caused the expected reduction in relaxation to ACh in all groups (Furchgott and Zawadzki, 
1980). 
6.3.2.1  Postnatal diet-induced obesity in male mice 
There was no difference in contractile response to PE in intact male femoral arteries (Figure 
6.1a). When denuded of endothelium there was a small leftward shift of the concentration-
response curve of DIO males (Figure 6.1b), though no difference in pD2 was found when 
compared by Student’s t-test (Table 6.2). DIO caused a leftward shift and higher maximum 
of the response curve to 5-HT in both intact and (Figure 6.1c) and denuded (Figure 6.1d) 
vessels. Consequently, the maximum contraction (Emax) was significantly higher in intact 
vessels from DIO mice compared with controls (Table 6.2). 
A rightward shift of the concentration-response curve to ACh was seen in DIO mice (Figure 
6.2a) when compared using analysis of variance. However no difference in –logIC50 was 
found when compared using Student’s t-test (Table 6.2). DIO vessels denuded of 
endothelium lost less tone than CON when treated with increasing concentrations of ACh 
(Figure 6.2b). Despite the reduced response, no differences were found when –logEC50 or 




 Systolic Blood pressure 
(mmHg) 
P value 
 CON DIO  
Postnatal obesity 
Males 121 ± 3 118 ± 3 0.57 
Females 119 ± 3 118 ± 3 0.85 
Maternal obesity Males 117 ± 4 121 ± 2 0.53 
 
Table 6.1 Exposure to an obesogenic diet does not alter systolic blood pressure 
Male and female mice were fed obesogenic (DIO) or control (CON) diets from 5 weeks of 
age. Male offspring from control (CON) and obese (DIO) mothers were fed a standard diet 
from weaning. Systolic blood pressure was measured at 14 weeks of age in all mice. Neither 
postnatal nor maternal obesity altered blood pressure. Data are mean ± SEM, postnatal 
obesity; n=8/group, maternal obesity; CON n=10, DIO n=6, analysed by Student’s unpaired t 
test. 
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Table 6.2 Myography summary data 
from male mice fed obese (DIO) or 
control (CON) diets 
Male mice were fed control (CON) or 
obesogenic (DIO) diets from 5 weeks of 
age. Femoral arteries were removed at ~15 
weeks of age and function assessed using 
wire myography. Summary data for the 
four drugs used are provided. Emax is 
expressed in force (mN/ mm) or as a 
percentage of response to 125mM KPSS; 
Maximum relaxation is expressed as a 
percentage of pre-constriction to 3x10
-7
M 
5-hydroxytryptamine. Data are mean ± 
SEM, analysed using Student’s unpaired t-
test; n=6/group except for phenylephrine 
n=5/group. 
 
  Intact Denuded 




2.37 ± 0.26 2.26 ± 0.11 0.70 1.31 ± 0.26 1.58 ± 0.42 0.60 
Phenylephrine 
pD2 5.90 ± 0.15 5.68 ± 0.11 0.28 6.00 ± 0.12 6.24 ± 0.16 0.26 
Emax 
(mN/mm) 
2.00 ± 0.28 2.04 ± 0.15 0.90 1.37 ± 0.35 1.69 ± 0.49 0.61 
Emax 
(%KPSS) 
88.4 ± 3.7 87.6 ± 7.0 0.92 96.5 ±10.3 101.6 ± 4.1 0.66 
5-
hydroxytryptamine 
pD2 7.04 ± 0.14 6.68 ± 0.46 0.46 6.99 ± 0.14 6.59 ± 0.49 0.45 
Emax 
(mN/mm) 
2.14 ± 0.22 2.34 ± 0.10 0.43 1.30 ± 0.28 1.59 ± 0.38 0.56 
Emax 
(%KPSS) 
91.2 ± 3.3 104.0 ± 4.4 0.04 94.0 ± 8.2 101.9 ± 4.7 0.42 
Acetylcholine 
-(log)IC50 7.88 ± 0.17 7.59 ± 0.19 0.28 7.77 ± 0.35 8.05 ± 0.41 0.61 
Max relaxn 
(%) 
94.7 ± 3.3 95.6 ± 2.3 0.82 60.9 ± 3.0 43.0 ± 9.4 0.10 
Sodium 
Nitroprusside 
-(log)IC50 8.60 ± 0.12 8.38 ± 0.20 0.36 8.55 ± 0.19 8.30 ± 0.29 0.48 
Max relaxn 
(%) 
99.0 ± 0.4 99.3 ± 0.3 0.54 102.5 ± 1.6 103.3 ± 1.0 0.66 
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Table 6.3 Myography summary 
data from female mice fed an 
obesogenic (DIO) or control 
(CON) diet 
Female mice were fed control (CON) 
or obesogenic (DIO) diets from 5 
weeks of age. Femoral arteries were 
removed at ~15 weeks of age and 
function assessed using wire 
myography. Summary data for the 
four drugs used are provided. Emax is 
expressed in force (mN/ mm) or as a 
percentage of response to 125mM 
KPSS, maximum relaxation is 




hydroxytryptamine. Data are mean ± 
SEM, analysed using Student’s 
unpaired t-test; n=6/group except for 
phenylephrine n=5/group. 
  Intact Denuded 




2.50 ± 0.17 2.70 ± 0.08 0.42 1.00 ± 0.13 1.30 ± 0.41 0.51 
Phenylephrine 
pD2 5.99 ± 0.14 6.10 ± 0.06 0.50 6.41 ± 0.07 6.58 ± 0.07 0.11 
Emax 
(mN/mm) 
2.16 ± 0.30 2.20 ± 0.18 0.91 0.94 ± 0.23 1.53 ± 0.47 0.30 
Emax 
(%KPSS) 
84.6 ± 7.3 83.0 ± 6.7 0.88 97.2 ± 0.4 106.3 ± 6.5 0.29 
5-
hydroxytryptamine 
pD2 6.92 ± 0.11 7.13 ± 0.05 0.12 6.99 ± 0.08 7.21 ± 0.10 0.12 
Emax 
(mN/mm) 
2.56 ± 0.25 2.84 ± 0.12 0.35 1.10 ± 0.18 1.48 ± 0.52 0.50 
Emax 
(%KPSS) 
101.5 ± 2.8 112.4 ± 6.6 0.16 103.7 ± 3.2 111.5 ± 6.9 0.33 
Acetylcholine 
-(log)IC50 7.75 ± 0.10 7.90 ± 0.14 0.44 7.44 ± 0.30 7.52 ± 0.26 0.84 
Max relaxn 
(%) 
95.5 ± 2.8 93.5 ± 4.4 0.71 45.6 ± 4.3 28.2 ± 5.9 0.04 
Sodium 
Nitroprusside 
-(log)IC50 8.34 ± 0.29 8.43 ± 0.27 0.82 8.02 ± 0.02 7.87 ± 0.12 0.25 
Max relaxn 
(%) 
98.2 ± 0.5 98.8 ± 0.6 0.49 102.2 ± 1.1 100.5 ± 1.1 0.29 
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Table 6.4 Myography summary 
data from male mice born to obese 
(DIOoff) or control (CONoff) 
dams 
Femoral arteries were removed at ~15 
weeks of age and function assessed 
using wire myography. Summary data 
for the four drugs used are provided. 
Emax is expressed in force (mN/ mm) 
or as a percentage of response to 
125mM KPSS and maximum relaxation 




hydroxytryptamine. Data are mean ± 
SEM; analysed using Student’s 
unpaired t-test, n=9/ CONoff group, 
n=8 DIOoff intact, n=7 DIOoff 
denuded. 
 
  Intact Denuded 




1.61 ± 0.19 1.18 ± 0.2 0.21 1.12 ± 0.28 0.60 ± 0.24 0.23 
Phenylephrine 
pD2 6.14 ± 0.20 5.91 ± 0.11 0.39 6.52 ± 0.12 5.70 ± 0.34 0.02 
Emax 
(mN/mm) 
1.35 ± 0.20 0.82 ± 0.24 0.10 0.83 ± 0.22 0.42 ± 0.17 0.19 
Emax 
(%KPSS) 
93.5 ± 3.6 86.6 ± 6.4 0.35 97.1 ± 4.8 103.8 ± 9.3 0.50 
5-
hydroxytryptamine 
pD2 7.10 ± 0.04 7.14 ± 0.09 0.95 7.14 ± 0.06 7.06 ± 0.07 0.41 
Emax 
(mN/mm) 
1.45 ± 0.22 1.37 ± 0.24 0.82 0.83 ± 0.22 0.46 ± 0.18 0.24 
Emax 
(%KPSS) 
99.2 ± 3.1 112.5 ± 5.3 0.04 97.9 ± 5.6 122.8 ± 18.0 0.16 
Acetylcholine 
-(log)IC50 7.56 ± 0.11 6.68 ± 0.19 <0.001 7.59 ± 0.18 7.31 ± 0.21 0.35 
Max relaxn 
(%) 
94.5 ± 2.2 84.3 ± 8.2 0.23 62.0 ± 4.6 54.0 ± 8.3 0.38 
Sodium 
Nitroprusside 
-(log)IC50 8.52 ± 0.14 8.34 ± 0.12 0.33 8.29 ± 0.16 8.36 ± 0.17 0.79 
Max relaxn 
(%) 




Figure 6.1 DIO caused agonist-dependent increases in femoral artery 
contraction in male mice. 
Male mice were fed obesogenic (DIO, squares) or control (CON, circles) diet from 5 weeks 
of age. Femoral arteries were removed at ~15 weeks of age and responses to phenylephrine 
(PE) (a & b) and 5-hydroxytryptamine (5-HT) (c & d) assessed using wire myography. Two 
rings were created from each vessel, one left intact (closed symbols) and one denuded of 
endothelium (open symbols). Denuded, but not intact, DIO vessels had increased sensitivity 
to PE. Increased sensitivity and greater maximum contraction to 5-HT was seen in DIO 
vessels. Data are mean ± SEM; analysed by 2 way ANOVA, n=5/group phenylephrine, 




Figure 6.2 DIO reduced endothelium-dependent and -independent relaxation in 
femoral arteries from male mice  
Male mice were fed obesogenic (DIO, squares) or control (CON, circles) diet from 5 weeks 
of age. Femoral arteries were removed at ~15 weeks of age and responses to acetylcholine 
(ACh) (a & b) and sodium nitroprusside (SNP) (c & d) assessed following a preconstriction 
with 5-hydroxytryptamine using wire myography. Two rings were created from each vessel, 
one left intact (closed symbols) and one denuded of endothelium (open symbols). DIO 
concentration-response curves were shifted to the right in intact vessels. Denuded CON 
vessels lost more tone during ACh treatment than DIO. Data are mean ± SEM; analysed by 2 




SNP concentration-response curve in intact vessels when compared with analysis of variance 
(Figure 6.2c). This small shift did not result in differences in the summary statistics (Table 
6.2). SNP-induced relaxation was comparable in femoral arteries from male DIO and CON 
mice (Figure 6.2, Table 6.2). 
6.3.2.2 Postnatal diet-induced obesity in female mice 
In female mice the response to PE in intact vessels was not affected by DIO (Figure 6.3a & 
Table 6.3). When denuded of endothelium a small rightward shift of the concentration 
response-curve was observed (Figure 6.3b) though comparison of pD2 values with Student’s 
t-test did not show any significant differences (Table 6.3). DIO caused a leftward shift and 
higher maximum in the concentration response curves for 5-HT both in intact (Figure 6.3c) 
and in denuded vessels (Figure 6.3d). However, changes in pD2 and maximum contraction 
did not reach statistical significance when compared using Student’s t-test (Table 6.3).  
DIO did not alter the vascular response to ACh or SNP in intact femoral arteries (Figure 6.4a 
& c, Table 6.3). However, as seen in the males, female DIO arteries did not lose as much 
tone with increasing concentrations of ACh when denuded of endothelium (Figure 6.4b); this 
was also reflected in the reduced maximum relaxation (Table 6.3). Removal of endothelium 
resulted in a small rightward shift in the concentration-response curve for SNP when 
compared by analysis of variance (Figure 6.4d). However comparison of -logIC50 using 
Student’s t-test did not show any differences (Table 6.3). 
6.3.2.3 Mice exposed to maternal obesity 
Denuded femoral arteries from DIOoff had reduced sensitivity to PE seen both as a decrease 
in pD2 (Table 6.4), and a large rightward shift of the concentration-response curve (Figure 
6.5b). Post-hoc analysis revealed differences specifically at 1x10
-6
 M and 3x10
-6 
M. Intact 
vessels from DIOoff also had a rightward shift of the concentration-response curve to PE 
(Figure 6.5a) but no difference was found in pD2 when compared using Student’s t-test 
(Table 6.4). Maximum vasoconstriction to PE was comparable between groups in both intact 
and denuded vessels (Table 6.4). In response to 5-HT, concentration response-curves from 
DIOoff and CONoff were significantly different, when compared using analysis of variance, 
post-hoc analysis revealed this to be due to a greater maximum in DIOoff which was 
maintained at the highest concentrations of 5-HT (Figure 6.6c & d). The maximum 
contraction to 5-HT in was greater in DIOoff intact vessels when summary statistics were 
compared using Student’s t-test (Table 6.4), this did not reach statistical significance in 
vessels denuded of endothelium (Table 6.4).  
184 
Figure 6.3 DIO caused agonist-dependent increases in femoral artery 
constriction in female mice 
Female mice were fed obesogenic (DIO, squares) or control (CON, circles) diet from 5 
weeks of age. Femoral arteries were removed at ~15 weeks of age and responses to 
phenylephrine (PE) (a & b) and 5-hydroxytryptamine (5-HT) (c & d) assessed using wire 
myography. Two rings were created from each vessel, one left intact (closed symbols) and 
one denuded of endothelium (open symbols). DIO concentration-response curves to PE were 
shifted to the left in denuded, but not intact vessels. Increased maximum contraction to 5-HT 
and a left shift of the concentration-response curve was seen in all DIO vessels. Data are 
mean ± SEM; analysed by 2 way ANOVA, n=5/group phenylephrine, n=6/group 5-




Figure 6.4 DIO causes a reduction in endothelium -independent relaxation in 
femoral arteries from female mice with DIO. 
Female mice were fed obesogenic (DIO, squares) or control (CON, circles) diet from 5 
weeks of age. Femoral arteries were removed at ~15 weeks of age and responses to 
acetylcholine (ACh) (a & b) and sodium nitroprusside (SNP) (c & d) assessed, following a 
preconstriction with 5-hydroxytryptamine, using wire myography. Two rings were created 
from each vessel, one left intact (closed symbols) and one denuded of endothelium (open 
symbols). Intact vessels had comparable sensitivity to both ACh and SNP, denuded DIO 
vessels lost less tone than CON during ACh treatment and had a small rightward shift of the 
concentration-response curve to SNP. Data are mean ± SEM; analysed by 2 way ANOVA, 
n=5/group. NS- not significant.  
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Figure 6.5 Maternal obesity causes a decrease in phenylephrine sensitivity and 
an increase in contraction to 5-hydroxytryptamine in offspring femoral arteries 
Vascular contraction was analysed in male mice born to obese (DIOoff, squares) or control 
(CONoff, circles) dams. Femoral arteries were removed at ~15 weeks of age and responses 
to phenylephrine (PE) (a & b) and 5-hydroxytryptamine (5-HT) (c & d) assessed using wire 
myography. Two rings were created from each vessel, one left intact (closed symbols) and 
one denuded of endothelium (open symbols). DIOoff had reduced sensitivity to PE and a 
greater contraction at high concentrations of 5-HT. Data are mean ± SEM; analysed by 2 
way ANOVA, Bonferroni’s post-hoc test, n=9/ CONoff group, n=8 DIOoff intact, n=7 
DIOoff denuded, *p<0.05, **p<0.01, ***p<0.001. 
 
187 
Figure 6.6 Maternal obesity causes an endothelium-dependent reduction in 
relaxation in femoral arteries of offspring 
Vascular relaxation was analysed in male mice born to obese (DIOoff, squares) or control 
(CONoff, circles) dams. Femoral arteries were removed at ~15 weeks of age and relaxation 
response to acetylcholine (ACh) (a & b) and sodium nitroprusside (SNP) (c & d) assessed 
following a preconstriction with 5-hydroxytryptamine using wire myography. Two rings 
were created from each vessel, one left intact (closed symbols) and one denuded of 
endothelium (open symbols). Intact DIOoff vessels had reduced sensitivity to ACh and SNP; 
these differences were lost when the endothelium was removed. Data are mean ± SEM; 
analysed by 2 way ANOVA, Bonferroni’s post-hoc test, n=9/ CONoff group, n=8 DIOoff 
intact, n=7 DIOoff denuded, NS- not significant, **p<0.01, ***p<0.001. 
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Exposure to maternal obesity caused a rightward shift of the concentration-response curve to 





(Figure 6.6a). This was also demonstrated by a reduction in –logIC50 (Table 6.4). When the 
endothelium was removed from vessels no difference in the response to ACh was seen 
(Figure 6.6b). A small right shift of the response-curve to SNP was seen in intact DIOoff 
femoral arteries when compared using analysis of variance (Figure 6.6c). However no 
difference in –logIC50 was found when compared using Student’s t-test (Table 6.4). No 
change in the response to SNP was found when vessels were denuded (Figure 6.6d). 
Maximum relaxation to either ACh or SNP was not affected by exposure to maternal obesity 
(Table 6.4). 
6.3.3 Vascular remodelling following intra-luminal wire injury  
Analysis of femoral arteries revealed consistent lesion development, in the form of 
neointima, as a result of intra-luminal wire injury analysed by both OPT and histology 
(Figure 6.7). Due to variability of vessel size, volumetric data are presented as a percentage 
of volume inside the IEL and 2-dimensional data are presented as a stenotic ratio.  
6.3.3.1 Mice subjected to post-natal obesity 
Postnatal obesity did not affect the volume of neointimal lesion formed in response to 
luminal wire injury (Figure 6.8a & d, Table 6.5). The same result was found when the largest 
area of lesion from each artery was analysed by OPT (Figure 6.8b & e, Table 6.5) and 
histology (Figure 6.8c & f, Table 6.5). 
6.3.3.2 Offspring of obese dams 
Exposure to maternal obesity did not affect lesion volume (Figure 6.9a, Table 6.6) or area 
(Figure 6.9b & c, Table 6.6) in male offspring. Analysis of lesion by OPT found both the 
total area inside the IEL and neointimal area were not affected by exposure to maternal 
obesity (Table 6.6). Lumen size (Table 6.6) and stenotic ratio (Figure 6.9) were also 




Figure 6.7 Representative optical projection tomography (OPT) scan, 2-D 
reconstructed cross sections and histology sections showing neointima formation 
following intra-luminal wire injury 
Following intra-luminal wire injury femoral arteries were perfusion fixed and embedded in 
agarose. Neointima was visualised by OPT scanning which generated 3D images of vessels 
(a) by reconstructing a stack of 2D images (b). Arteries were then processed for histology 
and stained with United States Trichrome (c) for further analysis. Cross-sectional images (b 
& c) are taken from the 3 points indicated on the full artery scan (a). Scale bar 200µm. 
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Figure 6.8 Postnatal obesity does not alter neointimal lesion formation following 
luminal injury  
Male (blue) and female (pink) mice were fed obesogenic (DIO, closed bars) or control 
(CON, open bars) diet from 5 weeks of age and at 15 weeks underwent femoral artery intra-
luminal wire injury. Neointimal volume was analysed using optical projection tomography 
and presented as a percentage of the total volume inside the internal elastic lamina (a & d) to 
account for variability in overall vessel size. The maximum stenotic ratio (neointima:lumen) 
from each artery was calculated from the 2D stack of images generated for optical projection 
tomography (OPT) reconstruction (b & e) and sections stained with United States Trichrome 
(c & f). Postnatal obesity did not alter the volume or area of neointimal lesion formed post 
injury in either sex. Data are mean ± SEM, analysed using students unpaired t-test; n= 6 
CON males and DIO females, n=7 DIO males and CON females.  
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Imaging 
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Table 6.5 The effects of post-natal obesity on vascular morphology and 
composition following intra-luminal injury 
Male and female mice were fed obesogenic (DIO) or control (CON) diet from 5 weeks of 
age and at 15 weeks underwent intra-luminal wire injury of the femoral artery. Volumes 
inside the internal elastic lamina (IEL) and of neointima formed in a defined region were 
determined using optical projection tomography (OPT). The area inside the IEL and 
neointima were determined from the 2D stack of OPT images and using histology at the 
point where the neointima was greatest. Lumen diameter was measured distal from the point 
of wire insertion where the vessel morphology had returned to normal. Data are mean ± 
SEM, analysed using Student’s unpaired t-test; n= 6 CON males and DIO females, n=7 DIO 




Figure 6.9 Exposure to maternal obesity does not alter neointimal lesion 
formation in the offspring 
Male mice born to obese (DIOoff, checked bars) or control (CONoff, dotted bars) dams 
underwent femoral artery injury at 15 weeks of age and neointimal hyperplasia was 
analysed. Neointimal volume was analysed using optical projection tomography and 
presented as a percentage of the total volume inside the internal elastic lamina (a) to account 
for variability in overall vessel size. The maximum stenotic ratio (neointima:lumen) from 
each artery was calculated from the 2D stack of images generated for optical projection 
tomography (OPT) reconstruction (b) and from sections stained with United States 
Trichrome (c). Exposure to maternal obesity did not alter the volume or maximum area of 
neointima formed following vascular injury. Data are mean ± SEM, analysed using Student’s 
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) 9.5 ± 2.4 6.8 ± 2.0 0.46 




















) 10.6 ± 2.3 11.5 ± 2.4 0.80 














) 9.1 ± 4.7 22.9 ± 6.2 0.09 
Lumen diameter (µm) 245.3 ±13.3 281.8 ± 24.4 0.18 
 
Table 6.6 The effects of obesity in early life on vascular morphology and 
composition following luminal injury 
Vascular remodelling following luminal wire injury was analysed in male mice born to obese 
(DIOoff) or control (CONoff) dams. Volumes inside the internal elastic lamina (IEL) and of 
neointima formed in a defined region were determined using optical projection tomography 
(OPT). The area inside the IEL and neointima were also determined from the 2D stack of 
OPT images and using histology at the point where the neointima was greatest. Lumen 
diameter was measured distal from the point of wire insertion where the vessel morphology 
had returned to normal. Data are mean ± SEM, analysed using Student’s unpaired t-test; n= 8 
CONoff, n=6 DIOoff. 
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6.4 Discussion 
The experiments described in this chapter addressed the hypothesis that mice exposed to 
obesity develop hypertension, alterations in vascular function and increased remodelling 
following intra-luminal wire injury. Two experimental paradigms of obesity were used: 
exposure to maternal obesity during development and suckling; or, diet-induced obesity 
during postnatal life. The results of this chapter must be interpreted with reference to the 
metabolic changes seen in the two models as presented in chapters 3 and 5. Briefly, postnatal 
DIO caused adiposity in both male and female mice, though the associated insulin resistance 
and dyslipidemia were more severe in males. In contrast maternal obesity did not have any 
overt effect on adiposity or metabolism. The results in this chapter show neither exposure to 
maternal, or post natal obesity, are associated with alterations in systolic blood pressure or 
lesion formation following intra-luminal wire injury. However, vascular function is affected 
by exposure to obesity, with exposure during development and suckling having a much more 
profound effect. These results imply exposure to postnatal or maternal obesity affect 
different vascular mechanisms. They also suggest maternal obesity can programme altered 
vascular function in the offspring, in the absence of overt alterations in metabolism described 
in chapter 5. 
6.4.1 Postnatal obesity and hypertension 
Rodent models of obesity have not consistently reported increased blood pressure and our 
study showed results comparable to Monassier et al. who found no difference in systolic 
blood pressure in diet-induced obese male and female mice (Monassier et al., 2006). One 
potential reason for the discrepancy in studies is the degree of obesity induced by different 
dietary manipulations, since fatter animals may have higher blood pressures. Indeed, 
Williams et al. fed C57BL/6 male mice a high fat diet for 15 weeks, 5 weeks longer than this 
study, and reported a moderate (8.6mmHg) increase in blood pressure (Williams et al., 
2003). However studies by Symons et al. (Symons et al., 2009) and Rahmouni et al. 
(Rahmouni et al., 2005) reporting increased blood pressure in association with dietary-
induced obesity showed equivalent levels of obesity, developed over the same time period, to 
those reported in our study. An alternative explanation for the difference in effects on blood 
pressure could be differences in the diets used. Notably Symons (Symons et al., 2009) and 
Rahmouni (Rahmouni et al., 2005) reported using ‘chow’ diet as a control which was not 
fully matched to the high fat diet for other nutrients such as salt. Differing salt concentrations 
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could affect blood pressure, particularly in salt sensitive individuals (Muntzel and Drueke, 
1992) although C57BL/6 mice have not been shown to be salt sensitive unless mutant. 
Other studies reporting hypertension in association with dietary induced obesity have used 
male mice (Rahmouni et al., 2005; Symons et al., 2009), which, given findings reported in 
chapter 3, are likely to have larger metabolic disturbances than females. Another important 
sex difference is the beneficial effects of estrogen on the vascular system (reviewed in 
(White, 2002)), this implies female mice may need an even greater degree of 
obesity/metabolic dysfunction, than males, before changes in blood pressure would be 
observed. 
It has been proposed that leptin is a key mediator in the development of hypertension in 
obese mice. In leptin deficient ob/ob mice blood pressure is lower than in lean controls, 
despite significant increases in adiposity (Mark et al., 1999). Leptin acts in the hypothalamus 
to increase renal sympathetic activity and blood pressure (Marsh et al., 2003). In situations 
of leptin resistance, as is proposed to occur in obese subjects, some of the functions of this 
adipokine are lost (Van Heek et al., 1997; Rahmouni et al., 2005) but the renal response to 
leptin is preserved (Rahmouni et al., 2005). Therefore it is unlikely that leptin resistance 
plays a role in the development of hypertension in dietary obesity. Recently a study has 
suggested inflammatory mediators are the neural link between obesity and high blood 
pressure (Purkayastha et al., 2011). Purkayastha et al. propose NFκB and TNFα, which are 
elevated in obesity (Hotamisligil et al., 1993; Zhang et al., 2008), to be regulators of neural 
hypertension in mice (Purkayastha et al., 2011). If this mechanism has not been activated it 
may explain the lack of changes in blood pressure. 
6.4.2 Maternal obesity and hypertension 
While no effect of maternal obesity on offspring blood pressure was reported here, a number 
of other studies have reported hypertension in offspring exposed to maternal obesity, in 
association with increased body weight or adiposity (Khan et al., 2003; Samuelsson et al., 
2008; Elahi et al., 2009). In contrast, no changes in glucose or insulin metabolism were 
found in the model used in this thesis (chapter 5). This, combined with the lack of increased 
blood pressure, may suggest that hypertension in offspring of obese dams is secondary to 
metabolic changes and results from an altered endocrine environment, rather than direct 
programming of hypertension as has been proposed to occur following maternal protein 
restriction (Langley-Evans et al., 1994; Langley-Evans et al., 1996). Sex differences in blood 
pressure have been found both in obese rodents (Monassier et al., 2006) and in offspring 
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exposed to maternal obesity (Khan et al., 2003). Khan et al. reported that hypertension 
occurred in female offspring of obese dams but not in males (Khan et al., 2003), females 
were not studied in this chapter but the results are consistent in male offspring. 
Blood pressure measurements in this study were determined using tail cuff plethysmography, 
a method demonstrated to give reproducible results comparable to those measured intra-
arterially (Krege et al., 1995). However, the technique can only measure systolic blood 
pressure and also is stressful as it involves restraint. These limitations of the technique may 
mask differences in diastolic, and resting or un-stressed, blood pressure. The use of 
radiotelemetery to measure arterial blood pressure has improved the accuracy of continuous 
readings in conscious free moving animals. Studies of rodent blood pressure using 
radiotelemetery have reported group differences in response to changing environmental 
temperature (Williams et al., 2003) and stress (O'Regan et al., 2008), which may be missed 
using a plethysmography method. Using radiotelemetery in the models used in this chapter 
would determine if the results found with the tail cuff procedure are also applicable in other 
situations (e.g. non-stressed). This may be particularly important in mice exposed to 
maternal obesity as there is potential that blood pressure could fluctuate between stressed 
and unstressed situations, as reported in offspring exposed to glucocorticoids in utero 
(O'Regan et al., 2008). Comparing blood pressure results with those previously reported in 
the literature is difficult as the origins of the strain and environment in the housing facility 
may impact on rodent blood pressure. The consistency of our results suggests a systolic 
pressure of 120mmHg is normal for the colony of C57BL/6 mice used for the studies in this 
chapter. 
Heart rate, cardiac output, and renal function all have roles in the regulation of blood 
pressure. These parameters were not measured in this study; however it has been shown that 
heart rate is unchanged in obese mice (Williams et al., 2003). Peripheral resistance and 
vascular tone can also alter arterial blood pressure. Although peripheral resistance was not 
calculated, measures of vascular function can indicate if differences in vascular resistance 
are likely. 
6.4.3 Femoral artery function following postnatal obesity 
Mice subjected to post-natal obesity had small changes in their vascular responses to PE, 5-
HT, ACh and SNP. The significant differences found when analysed using analysis of 
variance resulted from small but consistent shifts of concentration-response curves to the left 
or right of controls. However, when Student’s t-test was used to compare single data points 
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such as pD2 or maximum contraction, no changes were found. However, the differences 
found in the concentration-response curves are small and possibly unlikely to be 
physiologically relevant. Periadvential adipose tissue has been shown to release relaxation 
factors (Lohn et al., 2002), promote endothelial dysfunction (Ketonen et al., 2010) and 
regulate arterial tone of mesenteric arteries (Verlohren et al., 2004). The adipose was 
removed from vessels before function was analysed, to determine changes in the vessels 
alone. If the function of the same arteries was analysed in vivo greater differences may be 
found due to the effects of the periadventital adipose. In addition, the small alterations in 
function described may become more problematic if the system was further stressed with 
increasing levels of obesity, by infection or by vascular damage. 
Other groups have demonstrated anatomical differences in vascular dysfunction following 
obesity or diabetes (Crauwels et al., 2000; Bhattacharya et al., 2008; Oltman et al., 2006); 
this may account for some of the inconsistencies seen when comparing studies. The results 
of this chapter are specific to the femoral artery and should not be presumed to be the same 
in all vessels of the animal. The femoral artery was studied in this chapter in order to 
determine any functional changes which may impact on lesion formation following intra-
luminal injury which was subsequently investigated. 
A study by Molnar et al. using a similar experimental protocol to that in this chapter, 
reported differences in femoral artery vasoconstriction response to phenylephrine and in 
relaxation following treatment with acetylcholine and sodium nitroprusside (Molnar et al., 
2005). The differences in results to those reported in this chapter may reflect small 
differences in study design, for example, while the degree of obesity was similar, the dietary 
composition and constituents and the timing at which the diet was introduced (and therefore 
age of animals) differed. Ageing is a risk factor in the development of atherosclerosis and 
vascular dysfunction (Spagnoli et al., 1991; Lundberg and Crow, 1999). By using older 
animals Molnar et al. may have potentiated the small changes in vascular responses reported 
here. 
The most consistent change seen in post-natal DIO in both sexes was increased contraction 
to 5-HT, both in intact and endothelium denuded vessels. This suggests an alteration in 
receptor sensitivity or numbers on the smooth muscle cells in the vessel media. The loss of 
relaxation at high concentrations of 5-HT in DIO mice may reflect a reduction of the 
endothelium-dependent vasodilatory response to this compound (Cocks and Angus, 1983; 
Toda and Okamura, 1990). Physiologically greater sensitivity to endogenous 
vasoconstrictors may lead to increased peripheral resistance with time and, consequently, to 
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raised blood pressure. No major differences in response to the other vasoconstrictor, PE, 
were found, which suggests the change is specific to the 5-HT receptor and less likely to be a 
difference in downstream signalling which is common to both agonists. 
Most reports implicate insulin resistance as a key mediator in endothelial dysfunction in 
obese humans (Caballero et al., 1999; Steinberg et al., 1996; Rueda-Clausen et al., 2011) 
and in some animal models (Molnar et al., 2005; Erdei et al., 2006; Traupe et al., 2002). The 
results presented in chapter 3 demonstrate female DIO mice were not insulin resistant, which 
might explain the lack of change in ACh-mediated relaxation. However, DIO male animals 
had fasting hyperinsulinemia (chapter 3), but still a comparable ACh-mediated relaxation to 
controls. This result in males is consistent with two other groups who found no effect of 
obesity on thoracic (Noronha et al., 2005) or femoral (Bhattacharya et al., 2008) artery ACh-
mediated relaxation. Bhattacharya et al. have reported increased sensitivity of femoral 
arteries to ACh only when males are given a very high fat diet (Bhattacharya et al., 2008) 
which suggests specific diets may account for some of the differences between results. It is 
possible other vascular factors released in response to ACh, such as hydrogen peroxide 
(Matoba et al., 2000), prostacyclin (Holzmann et al., 1980), potassium (Savage et al., 2003), 
or other unknown endothelium-derived hyperpolarising factors (EDHF) (Brandes et al., 
2000), can compensate for a lack of vasodilation by nitric oxide. Brandes et al. demonstrated 
a vasorelaxation response to acetylcholine is still elicited in mice with eNOS genetically 
deleted (Brandes et al., 2000). They went on to find inhibition of prostacyclin did not reduce 
the vasodilation (Brandes et al., 2000), demonstrating other EDHFs have a role to play in 
murine resistance artery dilation. Increased EDHFs were reported as an explanation for the 
lack of difference in ACh mediated vasodilation of thoracic arteries of obese, compared with 
control, mice (Crauwels et al., 2000; Noronha et al., 2005). Consistent with this explanation, 
some groups have proposed that ACh-mediated relaxation of femoral arteries is mediated 
more by endothelium-derived hyperpolarisation, which is unaffected by obesity, than nitric 
oxide in the mouse (Brandes et al., 2000) and rat (Savage et al., 2003). However, other 
groups investigating femoral artery relaxation in rat suggest nitric oxide is the primary or 
only mediator (Zygmunt et al., 1995; Wigg et al., 2001). 
Endothelium denudation of vessels reduced response to ACh; however, vessels from obese 
animals maintained vascular tone to a greater degree than controls. This could be due to a 
greater loss of endothelial cells in the DIO group; if vessels were narrower the denuding 
method could conceivably have been more effective in this group. Inhibiting nitric oxide 
synthase before addition of ACh would determine if the difference in tone was due to 
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residual endothelial cells, following the denudation process, which could generate nitric 
oxide and cause relaxation in the CON group. Alternatively the difference may be due to a 
vasoconstriction response induced by ACh which has been reported in porcine (Kawamura et 
al., 1989) and bovine (Brunner et al., 1991) coronary arteries at high concentrations of 
agonist. By removing the endothelial cells, ACh will act on muscarinic receptors in the 
smooth muscle cells, if a greater response or number of receptors was present in the DIO 
mice it could account for the maintenance of vascular tone. Interestingly, the 
vasoconstriction response to ACh is augmented in intact vessels from humans with 
atherosclerosis and may form part of the pathogenesis of the disease (Ludmer et al., 1986).  
6.4.4 Maternal obesity and femoral artery function in the offspring 
Despite lack of overt metabolic changes in offspring of obese dams (data presented in 
chapter 5), profound changes in femoral artery function were found. The decreased 
sensitivity to PE was modulated in the presence of endothelial cells suggesting altered 
signalling predominantly in the smooth muscle cells. As maximum contraction was similar 
to controls it is unlikely to be due to decreased receptor numbers, but a decreased affinity or 
alterations in downstream signalling. If maintained this reduced sensitivity to PE could act as 
a compensatory mechanism to stop increases in peripheral tone. Increased sensitivity to 
noradrenaline, also an adrenergic agonist, has been reported in other models of programming 
by maternal exposure to glucocorticoid (O'Regan et al., 2008), or diabetes and obesity 
(Koukkou et al., 1998). Two other studies have looked at the vascular effects of maternal 
obesity in mice, one found no difference in aortic response to PE (Chechi et al., 2009), the 
other, reported increased sensitivity of mesenteric arteries to noradrenaline (Samuelsson et 
al., 2008). As discussed, the type of artery used to assess function could explain the different 
results. While the study by Samuelsson et al. also showed increased arterial contraction, the 
offspring of obese dams were reported to have increased adiposity and plasma 
concentrations of triglycerides, insulin and leptin (Samuelsson et al., 2008) making it 
difficult to determine to what extent the altered vascular contraction reflects programming 
effects and/ or the effect of altered metabolism. 
Exposure to maternal obesity also altered the response to 5-HT in offspring femoral arteries, 
giving a greater maximum contraction rather than altered EC50. The maximum contraction is 
greater than that elicited by KPSS, which is mediated by an influx of Ca
2+
; this suggests an 
increase in sensitivity to Ca
2+
 in response to 5-HT rather than a greater contractile ability in 
DIOoff. The maximum contraction was only statistically greater in intact vessels suggesting 
an effect of the endothelial cells. The difference in contraction was in fact emphasised by a 
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loss of tone in CONoff at high concentrations of 5-HT. It has been shown that 5-HT can 
release vasodilator substances from endothelial cells (Cocks and Angus, 1983), this 
mechanism may be impaired in DIOoff accounting for the difference in maximum 
contraction. No other published studies have looked at the vascular response to 5-HT 
following maternal obesity, though the results reported here are suggestive of endothelial 
dysfunction which was supported by decreased response to ACh. 
As well as decreased sensitivity to ACh, a reduction in maximum relaxation was also seen, 
though this was variable in DIOoff and did not reach statistical significance. Maternal 
obesity did not affect the offspring response to sodium nitroprusside, which causes relaxation 
by activation of guanylate cyclase. This indicates one downstream signalling pathway of 
nitric oxide in the smooth muscle cells is not affected by maternal obesity, and further 
suggests a dysfunction of the endothelial cells. The alteration in response to ACh could be 
due to reduced numbers of muscarinic receptors or reduced affinity for the ligand. Reduced 
sensitivity to ACh could also be mediated by nitric oxide, for example as a result of 
decreased production or increased scavenging in endothelial cells. As has already been 
discussed in this chapter, ACh causes release of other EDHFs (Brandes et al., 2000) and the 
lack of release or action of these could also cause the reduction in relaxation. On the other 
hand increased released of endothelial derived contracting factors (EDCFs) (Luscher et al., 
1992) could cause the reduced response to acetylcholine.  
Other studies of offspring of obese dams have found reduced relaxation response to ACh in 
rats (Ghosh et al., 2001; Khan et al., 2004) and mice (Samuelsson et al., 2008). Interestingly 
the rat studies, somewhat comparable to the results of this chapter, reported only small 
changes in plasma triglycerides (Ghosh et al., 2001) or no overt changes in metabolism 
(Khan et al., 2004) accompanying the endothelial dysfunction. However, as discussed above, 
the study in mice resulted in many changes in metabolism (Samuelsson et al., 2008) making 
the mechanism of endothelial dysfunction harder to pinpoint. In support of a programming 
effect distinct from altered metabolism; Koukkou et al. found reduced response to ACh in 
mesenteric arteries of rat offspring of obese dams aged only 15 days (Koukkou et al., 1998). 
The mechanism behind the endothelial dysfunction is unclear as some studies report reduced 
maximum relaxation (Ghosh et al., 2001) and others, like this, show reduced sensitivity 
(Samuelsson et al., 2008) to ACh. A study using specific inhibitors of nitric oxide and EDHF 
in offspring of obese dams suggests altered EDHF response in mesenteric but not femoral 
artery when treated with ACh (Taylor et al., 2004), though this was carried out in 180day old 
rat offspring of maternal obesity dams fed only a high fat, not high sugar, diet. The study 
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also suggested up-regulation of nitric oxide and prostaglandins in response to reduced EDHF 
release or sensitivity (Taylor et al., 2004). Whether similar mechanisms are involved in the 
reduction of response reported here are unclear but response to ACh following blockade of 
nitric oxide production and/or in the presence of potassium to depolarise cells and inhibit 
EDHFs would indicate the relative contribution of each factor. 
Endothelial dysfunction is associated with cardiovascular disorders (Drexler and Hornig, 
1999) and atherosclerosis (Bonetti et al., 2003) in humans. It is also observed in human and 
animal models of diabetes (Steinberg et al., 1996; Molnar et al., 2005). Interestingly the 
vascular function of offspring from obese dams presented here shares some similarities to 
that reported by Molnar et al. in a study of postnatal obesity (Molnar et al., 2005); 
specifically, decreased endothelium-dependent vasodilation. Despite hyperinsulinaemia, 
insulin stimulated phosphorylation of akt and eNOS were normal in the study by Molnar et 
al., but reduced eNOS protein dimers were present, potentially as a result of peroxynitrite 
disruption (Molnar et al., 2005). It could be assumed that insulin sensitivity is maintained in 
the DIOoff as no evidence for altered plasma insulin was found but, as shown by Molnar et 
al., it is still possible for the downstream signalling pathway of Ach (production of nitric 
oxide) to be altered. 
Whilst studies suggest a strong link between plasma lipids, hormones and vascular function, 
the results of this study suggest alternative mechanisms must also be present. In humans, 
obese pregnant women have been shown to have altered concentrations of lipids, hormones 
and inflammatory cytokines, similar to non-pregnant subjects (Ramsay et al., 2002). During 
development these factors will enter fetal circulation and it is possible they can cause 
changes in gene expression which impact on femoral artery function but not on whole body 
physiology. Thus the effect is still due to altered concentrations of plasma lipids and 
hormones but during development rather than in adult life. DIOoff themselves did not have 
altered plasma insulin concentrations following a fast or glucose tolerance test, and in fact 
had lower plasma triglyceride levels than controls. Likewise, female mice subjected to 
postnatal obesity did not show signs of vascular dysfunction, and therefore it would be 
unlikely to be present in the dams of DIOoff pre-pregnancy.  
Vascular dysfunction is often linked with hypertension as it can lead to changes in peripheral 
resistance. Increased contractility and/or decreased vasodilatory responses may increase 
peripheral resistance and therefore drive an increase in blood pressure unless other 
mechanisms can compensate. It is notable that the DIOoff have vascular dysfunction, but no 
change in blood pressure. It is possible that blood flow, controlled by heart rate which was 
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not measured in this study, could change to accommodate increases in resistance. The 
concentrations of agonist which were required to find differences in offspring vascular 
function are often greater than those that are found physiologically. The changes found in 
this study may represent differences seen with pharmacological doses and might not become 
physiologically relevant unless the system is stressed or another insult such as obesity is 
present. This study only investigated the function of femoral arteries, changes in vascular 
function have anatomical variation, as discussed above (section 6.4.3), and therefore the 
differences may not be present in other vessels. Resistance arteries are more important in 
regulating blood pressure than conduit arteries, such as the femoral, thus it would be of 
interest to look at the function of resistance arteries in this model. 
The novel results reported in this chapter show maternal obesity is associated with 
endothelial dysfunction in the offspring independently from alterations in plasma 
concentrations of glucose, insulin, triglycerides and cholesterol. 
6.4.5 Postnatal obesity and vascular remodelling 
The lack of profound functional changes in the femoral artery following postnatal obesity 
was mirrored by a normal response to intra-luminal wire injury surgery. The use of OPT 
allowed for volumetric analysis enabling investigations into neointima length not seen in 
standard two-dimensional analysis.  
There are many factors involved in vascular remodelling following injury, one being 
inflammation (Ross, 1999; Virdis and Schiffrin, 2003). As no difference in lesion size was 
found, further immunohistochemistry for specific cell types in lesions was not undertaken. 
However, descriptive notes of UST stained slides were made, and these revealed no increase 
in appearance of thrombosis, or suggestion of differential neointima composition. As was 
discussed with respect to vascular function, if obesity and metabolic dysfunction were the 
primary cause of increased lesion formation the results presented in chapter 3 would predict 
the effect to be greater in male mice than females. The OPT analysis did reveal a small 
pattern towards increase volume of neointima formed in male DIO, though the same pattern 
was seen in lumen volume, potentially suggesting outward remodelling of the vessel. 
Obesity and insulin resistance has been shown to increase neointimal proliferation following 
balloon arterial injury in rats (Park et al., 2001; J. Shelton, 2003; Desouza et al., 2006). In 
mice, ferric chloride-induced arterial injury was shown to increase neointimal proliferation 
in the C57BL/6 strain but not in ob/ob mice (Schafer et al., 2004) which lack functional 
leptin. When ob/ob mice were given recombinant leptin, lesion formation increased. In a 
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second genetic model of diabetes and obesity; db/db mice, which lack the leptin receptor, 
recombinant leptin administration did not alter lesion formation implicating a role for the 
leptin receptor (Schafer et al., 2004) in the injury response.  
Consistent with the results in this chapter, Molnar et al. used C57BL/6 mice fed high fat diet 
and did not find any significant difference in neointimal hyperplasia following femoral artery 
wire denudation injury (Molnar et al., 2005). A degree of leptin resistance may account for 
the lack of changes in lesion size found both in this study and in that of Molnar et al. 
(Molnar et al., 2005). However, if leptin were the only mediator of neointimal lesion 
formation it would seem logical that the transgenic models of obesity, which lack leptin 
signalling, would have smaller lesions than C57BL/6 mice which has not been described 
(Schafer et al., 2004). Species-specific responses to vascular injury can be seen in the 
literature which may account for the variability in the effects of obesity. A dramatic 
reduction in lesion size was reported by Stephenson et al. following intra-luminal injury in 
db/db mice, believed to be due to reduced smooth muscle migration (Stephenson et al., 
2003). However, studies using type 2-diabetic rats report increased lesion size following 
vascular injury (Park et al., 2001; J. Shelton, 2003; Desouza et al., 2006). 
Vascular injury has been proposed to initiate the build up of atherosclerotic plaques (Ross, 
1999), however, it is not possible to produce atherosclerotic lesions in wild type mice. In the 
study reported in this chapter we chose to use a model of arterial denudation, which 
generates a cellular intimal lesion, to study vascular remodelling. As discussed above various 
models have been used to study vascular remodelling, such as balloon arterial injury, ferric 
chloride cuff and even radiation and whether the same results would have been found using a 
different model is unclear. If it is possible to generate an injury which incorporates lipids in 
to the remodelling response, this is more likely to be directly modulated by obesity and 
increased plasma lipid concentrations. It would also be interesting to use a model in which 
the endothelial cells are not damaged as they display many chemoattractant and adhesion 
molecules which can initiate vascular remodelling responses and atherogenesis, and are 
increased in obesity (Ferri et al., 1999; Vachharajani et al., 2005).  
6.4.6 Maternal obesity and vascular remodelling in the offspring 
Differences in femoral artery function were attributed to changes both in smooth muscle and 
endothelial cells. The model of injury used denuded the vessel of endothelium; removing the 
cells would mean their contribution to lesion formation may be minimal. This suggests the 
changes in endothelial cell function induced by maternal obesity are unlikely to affect 
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vascular remodelling following this injury. However, cells proximal to the injury site would 
also have a role in the remodelling response and their dysfunction could be important in 
lesion formation. Non-denuded models of arterial injury, as discussed above in relation to 
post-natal obesity (section 6.4.5), may seem appealing to investigate. The lesions formed in 
these injuries are more focal and therefore may lead to difficulties in analysis. It is also not 
clear how some models initiate injury or endothelial damage and if physical, vessel 
restrictions, as well as chemical parameters are involved. 
No other studies investigating the response to intra-vascular injury in offspring of obese 
dams have been reported. The lack of overt metabolic dysfunction in the offspring in this 
study (chapter 5) may suggest no differences would be found, although the profound 
alterations in vascular function have already provided evidence for programming of the 
vasculature independent of changes in metabolism. Given that postnatal obesity does not 
consistently affect lesion formation following injury (as discussed above) maternal obesity 
might not be an influential factor on the same processes in offspring. 
Maternal obesity has been associated with increased inflammation and reactive oxygen 
species in the offspring (Bruce et al., 2009; McCurdy et al., 2009; Bilbo and Tsang, 2010; 
Yan et al., 2010) Alterations in inflammatory response may also provide a link between the 
changes found in vascular function, and the many varying metabolic and vascular 
phenotypes found as a result of maternal obesity in other studies. Atherosclerosis has a 
significant inflammatory component (Libby, 2002) and greater incidences of fatty streaks, an 
atherosclerotic precursor, are found in children of hypercholesterolaemic mothers (Napoli et 
al., 1999) and offspring of atherosclerotic rabbits (Palinski et al., 2001) and mice (Alkemade 
et al., 2007) independent of metabolic status. If inflammatory changes are involved, vascular 
remodelling may differ from controls in older offspring or those further challenged with an 
obesogenic diet, or in alternative arterial injury models. 
6.4.7 Study limitations 
The blood pressures reported in this thesis were consistent with one study (Elahi et al., 2009) 
but are higher than others (Rahmouni et al., 2005; Samuelsson et al., 2008; Symons et al., 
2009). This could be due to the technique used (discussed in section 6.4.2) or other intrinsic 
differences between housing environments and origin of the strain. It is possible that the 
control values are high and are therefore masking increases induced by exposure to obesity.  
The resting tension applied to femoral arteries to investigate function was kept consistent for 
all groups. For accurate results this relies on vessel diameter being unaffected by exposure to 
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obesity. The vessel diameter was not measured in femoral arteries used to investigate 
vascular function and therefore this cannot be ascertained for certain. Measures were made 
in separate cohorts of animals generated using the same protocols but subjected to 
intraluminal wire injury surgery. The measurements were made in UST stained slides at the 
furthest point away from injury possible. At this point the vessel morphology had returned to 
normal and therefore was unlikely to have been exposed to the wire. Although these results 
showed no effect of exposure to obesity on vessel diameter measurements in the actual 
vessels used would be highly preferential and should be made in future studies.   
6.4.8  Conclusions 
In summary, postnatal obesity does not cause changes in blood pressure, femoral artery 
function or remodelling following intra-luminal wire injury, suggesting obesity and/or the 
associated metabolic dysfunction must be well established before its effects become 
apparent. Maternal obesity does not alter blood pressure or neointima formation following 
intra-luminal injury in the offspring, but it does cause potentially detrimental changes to 
femoral artery function. This suggests that maternal obesity can program signalling pathways 







In recent decades the prevalence of obesity has rapidly increased, such that it is now one of 
the biggest global health problems (WHO, 2011). Obesity is a huge economic drain because 
of its role in the development of cardiometabolic disease including type 2 diabetes, 
hypertension, and atherosclerosis. In humans the prevalence of cardiovascular disease differs 
between sexes, potentially in part due to the distribution of adipose tissue; however, the 
exact mechanisms controlling adipose deposition and its effects on metabolic health are 
unknown. Most research attempting to delineate the links between obesity and 
cardiovascular disease has focussed on male animals and, therefore, sex differences are 
relatively unexplored. The effect of obesity in women of childbearing age is of particular 
interest due to the potential for over-nutrition to result in programming the metabolic and 
vascular physiology of the unborn fetus. Therefore, improving our understanding of sex 
differences in obesity, and elucidating the effects of maternal obesity on the offspring are 
important in informing attempts to reduce the incidence of cardiovascular disease in current 
and future generations. 
The overall objective of the work described in this thesis was to study the sex differences in 
murine postnatal obesity and also the effects of maternal obesity on offspring physiology. 
The results generated in the first chapter expanded this study to include an investigation into 
the effects of estradiol on male obesity and glucocorticoid metabolism. An additional aim of 
the project was to explore the link between obesity and vascular physiology in the models of 
postnatal and maternal obesity. 
7.1 Obesity in females 
In the 1990s the National Institutes for Health mandated that trials supported by them should 
be adequately powered to support the analysis of gender and racial subgroups, though 
interestingly many studies still fail to report their results by sex (Geller et al., 2011). The 
same equality is not seen in pre-clinical research with the search for drug targets and 
molecular pathologies of disease primarily focused on effects in male animals. Evidence 
suggests females are somewhat protected from the effects of obesity since, despite a greater 
percentage of adipose tissue, the rates of associated cardiovascular diseases are lower. The 
lack of research in females may mean that some of the molecular pathways that confer 
protection from obesity are being neglected. The most likely reason for the lack of use of 
females is the cyclic changes in physiology due to the estrus cycle. This makes study design 
more difficult since investigations should ideally be performed at a similar time point in the 
estrus cycle to control for the effects of fluctuating levels of sex steroids.  
208 
The anatomical distribution, as well as quantity, of adipose tissue has been postulated as the 
driving force behind sex differences in obesity-induced cardio-metabolic disease. The study 
reported in chapter 3 found a comparable increase in wet subcutaneous and retroperitoneal 
adipose tissue weight in males and females. However, the interaction between the effects of 
sex and obesity on mesenteric adipose indicated less visceral deposition in the female mice. 
Whether this small difference in distribution is part of the mechanism behind the sex-specific 
metabolic consequences of murine obesity is unclear and studies with estradiol did not 
enable a conclusion to be reached. In fact, treatment of males with estradiol (chapter 4) 
almost completely attenuated the diet-associated increase in adiposity. It is possible that 
glucose tolerance and insulin sensitivity were maintained in estradiol-treated mice due to the 
lack of adipose tissue accumulation, rather than the effects of estradiol on glucocorticoid 
metabolism or other target systems. It should be noted that plasma lipid concentrations were 
increased in estradiol-treated DIO mice, demonstrating that diet did have some physiological 
effects regardless of the steroid treatment. Although not a surrogate for females, estradiol-
treated males could be useful in understanding the mechanisms linking adiposity and 
metabolic dysfunction. The lack of adipose tissue deposition could be addressed by repeating 
the experiment with a lower dose of estradiol, or by pair feeding the obesogenic diet to 
estradiol and sham treated animals.  
7.1.1 Obesity and glucocorticoid metabolism 
The results of this thesis support a wealth of published data describing an association 
between the activity of 11β-HSD1 and the development of obesity and metabolic 
complications. In male obese mice, 11β-HSD1 activity is reduced in correlation with adipose 
accumulation and this may be a protective mechanism (Morton et al., 2004). While also 
apparent in females, 11β-HSD1 activity in adipose tissue was lower in lean females than 
males. This sex difference in glucocorticoid metabolism could be one mechanism accounting 
for the sex-specific metabolic responses to obesity in mice. Although studies have shown 
that 11β-HSD1 KO mice (Morton et al., 2001), or those treated with inhibitors (Alberts et 
al., 2002; Alberts et al., 2003; Hermanowski-Vosatka et al., 2005) are protected from the 
effects of a obesogenic diets, these studies were all carried out in male mice. Future studies 
treating diet-induced obese female mice with inhibitors of 11β-HSD1 or using female 11β-
HSD1 KO mice would help determine whether the sex differences seen in the activity of the 
enzyme contribute to the metabolic dysfunction associated with obesity. It would also be of 
interest to extend these studies to include tissue specific KO models as it is plausible that the 
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effects of 11β-HSD1 inhibition could be mediated through the brain, liver, and adipose 
tissue, independently or in combination, and this may also differ between sexes.  
The interaction between 11β-HSD1 and estrogen is of particular interest as this may provide 
a new selective target to modulate enzyme activity. The exact mechanisms by which 
estradiol affects 11β-HSD1 are still to be elucidated; and while estrogen has been shown to 
act as a non-competitive inhibitor of 11β-HSD1 in primary rat adipocyte cultures (Tagawa et 
al., 2009) the results presented in chapters 3 and 4 also suggest an effect on mRNA 
abundance. Increased glucocorticoid regeneration in post-menopausal, compared with pre-
menopausal, women has been described (Andersson et al., 2009); and it would be interesting 
to extend this study to include post-menopausal women receiving hormone replacement 
therapy (HRT). Both preliminary studies of 11β-HSD1 inhibition in humans (Rosenstock et 
al., 2010; Feig et al., 2011) used male and female patients, although the results were not 
analysed for the effect of sex. Additionally the patients studied were aged between 40-60 
years in one trial, and 29-66 in the other, and therefore hormonal status is likely to be 
heterogeneous. Reporting of sex specific results as well as combined data in future trials 
would be of interest in the light of the results of this thesis which suggests the effect of 
enzyme inhibition will be larger in males. 
Local glucocorticoid concentrations can be affected by A-ring reductase enzymes as well as 
11β-HSD1. Higher abundance of mRNA encoding 5βR was found in females, consistent 
with higher levels induced by estradiol treatment. To date no work has been published on 
direct inhibition or deletion of 5βR, though this would provide a new model in which to 
further investigate sex differences in glucocorticoid metabolism. The results of this thesis 
suggest greater metabolism of glucocorticoids by 5βR in females and, therefore, it could be 
hypothesised that deletion of 5βR would result in higher tissue specific concentrations of 
glucocorticoids in female mice. 5βR KO mice would also provide a model for further 
investigations into the differential effects of 5α- and 5β-reduced glucocorticoid metabolites 
on obesity and metabolic dysfunction. 
7.2 Sex steroid balance 
While the results presented in chapter 4 propose a role for estrogen in protecting males from 
the effects of an obesogenic diet, one large limitation of this study was the concurrent 
reduction in testosterone concentrations. As discussed in the chapter (section 4.4.6) the 
relative concentrations of estrogen and testosterone may be important. This highlights the 
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importance of studying both hormones together rather than in isolation, as it seems likely 
that the most metabolically beneficial combination of hormone concentrations varies 
depending on sex. Aromatase, which converts testosterone to estrogen, is found in adipose 
tissue and adipocyte hyperplasia in obesity may increase sex steroid conversion and alter the 
hormone balance (Cleland et al., 1985; Cohen, 1999). Androgen receptors are proposed as 
the primary route of sex steroid feedback in male mice, although estrogen administration to 
gonadectomised mice can also normalise luteinising hormone concentrations (Wersinger et 
al., 1999). As estrogen can bind to androgen receptors (Yeh et al., 1998), increased local 
concentrations in obesity may elicit an inappropriate negative feedback response and further 
alter hormonal balance. In humans, sex hormone binding globulin (SHBG) is a key regulator 
of the bioavailability of sex steroids so that measurements of SHBG as well as sex steroids 
are required to understand the changes in hormone milieu occurring in obesity. Androgens 
inhibit SHBG production, while estrogens stimulate it in vivo. Interestingly, glucocorticoids 
have also been proposed to stimulate SHBG production (Cunningham et al., 1985) 
suggesting a possible interaction between the changes in 11β-HSD1 reported in obesity and 
the bioavailability of sex steroids. As animal models provide a unique opportunity to control 
sex steroid concentrations without the interference of SHBG it would be interesting to repeat 
the studies of chapter 4 in mice with a) low concentrations of testosterone and estrogen b) 
low estrogen and high testosterone and c) high concentrations of both hormones. This would 
allow for further investigations into the hormonal control, and thus sex differences, in 11β-
HSD1 and the effects on diet-induced obesity. Complementary to this would be to measure 
the tissue concentrations of steroids and the activity of aromatase, to determine if conversion 
of testosterone to estrogen is enhanced with adiposity in mice. 
7.3 Programming by maternal obesity 
The well established links between low birth weight and future health outcomes in humans 
(Barker et al., 1990; Barker et al., 1993a) and animal models (reviewed in (Bertram et al., 
2001)) demonstrate the importance of the developmental environment as well as the 
plasticity of molecular physiology during early life. Over-nutrition has been proposed as an 
important environmental stimulus for early-life programming, so that the recent epidemic of 
obesity has great public health implications. Human studies require long-term follow up and 
are complicated by the impact of postnatal environmental factors such as diet, education and 
lifestyle, so that animal models provide a useful tool for the investigation of the mechanisms 
linking maternal obesity with offspring health. 
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7.3.1 Dietary composition 
The results presented in chapter 5 demonstrate little evidence for the programming of 
glucose, lipid or glucocorticoid metabolism in the offspring of obese mothers in this model. 
Although there is a wealth of literature to suggest maternal obesity causes increased 
adiposity and related metabolic disorders in rodent models (reviewed in (Drake and 
Reynolds, 2010)), offspring phenotypes differ between reports. Whilst it is possible to 
control the nutritional composition of diets fed to laboratory rodents this is often not 
accurately reported in experimental methods or results. Diets high in fat and/or sugar may be 
limited in protein content and variable with respect to macro- and micro-nutrients. Protein 
restriction in pregnant rodents leads to offspring with low birth weight and insulin resistance 
in later life (Ozanne et al., 1996a; Ozanne et al., 1996b), such that failure to control for 
protein content may result in programming effects in the offspring of obese dams. Less well 
studied are the effects of other dietary components including micronutrients on offspring 
physiology.  
Many programmed phenotypes become more apparent when the offspring are challenged 
with an additional stressor in postnatal life such as an obesogenic diet or infection. To extend 
the model used in this thesis, feeding offspring with the same diets consumed by the dams 
would be of interest. Although this may reveal an effect of exposure to maternal obesity it 
would need to result in a large exacerbation of the known detrimental effects of postnatal 
obesity reported in chapter 3 to be clinically relevant. In a population where obesity is 
rapidly becoming the predominant classification of body weight, a small variation due to 
maternal nutritional effects is unlikely to generate new health concerns, though it may extend 
the need for treatments for type 2 diabetes, hypertension and other cardiovascular diseases. 
The results of chapter 5 also raise the possibility of overcoming the effects of programming 
by maternal obesity through promotion of a healthy diet and lifestyle postnatally. Currently, 
the effects of maternal obesity are difficult to ascertain with any certainty but encouraging 
weight loss and a healthy lifestyle before pregnancy may reduce the chance of programmed 
effects, and potentially more importantly prevent the domino effect of passing on undesirable 
eating behaviours. 
7.3.2 Inter-generational programming 
An interesting proposal is the potential for inter-generational programming as has been 
described in other models of early-life programming (Drake et al., 2005b). This suggests that 
the gametes forming in a fetus of an obese dam may be altered such that a phenotype is seen 
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when the F1 offspring themselves have children. In human terms, the effects of an obese 
mother would be seen in her grandchildren. This is an interesting hypothesis as it would 
bring together subtle changes in nutritional status programmed in the F1 generation with 
epigenetic changes laid down during gamete formation potentially resulting in a stronger 
phenotype in the F2 generation. Due to the potential role of dietary components in 
programming, any inter-generational experiments must be designed with appropriate caution. 
The effects of paternal nutrition on offspring physiology must also be considered; new 
evidence demonstrates paternal obesity causes adiposity and β-cell dysfunction in female 
offspring (Ng et al., 2010).  
7.3.3 Sex differences in programming 
Although the results of this thesis have highlighted the sex differences in murine postnatal 
obesity, only male offspring of obese dams were studied, due to time and practical 
limitations. The studies of postnatal obesity would imply worse metabolic phenotypes in 
males; however, most studies investigating exposure to maternal obesity in both sexes find 
worse or more pronounced metabolic phenotypes in females (Han et al., 2005; Bayol et al., 
2008; Samuelsson et al., 2008; Elahi et al., 2009). Although the reasons for this are unclear, 
female fetuses may be more sensitive to environmental changes in early life and/or 
programmed changes may be more detrimental to females in later life. Maternal nutritional 
status could also result in the programming of reproductive function including sex steroid 
concentrations in the fetus or adult offspring which may have detrimental effects, for 
example a programmed reduction in estrogen may increase the risk of obesity. Interestingly, 
rodent studies of intrauterine growth restriction demonstrate a more severe phenotype in 
male, compared with female, offspring (reviewed in (Grigore et al., 2008)) suggesting that 
different mechanisms may be involved in programming by maternal obesity. Ideally, studies 
of programming effects should include both sexes and allow for investigation at several time 
points; however, time, space, technical and monetary practicalities rarely allow for such 
thorough investigations. 
7.3.4 Potential mechanisms 
Due to the comparable metabolic physiology of the offspring of control and obese dams, and 
practical constraints of a PhD, follow-up studies to investigate potential programming 
mechanisms were not undertaken. However, this should be a future direction of studies 
investigating programming by exposure to maternal obesity. One potential mediator of future 
offspring health is epigenetic modification which is important in establishing different 
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patterns of gene expression, without changing DNA sequence. Epigenetic modifications 
include DNA methylation, histone modifications, and non coding RNAs and are established 
early in development and maintained throughout life, which makes them prime candidates to 
explain programming. Maternal nutritional status can alter the epigenetic regulation of gene 
expression. For example, in rats, maternal protein restriction decreases methylation of the 
GR and PPARα promoters in offspring liver (Lillycrop et al., 2005) while maternal total 
calorie restriction increases methylation of the same genes (Gluckman et al., 2007). 
Additionally, feeding pregnant mice a diet high in methyl donors increases methylation of 
the agouti gene in many offspring tissues (Waterland and Jirtle, 2004). Changes in mRNA 
levels and gene expression have been repeatedly reported as a consequence of maternal 
obesity or fetal over-nutrition. However few studies have investigated the role of epigenetic 
regulation. Raising rats in small litters which increases postnatal nutrition has been shown to 
cause hypermethylation of the pro-opiomelanocortin (POMC) promoter, which inhibits the 
essential upregulation of POMC by hormones suppressing its anorexic effects (Plagemann et 
al., 2009). In addition, offspring of obese Japanese macaques have altered hepatic chromatin 
structure due to covalent modifications of histones (Aagaard-Tillery et al., 2008) further 
supporting the potential role of epigenetic modifications in programming by maternal 
obesity. 
7.4 Vascular function 
The majority of evidence suggests that changes in vascular function correlate with insulin 
resistance in addition to obesity. Studies have reported changes in vascular function in obese 
normoglycemic patients, although fasting plasma insulin concentrations and homeostatic 
model assessment (HOMA) insulin resistance index were higher in the obese subjects 
compared with controls (Van Guilder et al., 2006). In mice fed a high fat diet, insulin 
resistance occurs in the vasculature before peripheral tissues (Kim et al., 2008). If also true 
in humans, this suggests that the endothelial dysfunction consistently reported in obesity is a 
response to raised insulin concentrations, even when normal metabolic physiology is 
maintained. It is almost impossible to separate obesity and raised insulin concentrations in 
humans; however, the models presented in this thesis provided a unique opportunity to 
delineate the two by using obese male mice with fasting hyperinsulinemia and insulin 
resistance and obese female mice with normal plasma insulin concentrations. Interestingly, 
neither sex had any physiologically relevant changes in vascular contraction or relaxation. 
Mice may be able to protect the vasculature from the effects of an obesogenic diet and raised 
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insulin concentrations. The results presented in chapter 6 add to the inconsistency found in 
the literature with regard to vascular function in murine postnatal obesity. It would be 
interesting to see if the changes reported by other groups, particularly endothelial 
dysfunction, would occur in the model used in this thesis with more time/increasing obesity. 
Many other reports have suggested large species variability in vascular function which may 
be another reason for the inconsistency of results reported. 
7.4.1 In vivo imaging 
To understand the mechanistic links between obesity, changes in vascular function and 
lesion formation, in vivo monitoring would be a huge benefit. This would allow for lesion 
formation and progression to be tracked over time following the surgical injury. It would 
also allow for functional analysis of the vessels in situ, where additional vasoactive agents 
can be released by peri-adventital adipose tissue, or anatomical changes in diameter 
restricted. In humans, the vasculature of the forearm has been extensively used to study the 
response to dietary constituents, hormones and pharmacological agents in conscious patients. 
However, in animals this can only be carried out under anaesthetic which, depending on the 
specific drug used, may alter vascular resistance, cardiac output and blood pressure 
(Skolleborg et al., 1990) potentially limiting the relevance of the results.  
While the use of OPT has provided an excellent addition to vascular lesion quantification, in 
particular in allowing 3D measurements, in vivo quantification would be preferable. Non-
invasive imagining techniques are available to quantify lesions, which due to their relatively 
solid structure are not altered by anaesthetics. Ultrasound biomicroscopy has been used to 
assess plaque morphologies in the carotid arteries of mice (Gan et al., 2007), as has magnetic 
resonance imaging (Trogan et al., 2004). Both of these techniques would be useful in the 
early stages of lesion formation when the response to injury is at its greatest, and could be 
combined with specific cell markers to understand the patterns of cellular infiltration, 
migration and differentiation.  
7.4.2 Maternal obesity and vascular function 
Whilst postnatal obesity only had subtle effects on vascular function, the effects of exposure 
to maternal obesity were much greater. This is particularly interesting in light of the lack of 
overt changes in the metabolism of the offspring and suggests the potential to program 
altered vascular contraction and endothelial dysfunction without insulin resistance. A study 
investigating the effects of maternal obesity in rat offspring found altered vascular function 
from as early as 15 days of age (Koukkou et al., 1998). Although plasma glucose and 
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triglycerides were comparable to control offspring, one possible influence at this early time 
point is the composition of the mothers’ milk, and differences may be due to current 
nutritional intake rather than programmed changes. However, differences were maintained at 
60 days of age in the study by Koukkou et al. consistent with the results found in the mouse 
model presented in this thesis. The mechanisms behind the changes in vascular function are 
currently unknown but warrant investigation as maternal obesity may increase the incidence 
of cardiovascular disease through direct effects on the vasculature instead of, or as well as, 
being a consequence of offspring obesity. Investigations of the phenotype of the endothelial 
cells would be the immediate direction of future studies. This could be carried out by 
inhibition of endothelial nitric oxide synthase (eNOS) in functional studies. In addition, post 
mortem analysis of eNOS expression, location, phosphorylation, and dimer formation could 
be used to determine whether the potential to synthesise nitric oxide has been altered by 
programming. 
7.4.3 Alternative models 
In the experiments described in this thesis, lesion formation was investigated 28 days after 
luminal wire injury, when the neointima is believed to be stable (Sata et al., 2000; Dover et 
al., 2007). Even with the addition of in vivo imaging or increased length of study this model 
may not be the most appropriate to explore the relationship between obesity and vascular 
response to injury in mice. There are other models of vascular injury which do not damage 
the endothelium such as direct ligation or placement of a perivascular cuff. As endothelial 
dysfunction is the most consistently reported vascular response to obesity these injuries may 
demonstrate differences in lesion formation as a result of changes to the endothelium. This 
would be of particular relevance in the model of exposure to maternal obesity where 
evidence of endothelial dysfunction was found. The advantage of the wire injury model used 
in this thesis is the similarity to the vascular damage seen in angioplasty and the maintenance 
of blood flow within the region of injury. This method reproducibly produces large 
neointimal lesions and is well tolerated in the animals, thus it is the preferred model of 
neointimal hyperplasia in the department. 
Endothelial dysfunction and altered lesion formation may indicate a propensity for 
atherosclerosis, though this does not spontaneously occur in mice. To study atherosclerosis 
in mice, transgenic models, often in combination with high cholesterol diet, are required. 
Whilst these models have been useful in understanding the molecular pathology of the 
disease, the high plasma concentrations of cholesterol and changes in lipid metabolism due 
to deletion of genes generates a model quite different to simple obesity. In fact, studies in our 
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department found feeding ApoE KO mice an obesogenic diet as opposed to a western diet 
high in cholesterol did not result in atherosclerotic lesion formation (personal 
communication Dr. P. Hadoke). Thus larger mammals may be more clinically relevant for 
studying the relationships between atherosclerosis or lesion formation and consumption of an 
obesogenic diet.  
7.5 Conclusions 
In conclusion, these studies have provided valuable insights into the complex, sex-specific 
nature of obesity. They demonstrate that the relative protection of women from the metabolic 
effects of obesity is also found in mice and can be induced in males by treatment with 
estrogen. In addition they suggest a role for glucocorticoid metabolism in the sex differences 
associated with obesity. The results also demonstrate that maternal obesity can program 
vascular dysfunction in the offspring, independent of metabolism, which could have major 
public health implications if true in humans. The animal models developed and utilised in 
this thesis will allow for further investigations into the mechanisms of the sex differences 
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